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CHAPTER ONE
A BRIEF HISTORY OF THE DEVELOPMENT OF MEDICAL RESEARCH
Introduction
The rapid development of medical research over the past 150 years has resulted in
scientific innovations with greater capabilities of addressing catastrophic and populationbased health events, treating acute health needs, developing new drugs, and utilizing cuttingedge technology to improve medical care. Describing the details of these advances in
medicine would require several dissertations; therefore, this chapter modestly aims to
provide a brief sketch of the way medical research develops over the past century and a half.
I will focus on the ways in which medical research contributes to bettering the health of
individuals and populations and the effect of these innovations on society at large. However,
this dissertation is not simply about the development of medical research, but also about
how the trajectory of these developments has led to a socio-economic and global imbalance
with respect to the beneficiaries of medical research.
In order to understand the unequal distribution of the developments within medical
research, a first step requires understanding what constitutes medical research, as well as the
implications for individuals and for communities. Medical research in the late nineteenth
century, begins by taking-up local concerns. However, larger political and economic contexts
shape local health concerns. While the Second Chapter takes up the ethical norms aiming to
protect research subjects, this First Chapter describes the various contexts in which medical
1

research develops.
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This chapter begins with a brief description of what constitutes medical research.
The remaining three sections describe the progress made in medical research beginning from
the mid-nineteenth century, by turning to exemplary case studies to describe the variety of
research being conducted and the contextual problems to which it responds. The first of
these periods focuses on the research from the cholera epidemic of 1850s London and the
acute and population-based health responses. The work of John Snow, Robert Koch, and
the international hygiene movements exemplify the research of this period. The practices of
the hygiene movements within this period mark an important development in research
translation and the dissemination of new knowledge. Dissemination of knowledge plays an
essential role in the second period I consider in this chapter—research during the pre and
post-World War era.
Research during and after the World Wars centers on the health of particular classes
or groups of people, chief among them workers and soldiers. Yellow fever research,
emerging surgical techniques, and eugenic research all play key roles in advancing scientific
knowledge in the hope of developing a stronger and “more fit” society. While this second
period is characterized by a focus on particular groups of people, the examples in the third
period demonstrate an interest on broader global health concerns that target disease
eradication and new ways of improving the lives of those suffering from chronic and
infectious disease.
In this final section, the eradication of smallpox, the necessity of medicating
hypertension, and the possibilities of research in synthetic biology demonstrate the potential
of research that targets the treatment or prevention of particular diseases. The focus on
smallpox, and its eradication, represents a targeted approach to research that allows for more

intentional focus on populations who disproportionately bear the burden of particular
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diseases. The importance of concentrating on diseases that affect the global poor, as
smallpox did, is a practice that I will emphasize throughout my argument. However, as the
cost of research rises, so too has the importance of earning an economic return on
investments in research—explored most fully in Chapter Four. While economics now plays
an important role in deciding which medical research options to pursue, judging from the
definitions of medical research from international research institutes, the emphasis placed on
financial gain as an explicit goal of the practice of medical research varies.
What is Medical Research?
Henry Sigerist, a medical historian from Switzerland, describes medicine as a practice
motivated by bettering the health of individuals. He describes medicine’s task “under the
following four headings: 1. Promotion of health; 2. Prevention of illness; 3. Restoration of
health; and 4. Rehabilitation.”1 Following Sigerist, medicine concerns itself about positive
health outcomes. Medical research, then, participates in this mission by combining the focus
on disease prevention and restoration of health with scientific investigation. Thus, one of the
many motivations in the development of a medical research, as related to the goals of
medicine, requires a genuine interest in improving the lives and health of people.
International Definitions of Medical Research
Highlighting different international definitions of medical research contributes to a
broader understanding of what constitutes medical research, and, additionally, the diversity
in motivations for its pursuit. France’s Institut national de la santé et la recherche médicale (Inserm)
articulates its mission as the only public institute in France focusing “entirely on human
1 Robert J. Levine, “The Nature, Scope, and Justification of Clinical Research: What is Research? Who is
Subject?” in The Oxford Textbook for Research Ethics, ed. Ezekiel J. Emanuel, et al. (New York: Oxford University
Press, 2008), 211.

health.” Its definition emphasizes the humanistic element present in medical research and

4

2

also highlights the public and private partnerships necessary in making research possible.
University hospitals and research centers serve as two of Inserm’s primary collaborators.3 In
the U.K., the Medical Research Council (MRC) more broadly states their intention to
support research in order to “produce skilled researchers, advance and disseminate
knowledge and technology to improve the quality of life and economic competitiveness of
the U.K.; and promote dialogue with the public about medical research.”4 Here the MRC’s
definition begins to point to the role medical research can play economically in promoting
research. The U.S.’s National Institute of Health (NIH) takes a slightly different tone by
describing it as “fundamental knowledge about the nature and behavior of living systems and
the application of that knowledge to enhance health, lengthen life, and reduce illness and
disability.”5 The NIH emphasizes the importance of increasing and disseminating the
discoveries of medical research in the hope of enabling longer and healthier lives. Offering a
different perspective, and at the least a non-western perspective, is that of the Indian Council
of Medical Research (ICMR). The ICMR describes the types of projects that fall within the
purview of medical research as:
control and management of communicable diseases, fertility control, maternal and
child health, control of nutritional disorders, developing alternative strategies for
health care delivery, containment within safety limits of environmental and
occupational health problems; research on major non-communicable diseases like
cancer, cardiovascular diseases, blindness, diabetes and other metabolic and
Institut national de la santé et de la recherche médicale, “The Institute Mission,” Institut national de la santé et de
la recherche médicale, http://english.inserm.fr/what-s-inserm/the-institute-missions (accessed October 23, 2014).
2

3

Institut national de la santé et de la recherche médicale, “The Institute Mission.”

Medical Research Council, “Our Mission,” Medical Research Council - United Kingdom,
http://www.mrc.ac.uk/About/Missionstatement/index.htm (accessed October 23, 2014).
4

5 National Institute of Health, “Mission,” National Institute of Health,
http://www.nih.gov/about/mission.htm (accessed October 23, 2014).

5

hematological disorders; mental health research and drug research (including
traditional remedies). All these efforts are undertaken with a view to reduce the total
burden of disease and to promote health and well-being of the population.6
The ICMR does not include economic interests or pursuit of new knowledge in its mission
statement, and instead lists specific types of research concerning the importance of the
population’s overall health. The wide-ranging mission statements from leading international
medical research organizations give strong indications, not only as to the type of initiatives
that constitute medical research, but also the intellectual, economic, and health-based
commitment of the various research institutes.
While high-income countries focus on economics and technological innovation as a
component of medical research, India’s ICMR, a low-middle income country, does not

mention either of these aspects, focusing instead on research that impacts population health.
Population health is not only concerned with outcomes, but also with the underlying
factors—environmental, social, political, economic, etc.—that contribute to the health
challenges of particular communities and how they can be overcome.7 The ICMR values
medical research pertaining to the health of individuals within the context of the health of
the community as a whole. Any allusion to community or public health, which is a
constitutive dynamic of improving or maintaining health, remains absent from the
descriptions from Inserm, NIH, or the MRC. The inattention to the health concerns of
community in framing the goals of medical research creates a tension that contributes to
health disparities and disparate medical research priorities between lower and higher income
countries, a topic I address in Chapter Four and Five. For the purposes of this chapter,

6 Indian Council of Medical Research, “About ICMR,” Indian Council of Medical Research,
http://icmr.nic.in/About_Us/About_ICMR.html (accessed October 23, 2014).
7

Joshua M. Sharfstein,“The Strange Journey of Population Health,” Milbank Quarterly 92, no. 4 (2014): 640.

however, it is important to note who has established the priorities for research historically

6

and overseen its progress, as well as who stands to benefit from the basic science, clinical,
and epidemiologic research being conducted.
Basic, Epidemiologic, and Clinical Research
Basic science research is driven by a desire to discover and/or to understand some
biological phenomena. The NIH describes basic science research broadly as an area that
leads to a deeper understanding of the “biological rules of life.”8 While basic research
provides the building blocks, clinical research sets out to apply the fruits of basic research in
an effort to understand more fully their efficacy in the clinical setting.
Clinical research is broken down into three sub-categories: epidemiologic-based,
patient-oriented, or outcome/delivery-based.9 In some instances clinical research can be
difficult to distinguish from good clinical practice, which can operate as a research-like
process.10 However, arriving at the best approach to patient care transcends the latest

Toby E. Huff, Intellectual Curiosity and the Scientific Revolution: A Global Perspective (Cambridge: New York:
Cambridge University Press, 2011), 171-208; National Institute of General Medical Sciences, “Curiosity Creates
Cures: The Value and Impact of Basic Research,” National Institute of Health,
http://www.nigms.nih.gov/Education/factsheet_CuriosityCreatesCures.htm (accessed October 26, 2014).
8

While epidemiological research is a form of medical research in its own right, it also functions as a subcategory of clinical research. An example of this type of study might be a clinical trial that sets to study the
effects of a particular drug on a certain group of people in a particular area.
9

10 Robert J. Levine, Ethics and Regulation of Clinical Research (New Haven, Conn: Yale University Press, 1988);
Ruth R. Faden et al., “An Ethics Framework for a Learning Health Care System: A Departure from Traditional
Research Ethics and Clinical Ethics,” Hastings Center Report 43, no. s1 (2013): s16. An example of this can be
seen when a patient is being treated for pain management or when treating a psychological disorder. In both
instances, the concern of the physician is to try a variety of treatments aimed at curing or managing symptoms.
The treatment is therapeutic in nature, specifically focusing on the care of the patient’s health, but could also be
considered a form of research because it is not immediately clear what the best course of treatment for the
patient is. Those responsible for the care of the patient inevitably enter into a process of trial and error in an
effort to discover the possible treatment. Many of the ethical issues in research stem from clinical trials,
particularly ensuring that patient’s understand they are participating in an experiment and may not receive any
therapeutic benefit from their participation. Questions of research ethics will be taken up in more detail in the
next chapter.

scientific advances in order to consider how these advances affect or fail to affect change in
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the health of the population—a practice often left to epidemiologic research.
Epidemiologic research works within the discipline of epidemiology to apply
knowledge related to a population’s health and the spread of disease by drawing on both
basic science and clinical research, with the goal of improving the health of particular
persons or groups of people. Leon Gordis defines epidemiology as the “study of how
disease is distributed in populations and of the factors that influence or determine this
distribution.”11 Epidemiologic-based medical research, then, begins with a focus on the
particular health-related needs of the community and considers other factors that contribute
to this particular distribution of health.12 Epidemiologic-based medical research proves
important when identifying health challenges faced by particular communities. Both
epidemiologic and basic science research prove crucial in the first phase of research
development that discovered the relationship between bacteria and hygiene and its effects on
particular communities during the cholera epidemics of the latter half of the Nineteenth
Century.
Bacteria and Hygiene
The developments in medical research from 1850 to the early parts of the twentieth
century focus largely on controlling widespread and population-based health problems. At
that time, one of the more rampant health problems stemmed from frequent cholera
epidemics. Cholera is a bacterial disease that spreads by drinking water or eating food that
has been contaminated by fecal matter. While the transmission of the disease is now
11

Leon Gordis, Epidemiology (Philadelphia: W.B. Saunders, 2000), 3.

12 Gordis defines five objectives for epidemiology: 1) identify etiology cause of disease, and risk factors; 2)
determine extent of disease in a given community; 3) study natural history and prognosis of disease; 4) evaluate
existing and new preventative and therapeutic measures; 5) provide foundation for developing public policy
and regulatory decisions related to environmental problems. See Gordis, Epidemiology, 4.

commonly understood, it remained a mystery until late into the nineteenth century. At that
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time, it was thought to have spread through air that smelled, i.e. “bad air.”
The epidemiologic research of John Snow and the basic science efforts of Robert
Koch, some 20 years after Snow’s epidemiologic research, contradicted the miasma (“badair”) theory. Koch’s scientific proof of Snow’s epidemiologic-based hypothesis leads to the
mobilization of global campaigns to promote hygiene and prevent the spread of disease.
These hygiene campaigns, largely funded by the U.S.-based Rockefeller Foundation, serve as
catalysts for an array of international efforts to improve hygiene practices. What proves
distinctive about the development of medical research in this period is the importance placed
on public health strategies by various stakeholders within the research community, including
public and private investors.
John Snow
English physician John Snow’s anesthesia research provided him necessary
physiologic data that offered an alternative to the miasma theory. 13 The miasma theory
posited that cholera was spread through the inhalation of noxious fumes. If this were valid,
Snow concluded the same physiologic process that took place in aestheticizing a patient
would hold true for the inhalation of cholera. 14 It was his anesthesia research, focused on
understanding the physiological interaction between the respiratory and circulatory systems,
13 Steven Johnson, The Ghost Map: The Story of London's Most Terrifying Epidemic and how it Changed Science, Cities,
and the Modern World, (New York: Riverhead Books, 2006). London’s population in 1853 was near three million
people, with most people living in close proximity to one another. Johnson’s book offers an insightful look at
the story around John Snow and the city of London during the epidemic’s outbreak.
14 Michael Ramsay, “John Snow, MD: Anesthetist to the Queen of England and Pioneer Epidemiologist,”
Baylor University Medical Center Proceedings 19, no. 1 (2006): 24. Snow’s understanding of the beginnings of his
investigations took place, unbeknownst to him, as a medical student. During his time as a student, he and
others participated in the examination of patients after death, a process which made many students became
sick. He then set up a series of experiments in which he traced the cause of his colleagues’ nausea to the
inhalation of the arsenic vapors from the embalmed bodies. Not only was arsenic a common source for
embalming, it was also used in candles in order for them to burn longer and brighter. Snow’s research also
paved the way for a halt in the sale of candles that used arsenic.

that played a crucial role in his ability to offer an alternative theory. Armed with the
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knowledge that the breathing in of oxygen led to its circulation throughout the body, Snow
hypothesized that he would find a high percentage of cholera deaths within the same
household. When this proved not to be the case, he took up a more diligent study of the
weekly notifications of deaths in London to determine if a common location or pattern
existed between the various deaths.
Snow’s physiologic understanding of the airborne transmission of disease, combined
with the Weekly Return’s reports of births and deaths in London, provided him with the
necessary information to theorize how cholera spread. The Weekly Returns, published by
London’s primary demographer, William Farr, proved essential to Snow’s project. If cholera
spread because of an airborne disease, then those living in the same neighborhood and the
same home were significantly more likely to have contracted the disease. 16 After reviewing
the Weekly Returns, Snow traveled door-to-door to investigate the households of those who
suspected to have died of cholera in an effort to determine if anyone still living was
symptomatic. Though he could not definitively prove that other family members did not
have the disease, his respiratory and circulatory background led him to believe that if the
miasma theory were true they should display symptoms of cholera. Given the absence of
these factors, Snow believed the disease was not airborne.
Snow’s research during the cholera epidemic functioned as epidemiologic research
through its focus on the health of a particular population and studying the factors that
contributed to the disproportionate distribution of cholera in certain areas. The uneven
15

Ramsay, “John Snow, MD,” 24.

16 D.E. Lilienfeld, “Celebration: William Farr (1807–1883)—an Appreciation on the 200th Anniversary of His
Birth,” International Journal of Epidemiology 36, no. 5 (October 01, 2007): 985; John M. Eyler, Victorian Social
Medicine: The Ideas and Methods of William Farr (Baltimore: Johns Hopkins University Press, 1979).

distribution of cholera led him to focus his research on various companies that provided
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water to some 300,000 persons. Snow’s study included:
people of both sexes, of every age and occupation, and of every rank and station, from
gentlefolks down to the very poor, were divided into two groups without their choice,
and in most cases, without their knowledge; one group being supplied with water
containing sewage of London, and, amongst it, whatever might have come from the
cholera patients, the other group having water quite free from impurity.17
His study represented a wide segment of the population and focused tested a very specific
outcome related to water consumption. Snow’s had to test the water supply from two
companies: Southwark and Vauxhall Company and the Lambeth Company. In one of the
sub-districts that drew Snow’s attention, 44 deaths had occurred due to cholera. Of those 44
deaths, 38 had their water supplied by Southwark and Vauxhall, four from Lambeth, and
two from personal pumps.18 Yet, the most compelling aspect of his study came from the
research undertaken near his own home. Snow began canvassing his own neighborhood, and
discovered the most frequently used water source was the Broad Street pump. The pump did
emit noxious fumes, contributing to the miasma theory, but the source of the fumes came
from London’s raw sewage leaking into the city’s water supply underneath the pump and the
source of contagion.19 Though Snow had discovered the contamination source, he could not
corroborate it as the culprit of the epidemic due to the infant stage of bacteriological studies.
The slow acceptance of his conclusions signaled the necessity of complementary research to
affect health outcomes. The research of Robert Koch proved to be the missing link in
understanding the spread of cholera.

John Snow and Stanton Friedberg M.D., On the Mode of Communication of Cholera, (London: John Churchill,
1855), 75.
17

18

Ramsay, “John Snow, MD,” 76-77; Johnson, The Ghost Map, 81-109.

19

Johnson, 178-179.

Robert Koch
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Robert Koch’s discovery of the cholera causing bacteria validated both Snow’s
research outcomes and Louis Pasteur’s “germ theory.” Pasteur’s germ theory evolved
through his work in the 1860s that demonstrated certain diseases developed from
microscopic bacteria that infect the body. Koch built on the groundwork laid by Pasteur by
devising a scientific process capable of isolating, reproducing, and establishing particular
bacteria as the root cause of certain diseases, cholera being one of them. In an address at the
1890 International Medical Conference in Berlin, Koch described the method for
determining the pathology for a bacteriological disease.
If, however, it can be proved: First that the parasite is met with in each individual
case of the particular disease and under the conditions which correspond to the
pathological changes and the clinical course of the disease; secondly that in no other
disease is it found as an accidental non-pathogenic guest; and thirdly, that if
completely isolated from the body and cultivated in pure cultures with sufficient
frequency it can reproduce the disease—then it can no longer be considered an
accidental accompaniment to the disease, but in that case no other relation between
the parasite and the disease can be admitted than that the parasite is the cause of the
disease.20
The talk at Berlin proved essential in describing to the scientific community the
fundamentals of bacteriology, and in particular how it applied to cholera. The cholera
bacteria consistently manifested itself when isolated and cultivated in an uncontaminated
host. By proving that certain bacteria existed as the root cause of the disease, Koch’s
presentation became a high point the conference, and led to his appointment on the German
Cholera Commission.21

20

Robert Koch, “An Address on Bacteriological Research,” The British Medical Journal 2, no. 1546 (1890): 381.

21 Koch’s presentation was able to articulate how to reproduce bacterial cultures of several micro-organisms
including: anthrax, which commonly resulted in the death of farm animals in Germany, and tuberculosis in
1882. Koch attempted, but ultimately failed, at developing a vaccine for tuberculosis, tuberculin, which

Koch’s role allowed him to continue his research and work with those in both
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Europe and Northern Africa to prevent the further transmission of bacterial disease. In his
capacity as a member of the German Cholera Commission, Koch discovered that the
bacteria developed from a foodborne infection. This discovery, ultimately led Koch’s to
translate his findings from the scientific discovery to the implementation of public health
practices that proved crucial for the success of international hygiene commissions.
The scientific research of Koch paved the way for further developments of the
international hygiene movement. By the mid 1860s, the International Sanitary Conference
(ISC) had built on the work of Koch and Snow and concentrated its efforts on cholera as the
disease that Europe needed to prevent from returning.22 In an effort to stop its spread, a
more coordinated international effort centered on effective communication of the necessary
preventive measures needed to take hold. The purpose of the ISC was to serve as a type of
clearinghouse for communicating and developing strategies aimed at disease prevention.23
Among the practices implemented were quarantining of those who had contracted
communicable diseases and simple education about disease transmission. The ISC, however,
was not the only organization that would take this as its mission.
International Hygiene Movements
The ISC was the first in a number of international organizations aimed at
establishing and implementing hygiene standards and practices. As a direct result of the ISC,
the International Sanitary Bureau (ISB) was established in 1902 to implement the strategies
somewhat tainted his legacy as a researcher, see Christoph Gradmann, “Robert Koch and the Pressures of
Scientific Research: Tuberculosis and Tuberculin.” Medical History 45, no. 1 (2001).
Alison Bashford, “Global Biopolitics and the History of World Health,” History of the Human Sciences 19, no. 1
(2006): 67.
22

23 Jeremy R. Youde, Biopolitical Surveillance and Public Health in International Politics, (New York: Palgrave
Macmillan, 2010), 151.
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of the ISC in the Americas. In 1907, L’Office International d’Hygiene Publique was established to
focus on regional European concerns facing the shipyards of European ports. The shipyards
represented potential sources for importing or exporting cholera and/or other epidemiccausing diseases.24 As the growth of the shipping and trade industry continued throughout
the early part of the twentieth century, so too did the development of hygiene commissions.
In addition to the multiple hygiene commissions already established, in 1923, the League of
Nations Health Organization (LNHO) added to the growing list of organizations charged
with preventing the spread of disease. These various international sanitary commissions
assumed the tasks of studying epidemic diseases, revising and administering preventive
guidelines, and preparing international conferences at which important epidemiologic and
public health information could be exchanged.25 By implementing new preventive strategies
and communicating best practices, these institutions became laboratories for studying public
health and hygiene, but, like most research endeavors, funding proved essential.
The institutionalization of the sanitary and hygiene movement ushered in an era of
public institutes of health that required significant financial and intellectual investments in
order to perform the research necessary to prevent the spread of disease. The New Yorkbased Rockefeller Health Commission (RHC) provided funding for research investigating
the cause of disease and its prevention. The Rockefeller Foundation made substantial
contributions to implement the protocols developed by the sanitation movement by
establishing its own health commission in 1913. In its 1914 annual report, the Rockefeller
Foundation reflected on its commitment to “the advancement of public health through
Akira Iriye, Global Community the Role of International Organizations in the Making of the Contemporary World,
Berkley: University of California Press, 2002; Youde, Biopolitical Surveillance and Public Health in International
Politics, 152-153.
24
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medical research and education, including the demonstration of known methods of treating
and preventing disease, afforded the surest prospect of such usefulness.”26 The RHC, unlike
the other hygiene commissions, supported medical research that could lead to new
information aimed at prevention or treatment. In the foundation’s efforts to demonstrate
their successful methods, the RHC centered its U.S. efforts on hookworm disease.
The Rockefeller Health Commission and Hookworm
At the turn of the century, the southern U.S. states were a particularly agrarian
society, and given the nature of the work in the fields, those living in the south had a higher
risk of contracting the disease.27 While cholera contaminated water, the hookworm bacteria
contaminated the soil.28 Hookworm caused “vast suffering, partial arrest of physical, mental
and normal growth, great loss of life, and noticeable decrease in economic efficiency over
vast regions…”29 The U.S.-based program had been able to treat some 500,000 persons by
establishing agencies focused on promoting “public sanitation and the spread of the
knowledge of scientist medicine.”30 These efforts included a focus on personal hygiene, but
also testing the possibilities of “scientist medicine” to gauge dosing amount and frequency.
A.G. Fort reported at the 1914 meeting of the American Public Health Association on
collaborative clinical research between the state of Georgia and the RHC that demonstrated
the effectiveness of particular drugs over others, which resulted in differing mortality rates
26 The Rockefeller Foundation, “The Rockefeller Foundation Annual Report 1913-14,”
http://www.rockefellerfoundation.org/uploads/files/812e6b1a-4785-4d58-b2e3-77eb3f5a2b0d-1913-1914.pdf
(accessed October 17, 2014).
27

Hookworm is a disease that has not been eradicated and remains a problem in 2/3rds of the world.
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amongst those who were compliant versus non-compliant with recommended treatments.
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The RHC wanted to take the collaborative works on hookworm, however, beyond the
southern U.S. states and beyond hookworm.
In their 1913-14 annual report, the RHC described their efforts to combat the spread
of disease through a variety of “military-sanitary campaigns” in collaboration with the U.S.
government. These campaigns extended beyond the U.S. and included work with Britain’s
territories, British Honduras (Belize), Federated Malay States (Malaysia), Fiji, and Australia.32
By 1922, the Rockefeller Foundation was a key contributor to the League of Nations and
was essentially the sole funder of the Epidemiological Intelligence Service of the League of
Nations. In other words, without the Rockefeller Foundation, health-based research in both
the U.S. and abroad would have been quite limited. Furthermore, the targeted and diseasefocused approach of the Rockefeller Foundation played an essential role in influencing the
practice medical research. The RHC’s international and targeted approach to research shifted
from the general sanitary and hygiene practices of the international commissions concerned
with public health. They now took a disease-based approach to medical research that
targeted the treatment of individuals, once treatments regimens were verified through clinical
trials.
From the middle of the nineteenth century through the 1920s, medical research
developed significantly in three impactful ways: understanding of disease, the importance of
public health/hygiene practices, and the necessity of investment in clinical research. John
Snow and Robert Koch distinguished themselves as examples of how diseases came to be
understood and how the spread of disease could be controlled. Building on the work of
31
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Snow and Koch, public health measures proved important as a key development to prevent
the spread of disease and to improve health outcomes. This was one of the key tasks of the
hygiene commissions that served as clearinghouses for best preventive practices. These
practices placed a priority on the needs of the community above those of individuals.
Examples of this can be seen in the practice of quarantine in which one individual was
isolated in order to prevent others from contracting the disease. Yet, prevention does not
always happen, and, therefore, it proved necessary to develop methods for targeted
treatments. Within this initial phase, tension began to develop between disease prevention,
promoted by the public health and hygiene commissions, and disease control, focused on
research for developing curative treatments. The Rockefeller Foundation found itself as one
of the key players in emphasizing research both for prevention and treatment of particular
diseases.
The RHC’s hookworm strategy demonstrated the confluence of the contributions of
epidemiologic and basic science to developing targeted clinical trials aimed at controlling the
spread of disease by treating it and ultimately eliminating it. Their targeted approach to
research and generous financial investments, set the stage for how the Rockefeller
Foundation would shaped development of research during the second phase of research
described in this chapter. This second phase of research was influenced heavily by the two
World Wars, which provided the catalyst for countless developments in medical research
aimed at responding to the acute injuries of soldiers and the importance of health in the
rebuilding of society during the aftermath of war.
Disease, Wars, and the Pursuit of Perfection
The two World Wars provided the catalyst for many technological and scientific
innovations that advanced medical research by focusing on the health of individuals and

their ability to contribute to the rebuilding of a post-war society. With countless economic
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and human resources being poured into the Wars and the expansion of international trade
through the Panama Canal, there was heightened concern about preventing the potential
global spread of a disease. The first example of research in this period highlights a diseasebased approached focusing on disease prevention through vaccine development. Resaerch
on disease prevention research addressed directly the concern about transporting the
contagious yellow fever disease through trade routes, while also allowing for the vaccination
of soldiers fighting abroad. Yet, diseases were not the only threat soldiers faced, the nature
of combat had changed to the degree that wounds sustained in battle had never before been
seen.
The second example described below details the improvements in surgical
innovations for those suffering facial wounds in battle. Utilizing a surgical team comprised
of dentists, surgeons, nurses, and artists to treat persons was an experiment in and of itself,
but also proved significant for enabling soldiers to return from war and function in society
after the war. Being able to contribute to society was crucial following the World Wars. The
importance placed on working in society, and limiting the roles of those who were not
judged to be adequately contributing, was of central importance in the global efforts in
eugenics research.
The final example from this section focuses on the international development of
eugenics programs that reached a crescendo with the Nazi eugenics experiments. While the
Nazi eugenic experiments were the most ethically egregious in their practice, centers for
eugenics were widespread. Eugenics research, in many ways, reduced the measure of
prevention and promotion of health to a genetic level, compared to vaccines that had the
potential to benefit all. Moreover, the differences in eugenics and vaccine research highlight

tensions in priorities of research that had the potential to benefit a select few versus the
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majority. The tensions between health benefit for a few or the many, seem to be fueled
during this period of war and economic expansion as the world became increasingly
interconnected. The beginnings of this interdependence can be seen in the Rockefellersponsored yellow fever research.
Yellow Fever
William Gorgas served as the U.S. Surgeon General in 1914, leading the first of three
Rockefeller-funded yellow fever research teams throughout South America. The first
commission ran from 1914 until 1916, but was halted by the shifting of U.S. resources after
their entrance into World War I in 1917. While the war caused the delay in research, it was
the presence of increased trade routes via the Panama Canal that served as a significant
source of concern for Gorgas. Gorgas, and others, feared that the frequent merchant travel
would add to the prospect of disease spread to the U.S. and beyond. “Yellow fever could be
carried directly to South Africa and India, and through the Panama Canal, to Hawaii, the
Philippines, Australia, and China.” 33 Given the increased risk of the spread of disease, the
importance of developing a treatment, or at the least an etiological understanding of the
disease, became the focus of the work of the next commission in 1918. The second
commission made significant strides toward understanding yellow fever and paved the way
for vaccine development.
Hideyo Noguchi played a key role in the work of the RHC’s second yellow fever
commission in Ecuador. Noguchi believed the cause of yellow fever originated from a

33 John Farley, To Cast Out Disease a History of the International Health Division of the Rockefeller Foundation (19131951), (New York, NY: Oxford University Press, 2004), 89.
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bacterium similar to jaundice. Noguchi reproduced the suspected bacterium by taking
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blood from those who had died from yellow fever and experimenting with potential cures.
By the fall of 1918 he was confident he had discovered a vaccination. 35
That fall, Noguchi and his team vaccinated 325 military members and their families,
for a total of 427 non-immune individuals. Of those vaccinated, only five developed yellow
fever, compared with 386 reported cases in the unvaccinated population. Out of the 386
cases, 217 victims died.36 Given the success of these initial trials, inoculation efforts were
made to expand beyond Ecuador and into Brazil, Mexico, and Peru. After this expansion,
over 20,000 individuals were vaccinated in the region.37 Though widespread research efforts
had begun in Central and South America, the West African arm of the RHC began to
discover results that differed from those of Noguchi.
By the mid 1920’s the West African RHC group had begun to conduct corollary
experimentation following-up on Noguchi’s findings. Their research with monkeys,
mosquitos, and human victims of yellow fever resulted in strikingly different results. In one
such experiment the team drew blood from a human victim and injected it into a host
monkey. Upon showing symptoms, a swath of mosquitos fed upon the monkey. “By
December, the Asisbi strain of ‘virus’ had been passed by mosquitoes through 26 monkeys,
34 Center for Disease Control and Prevention, “Yellow Fever,” Center for Disease Control and
Prevention, http://www.cdc.gov/yellowfever/ (accessed January 15, 2015). Jaundice causes yellow

discoloration of the skin that is frequently linked to liver disease, particularly in forms of hepatitis or gastrointestinal cancers. The initial symptoms of yellow fever include: sudden onset of fever, chills, severe headache,
back pain, general body aches, nausea, and vomiting, fatigue, and weakness.
35 Farley, To Cast Out Disease a History of the International Health Division of the Rockefeller Foundation (1913-1951),
93.
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37 Here some real ethical questions emerge, particularly with respect to informed consent, i.e. did the research
subjects people want to be inoculated? Was the vaccination sufficiently tested? The ethical implications of this
research and the development of bioethics and research ethics in particular will be taken up in Chapter Two.
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all but two of which developed a high fever and died.” This led the West African research
38

team to conclude that Noguchi mistook jaundice for yellow fever. Upon hearing these
results, a disbelieving Noguchi came to work with the West African research team in 1928.
After several weeks of experimentation he concluded that he had made a serious error and
had not developed an effective vaccine for yellow fever. This insight proved crucial to the
continued work of the yellow fever commission in its third phase, a phase marked by an
increased sense of urgency with the looming possibility of biological warfare during World
War II.
Fred Soper served as the regional director during the third commission of the RHC’s
International Health Division in South America. With the disproven results of Noguchi’s
experiments, a greater urgency existed to study the disease more closely. While this included
focusing on vaccine development, it also meant taking measures to control the disease.
During this third phase, Soper and his researchers began the practice of taking liver cultures
from victims to develop vaccines. The preferred method of study was through viscerotomy,
a procedure through which the pieces of liver would be resected from the victims in order to
be cultured and studied. The procedure was performed on persons who died from yellow
fever, or from an unknown fever where yellow fever had not previously been reported. In
order to have access to the deceased, Soper’s group received government authorization to
“prevent burial of anyone dying of a fever until a ‘viscerotomia’ had been performed.”39
Greater access to cadavers allowed for some 14,000 examinations that resulted in the
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discovery of yellow fever in seven states and 25 rural municipalities in which the disease had
never before been reported or suspected.40
The systematic way in which information was gathered and stored gave Soper’s
commission a wealth of epidemiologic data with respect to where people lived, what they
did, and how they might have become infected with the disease. Included in these findings
was the recognition of a higher prevalence of disease in rural locales, as opposed to
urban/port areas, a different outcome than previously expected. The increased etiological
and epidemiological knowledge of the disease garnered during this phase of research proved
important for implementing the next stage of research that included vaccine development.
The ability to produce a successful vaccine was fraught with challenges that
culminated in two mass vaccination campaigns, one targeting Brazilians and the other U.S.
and U.K. military personnel. The development of a vaccine proved difficult because of the
research team’s inability to standardize a method for replicating the virus. Once they could
replicate the virus, they began testing the vaccine on mice. However, rather than developing
immunity, mice frequently became sick or died.41 It was not until a third round of
experiments, in 1933, that a vaccine was produced. The successful development took place
once the virus, “passed through brain-less tissue cultures, became less and less virulent, until
after 114 passages none of the monkeys inoculated with the virus showed any signs of the

40 Ibid. While the results of this third commission led to important discoveries, ethical question arise given the
foreign influence that Soper and the RHC sponsor had within the region. Secondly, the communities in which
they worked were disproportionately poorer than their city counterparts. Third, and perhaps most troublesome,
the research priority allowed Soper and his team to usurp any family preferences of what to do with a family
member after he or she died. Essentially the bodies functioned as cadavers from which the scientists could
learn.
41 Ilana Loewy, “Epidemiology, Immunology, and Yellow Fever: The Rockefeller Foundation in Brazil, 19231939,” Journal of the History of Biology 30, no. 3 (1997): 411.

disease.” Once the vaccine was deemed safe for mice and monkeys, a massive campaign
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began in 1937. During this campaign, 59,532 workers in the coffee plantations of Minas
Gerasi, Brazil were vaccinated.43 The success of this vaccination efforts, led to the 1940
recommendation that all military personnel be vaccinated with the newly tested vaccine.
Between 1940-42, over six million doses of the vaccine were distributed to the U.K. and U.S.
armed forces.
The research on yellow fever points to a confluence of factors that made it an
important field of research, the most influential being new trade possibilities because of the
Panama Canal and the threats during two World Wars. Though this research was not
without its setbacks, particularly those of Noguchi and the death of several military
personnel during the inoculations campaigns, the three yellow fever commissions
demonstrated the importance of translating research from basic science and epidemiology
research to vaccine development and “clinical trials.”44 While these were not official clinical
trials, at least in the way one thinks of trials today, it is worth noting that earlier versions of
the vaccine were repeatedly tested on those workers who played prominently in trade
practices running through the Panama Canal, while others who had no business associations
42
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Here one can see the economic concern of the government. For them, the health of coffee plantation
workers was essential given that coffee was historically the mainstay of the Brazilian economy. Thus, a real
incentive existed for them to give the Rockefeller Foundation free reign in addressing the yellow fever virus,
which stood to benefit both the health of a particular population and allow for important advances in medical
research, not to mention the interests of the newly empowered Brazilian government.
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when the vaccine was mixed with human serum one of the strands was infected with Hepatitis B. This did not
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vaccine. It was only after those vaccines proved successful that over six million service men
from the U.K. and U.S. were then vaccinated.45
By the end of the yellow fever vaccination developments, research on disease and
injuries affecting soldiers during the war had to take utmost priority. The addition of
prophylactic health measures, such as vaccinations, proved crucial in preventing many nonwar related deaths. However, these preventive and public health measures were not the only
life saving innovations during World War II. Individually-focused research proved crucial for
treating injuries suffered in the midst of battle was also needed, given the advances in
weapons technology. These surgical techniques for reconstructive surgeries resulted in truly
experimental medical care.
Maxillofacial Reconstruction
The surgical procedures undertaken to repair and reconstruct facial and head injuries
during both World Wars took an experimental approach to the practice of surgery. The
experimental nature of these surgeries began with the development of new surgical
techniques to the diversity of persons who comprised the surgical teams. At the time of the
First World War (1914-1918), much of the medical community remained unprepared for the
injuries soldiers would face. 46 The trench warfare presented debilitating and grotesque
45 The inequity in the benefits of research and the burden placed on the research subjects raises a pertinent
topic for research ethics. While informed consent has been seen as one of the ethical hallmarks of the yellow
fever experiments, other socio-ethical questions remain. Questions of justice arise when considering the use of
vulnerable populations for research that will not benefit the same community, or vaccinating only a portion of
the community that proved most likely to have negative consequences international trade. Although the
rationale of containing the international spread is certainly important, it does not obviate the responsibility to
ensure that the community in which the disease is endemic is also protected. In this case, the yellow fever
experiments disproportionately benefited those financially invested in the Panama Canal and U.S. and U.K.
soldiers.
46 Donald A. Simpson, “World War I: The Genesis of Craniomaxillofacial Surgery?” Journal of Surgery 74, no. 12 (2004), 72. When reflecting on the historical context of war the French and Germans had not been in conflict

wounds that, when not resulting in death, led to extreme pain, disfigurement, and the need
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for immediate medical attention. The medical care received, however, was primitive and in a
constant state of development. The field hospital, in many ways, was transformed into a
clinical laboratory in which new surgical, anesthetic, and dental approaches were explored.
Though particular types of cosmetic surgery existed already, few techniques demonstrated
the capacity for confronting the sheer volume of never before seen injuries. 47
It seemed impossible to evaluate, let alone to operate on all of those who needed
surgery. However, the large volume of patients allowed for a pool of patients on which to
learn and develop new innovative surgical techniques. In the 1916 Battle of Somme, a
surgical team headed by Australian Harold Gillies saw 2,000 patients in a single day.48 Gillies
served as one of the pioneers in skin grafting. Skin grafting made reconstruction possible
through by utilizing a “tube pedicle enable[ing] surgeons to transfer skin in stages from one
location another while maintaining the blood supply, which helped ensure that grafts would

for over 40 years, in which the innovations of rifles and modern artillery was not of use. British surgeons found
themselves in better position following their involvement in the Second Boer War, fought over land rights in
South Africa from 1899-1902. Despite this preparation the introduction of trench warfare and the proximity of
violent attacks provided a unique challenge.
47 Charles Conrad Miller, The Correction of Featural Imperfections, (Los Angeles, CA: University of California
Medical School, 1908). Miller’s work focused on what today would be considered cosmetic surgery, but this
work was certainly unique during the 1920s. While these injuries were unique, the foundation for some of these
surgical techniques had been developed through, what he descried as, “featural surgery.” Charles Miller, one of
the pioneers in the field, wrote a book on featural surgery describing the type of imperfections that might
benefit from surgical intervention. His list included: the head, folds, bags, and wrinkles about the eyes, face
lifting, palpebral fissures, “double chin,” wrinkles of face and neck, softening of nasolabial lines, forming
dimples, various nasal reconstructive surgeries, external era, the notorious “unduly large mouth.” Miller’s work
in correcting imperfections signaled one of the earliest instantiations of cosmetic surgery. His efforts, more
importantly, laid conceptual groundwork from which further innovative procedures could develop, giving at
least a starting point for helping some of the patients that these surgical teams saw.
48 Caroline Alexander, “Faces of War,” Smithsonian Magazine, February 2007, accessed May 2, 2015,
http://www.smithsonianmag.com/history/faces-of-war-145799854/?no-ist.
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This procedure allowed for better cosmetic results and improved health outcomes
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in these life and death situations.
Those with the most severe injuries received as urgent care of as possible from the
surgical team on-site. Some of the soldiers suffered multiple bullet wounds to the face and
eyes, while for others the bullets passed completely through their head. While these surgical
teams included experts from highly respected universities, Yale, Harvard, Colombia, they all
remained relatively inexperienced in tending to these types of wounds. The inexperience and
diversity of the teams, coupled with the challenges presented by war-wounds, resulted in the
development of different approaches to treat the same problem.
For certain neurological wounds, the Germans opted to leave parts of the brain
exposed in order to allow for free drainage in an effort to prevent infection. Conversely, the
British favored swift operations focused on removing foreign bodies and quickly closing the
scalp.50 In 1917, American neurosurgeon Harvey Cushing utilized an electromagnetic
procedure to extract iron shell fragments and “devised a simple method of debridement by
suction and he urged water-tight two-layer scalp closure. Most importantly, he maintained
meticulous records and surgical audits, finishing with a case mortality of 28.8%, which was
then a marked improvement.”51 Cushing later published his findings, laying the groundwork
for other surgeons working in the field to learn how to treat head wounds beyond the
battlefields. Credit for successful treatments was the result of the interdisciplinary nature of
the surgical teams.
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The successful approaches to treating the wounds seen during World War I
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incorporated an interdisciplinary approach comprised of nurses, doctors, surgeons,
anesthesiologists, dentists, and perhaps the most unique addition to the team came from the
use of artists in facial reconstruction. Artists created masks initially to give a rendering of
what the patient’s face should look like following surgery, but also for a patient to wear
whose surgery was unable to be completed to the team’s or patient’s satisfaction.52
Furthermore, the interdisciplinary nature of the team, at its most basic level, resulted in fresh
ways of thinking through the complex problems that presented in their operating rooms and
led to significant surgical advances.
The increased level of education and the experimental approach to surgical
treatments led to significant advances in patient care. One commentator told the New York
Times, “that medicine and surgery had advanced half a century in four years.”53 While this
statement may tend towards hyperbole, the advances were nevertheless dramatic.
Interdisciplinary teams brought together professionals who had never worked or trained
together to care for patients. The patients they treated would have died in ordinary
circumstances, but were saved through the use of procedures that had never been attempted.
Teams utilizing the different techniques and publishing the results, as Cushing did, allowed
for education to spread beyond the battlefield and into hospitals and medical schools
throughout the world.
The techniques developed not only applied to battle wounds, but also would be
applied to a variety of reconstructive surgeries brought on by disease and non-war related

52

Ibid.; Haiken, Venus Envy, 33; Alexander, “Faces of War.”

53 Haiken, Venus Envy, 31. The Times quote comes from Major George A Stewart of the Rockefeller Institute’s
War Demonstration Hospital.

injuries. Positively, one can say that an interdisciplinary approach to research that targeted
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patients with critical needs resulted in rapid advances in the field and cultivated new
approaches to reconstructive surgery, even leading to the development of the field of
cosmetic surgery. Negatively, however, one might see this type of surgery lending itself to
the objectification of the body when done outside of an emergent medical need. Yet, nonemergent procedures were becoming more frequent throughout the 1930s as beauty and the
striving towards perfection was increasingly becoming a priority. The arguments for
perfection, however, extended beyond the operating room and into eugenic research centers
focused on enhancing particular individuals, while at the same time limiting the participation
several other individuals and social groups deemed less desirable, in the hope of building a
stronger society.
Eugenics
Discussions of eugenic-based research typically center on Nazi scientists during
World War II, but the groundwork for this type of research was well established globally
prior to the war. Eugenics research focused on experiments aimed at genetically enhancing
and improving upon certain genetic traits, and the elimination of others, in the hope of
developing a more advanced society. In a certain sense, the approach was very individualistic
and seemingly beneficial to society. The goal was to find and enhance particular individual
characteristics that made for healthier, stronger, and more independent individuals. This
meant eliminating negative characteristics such as physical disabilities and proclivity for
disease. Yet, while eugenics focused on individual procedures, the intended aim was the
good of society. Sterilizations and even the killing of racially ethnic, and/or religious “sub-
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groups” were just some of the control methods considered by eugenicists that relied on the
contributions of science. 54
From the perspective of eugenics, science served as a tool to maximize the potential
of human beings for the betterment of society. Science focused on improving the quality of
human beings responsible for continuing society’s progress in a variety of forums.
Ultimately, it “would allow man to conquer space, conquer time, overcome ‘the dark and evil
elements in his own soul,’ and ultimately refashion ‘his own body and those of other living
beings.’”55 For eugenicists, science was about human progress and improvement. The
prevalence of this vision made eugenics appealing globally, especially in the economic
depression following World War I. It was thought that by maximizing human potential,
hope would emerge from that the stark economic reality, health challenges, and disabilities
that people faced.
At the turn of the twentieth century, Sir Francis Galton’s research built on the
earlier genetic research of Gregor Mendel to fulfill what he understood to be the duty and
responsibility of a scientist to engage in research aimed at improving the human species as a
whole.56 Galton saw eugenics as a process of “supplanting inefficient human stock by better
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Dennis O’Neil, “Basic Principles of Genetics: Mendel’s Genetics,”
http://anthro.palomar.edu/mendel/mendel_1.htm (accessed November 21, 2014). Gregor Mendel was an
Augustinian Monk who lived and worked in the middle of the nineteenth century. Mendel’s work proved
foundational to the understanding of genetics and allowed for the development of eugenics-based research in
the early part of the twentieth century. Mendel’s contribution to genetics came from findings while working
with multiple generations of peas. His research led to the discovery that only isolated traits develop in offspring
without any “blending of parent characteristics.” It was traditionally held that characteristics of offspring were
formed through an amalgamation of parent characteristics, rather than a predictable pattern resulting in one
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strains, and to consider whether it might not be our duty to do so by such efforts as may be
reasonable, thus exerting ourselves further over the ends of evolution more rapidly and with
less distress than if events were left to their own course.”57 For Galton, science was not
about observing nature, but rather taking control of nature. His scientific focus resulted in a
research fellowship in National Eugenics at the University College of London. In 1904,
Galton and his team of researchers engaged in work that sought to understand differences in
human beings based on race. Galton’s emphasis on race was not unique and fell in line with
much of the work of other eugenic researchers, influencing one of the U.S.’s leading
eugenicists: Charles Davenport.
In 1910, Charles Davenport followed Galton’s lead by starting the Eugenics Record
Office in Long Island, New York. This office focused on establishing “research via houseto-house surveys and by studying records from prisons, almshouses, and institutions for the
mentally deficient, deaf, blind, and insane…the Office supported scholarship students to
study human heredity and collect data, primarily on the subjects of ‘feeblemindedness’…”58
To this end, Davenport’s research concentrated primarily on research subjects who would
have been mostly physically or mentally disabled and were considered unable to contribute
to society. Davenport’s work can best be characterized as negative eugenics because his
efforts centered on methods of eliminating particular characteristics from certain persons. In
the U.S., his research extended beyond the Eugenic Record Office and resulted in state-

or short; seeds round or wrinkled; the seed colors were yellow or green with the pod shape either inflated or
constricted; and lastly that the pod’s color was either yellow or green. More important for genetic and eugenic
research was the fact that he could selectively cross-pollinate purebred plants with particular traits and observe
the impact over these several generations.
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enforced sterilization practices based on any number of “disabilities,” including race. By
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1934, sterilization laws were on the books in 27 U.S. states for “feebleminded” persons.59
These race-related protocols were made possible by the research of Galton in Britain and
Davenport in the U.S. The efforts of Galton and Davenport were furthered by the work of
the Kaiser Wilhelm Institute during the rise of German nationalism.
The Kaiser Wilhelm Institute operated as one of a number of research institutions
that pursued eugenics research for the advancement of society as a whole. By 1922,
Germany joined Great Britain, Switzerland, Sweden, and the United States in establishing its
own research center for eugenics.60 Germany, in many ways, built on already established
eugenics programs, but was divided as to the type of research that ought to be pursued,
positive or negative. A “positive” approach would focus primarily on the promotion of
improvements that could be offered by pairing genetically desired characteristics together.
While initially taking this path, the rise of German nationalism gave way to a negative focus
of genetics research that emphasized the elimination of undesirable characteristics, similar to
the U.S. approach, through sterilization. This type of negative research was exemplified in
the work of Otmar Freiherr von Verscheur.
Von Verscheur became the director of the Kaiser Institute in 1942, and played a key
role in establishing the research priorities in the concentration camps.61 He was a noted
“racial hygienist” who, in his primer on race hygiene, took six pages to detail the “racial
Harriet A. Washington, Medical Apartheid: the Dark History of Medical Experimentation on Black Americans from
Colonial Times to the Present, (New York: Doubleday Press, 2006), 202-203. By 1941 somewhere between 70,000100,000 people had been sterilized, and, as Harriet Washington notes, a disproportionate number of those
people were black.
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genetic differences between Jews and Germans and the various forms of separation which
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were, at the time, imposed on Jews and [Roma].”62 It is the relationship between race and
genetics that becomes the driving force, not only of his research, but also that of much of
the research conducted in Nazi Germany. Moreover, Von Verscheur’s previous work on
genetics and twins proved important to the work of the notorious “camp doctor” at
Auschwitz, Josef Mengele.63
Mengele’s research agenda in Auschwitz centered on race and infectious disease,
which included experiments that required the killing of and subsequent dissection of Roma
twins. He attempted to decipher genetic differences among “Jews, [Roma], and others who
proved resistant to various infectious disease in particular to tuberculosis and typhoid.”64
Many of Mengele’s experiments focused on infectious disease, genetics, and resistance to
specific diseases including tuberculosis and typhus. Mengele’s hypothesis was that genetics,
inclusive of race, proved indicative of those likely to contract and/or disseminate disease.
While his research did not prove this to be true, it did not disprove the theory either. In fact,
his research bias has been influential in the way in which research developed throughout the
remainder of the century, which initially focused exclusively on white males, and certainly
contributed to some of the current debates in health disparities and outcomes research.65
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Though eugenics research may have prompted broader ethical considerations in
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research—explored in Chapter Two—it nevertheless focused on the importance of research
that benefited the health of society, even if only the minority within society. In fact, all of the
research in this period tried to balance the needs of individuals with those of society. The
scientific efforts of the Rockefeller yellow fever commissions, the emergence of plastic
surgeons, and even eugenic researchers used medical research—at least from their
perspective—to improve society. Vaccine development addressed the health needs of
workers in South America in developing a vaccine that was useful with the opening of the
Panama Canal and the onset of two World Wars. The surgical techniques, while focused on
improving the health of individuals, the real impact was on the interdisciplinary nature of the
surgical team and the unique procedure being performed. These efforts were so unique that
a new medical specialty, cosmetic surgery, was born. The post World War era, however, saw
a shift in the types of medical research projects pursued. The Wars brought a new
perspective to the importance of controlling diseases and the global impact that research can
have on the health of persons.
Medical Research: More of the Same or a New Era?
The third phase in the development of medical research began in the late 1950’s and
endures through the present. This phase of research begins to take into account the global
reality of disease and the potential role of medical research to alleviate some of these
burdens. The paradigmatic examples in this period focus on diseases that potentially affect
everyone. Though individual expertise within the disciplines of basic science, clinical, and
epidemiologic research constantly improved, addressing the complex challenges of global
health required a collaborative and interdisciplinary approach to research. The epidemiologic
emphasis on the eradication of smallpox, the first example, demonstrates the need for both

interdisciplinary and multi-national collaboration between basic scientists, health care
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workers, and public health experts. The process of eradication took years to achieve, but still
provides a model for preventing the global spread of disease by focusing on the low-income
countries where the infectious disease was endemic.
The second and third examples, the Veteran’s Administration (VA) clinical
hypertension studies and developments for treating malaria through synthetic biology, focus
on the importance of institutional collaboration to treat two global threats to health. 66 The
VA hypertension studies demonstrate the importance of clinical trials and introduce the
“gold standard” of the double-blind placebo controlled trial. At the time of the VA study,
there was much debate surrounding the health risks of high blood pressure, and the doubleblind placebo control trial removed researcher bias in observing the different outcomes of
those being treated compared to those in the control group. Unfortunately, malaria research,
the third example, is not at the clinical trial stage.
It is, however, the hope of U.S. researcher Jay Keisling that, through synthetic
biology, new treatments will emerge from his work. Synthetic biology is a relatively new field
of research that has played an important role in the creation of new and previously unknown
biological phenomena through scientific engineering. Most recently, it has been applied to
the production of artemisinin in the hope of addressing the global health challenges

66 World Health Organization, “The Top 10 Causes of Death,”
http://www.who.int/mediacentre/factsheets/fs310/en/index1.html (accessed December 20, 2014). It is worth
noting that stroke and ischemic heart disease are the leading causes of death in lower-middle, upper-middle,
and upper-income countries. In low-income countries stroke and ischemic heart disease are four and five,
respectively. In Chapter Three, I will return to the importance of taking social and economic factors into
consideration in establishing research agenda. While malaria does not rank among the leading causes of death
when considering all countries, it does rank in the top five causes of death in low-income countries. Thus, at a
time when millions of resources are being focused on genetic research, synthetic biology represents a unique
approach to addressing problem primarily of low-income countries.
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progress towards discovering a cure for one of the great challenges in global health.
These three examples address a range of needs in global health research, which
provides the context for research today. Global health research focuses on health concerns
that exist on both a local and international level. In this way, research undertaken locally has
global ramifications. Yet, as will be described in Chapter Four, pressing global health needs
do not always receive priority in research. These examples represent a departure from the
type of research that tends to focus more on individual or personalized approaches to
research. On the contrary, global health research emphasizes the importance of the health of
the community and communities. While this emphasis is not assumed at the exclusion of
individual health concerns, it certainly prioritizes research that will improve the health status
of a large portion of the community both locally and globally. It is the focus on research that
is both local and global that characterizes the multifaceted effort to eradicate smallpox.
Smallpox
In 1980, the World Health Organization (WHO) officially declared the eradication
of smallpox. The eradication process was a complex journey driven by a confluence of
factors, the least of which was the scientific capability of eliminating the disease. Though the
ability to inoculate against smallpox was discovered in 590 BCE in China, it took over 2,000
years for smallpox to be eradicated.67 Smallpox represented a constant health threat that had
historically passed indiscriminately between the rich and poor. The disease seemingly struck
at random and was fueled by prolonged human-to-human contact during the critical period
of contagion. As living conditions improved in most of the global north, the conditions for

67 David A. Koplow, Smallpox the Fight to Eradicate a Global Scourge, (Berkeley, CA: University of California
Press, 2002); Youde, Biopolitical Surveillance and Public Health in International Politics, 68.

35
the majority of the world in the global south remained unchanged and ripe for the spread of
a disease such as smallpox. The facility with which the disease was transmitted made it a
challenge to contain.
Smallpox was a variola virus that presented as a rash and appeared in both a major or
minor form. Variola minor was less common and less deadly, resulting in the death of
approximately 1% of persons that contracted the virus. In contrast, the variola major
accounted for about 90% of all smallpox cases, of which 30% proved to be fatal.68
Characteristics of its transmission included relatively close contact, either through the air or
physical contact with another person, and were secondarily transmitted through clothes,
sheets, and rags.69 Historically there were persons who proved more likely to contract the
disease than others. Medical students, nurses, doctors, hospital staff proved more susceptible
to the disease because of their work with the unprepared bodies, skin legions, shrouds, and
dissection.70 The incubation for smallpox typically lasted from 7 to 17 days, and averaged 12
to 14 days.71 Once a person had become infected there was no cure, though if they survived

68 Center for Disease Control and Prevention, “Smallpox Disease Overview,” Center for Disease Control and
Prevention, http://www.bt.cdc.gov/agent/smallpox/overview/disease-facts.asp (accessed December 14,
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71 Center for Disease Control and Prevention, Smallpox Disease Overview; Youde, Biopolitical Surveillance and Public
Health in International Politics, 65. My subsequent understanding and explanation of smallpox’s disease process
relies the descriptions offered by the CDC and Youde. The second phase of the disease was associated with
high fevers ranging from 101-104, aches, chills, vomiting, and could last from 2 to 4 days. At this point a
person had become contagious though not the most contagious, which took place during the third stage. It was
in this third stage that a rash spread from the mouth and tongue to the arms and legs. This rash took
approximately 24 hours to spread over the entire body. The sores in the mouth broke open and released a large
amount of the virus. The rash that covered the body now became a series of raised bumps that resembled
chickenpox. At this point sores filled with an opaque fluid forming a depressed center. This depressed center
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person with smallpox and lasted about four days. The bumps formed pustules that were firm to the touch, and
the pustules began to scab over and fall off within three weeks. While the person was most contagious during
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person initially became contagious with relatively mild flu-like symptoms that quickly
escalated into a rash and raised bumps that secreted a highly contagious fluid passed easily
from individual to individual. Thus, the most crucial aspect of the global effort to eradicate
smallpox was the urgency of identifying the individual who was the source of the infection
and to develop a coordinated effort at containing the disease.
By the latter half of the twentieth century, smallpox had been virtually eliminated
from high-income countries, leaving the disease burden resting on low and low-middleincome countries in Asia, Africa, and South America.72 In 1958, the World Health
Organization (WHO) considered mounting a global campaign to eradicate smallpox at the
behest of Viktor Zhdanov of the Soviet Union. He noted that there remained only 59 global
states in which smallpox existed, and proposed an effort to inoculate 80% of the world’s
population within two years. This quick turnaround, however, required the immediate
training of health workers to respond more readily to the disease.
Zhdanov’s insistence proved important not only for the validity of the argument he
was making, but also for the reemergence of the Soviet Union as a member of the WHO
assembly for the first time since 1949. Zhdanov and his country were crucial to the plan,
because it could demonstrate an eradication plan for smallpox that mimicked important
features of a global plan, i.e. a large land area with a varied climate and a diversity in
population and cultures. Though the Soviet plan took longer than expected due to a
constrained budget, an increase in financial resources—by 1966 $2 million would be given
the transformation from a rash to raised bumps, the individual remained highly contagious over the course of
the next three weeks. It was not until the person’s scabs had fallen off that they were no longer contagious.
72 Youde, Biopolitical Surveillance and Public Health in International Politics, 69. The last reported case from the U.S.
was 1949 in Texas, while Western Europe saw its last case from Portugal in 1953.
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annually to the cause for the next five years—facilitated more effective results. By 1973,
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Brazil and Indonesia both were declared free of smallpox. India, who had been home to
over half of the world’s smallpox cases, joined the list of smallpox-free countries by 1975.
Finally, in 1977, Ali Maow Maalin, a Somalian man who ultimately survived the disease,
contracted the last known case of smallpox.
The eradication process of this disease was made possible through the collaborative
efforts of different nations and the coordinated training of health workers, financial support,
political good will, scientific ingenuity, and timely action on the part of on the ground
surveyors. The targeted efforts on smallpox allowed for the translation of medical research
beyond the laboratory and clinic to transform the health of persons. While individuals
ultimately benefited, it was out of concern for public health that the WHO eventually
championed the issue. The coordination through the WHO made the eradication of
smallpox possible by facilitating international collaboration and sharing of scientific findings
amongst the research team. The collaborative approach espoused by the researchers, which
proved crucial to Zhdanov’s plan, remained essential for addressing future challenges in
global health.
Given the recent outbreaks of the Ebola, the lessons of smallpox eradication efforts
prove relevant once again. Focus on controlling or eradicating a disease requires moving
beyond political differences, economic concerns, and making a concerted effort to involve a
variety of health professionals. While many national research programs have been reluctant
to take on the health challenges that plague primarily low-income countries, Ebola heightens
In part the slow start was due to the then director of the WHO, Macolino Candau, was uncertain of the
possibilities of a successful eradication campaign, particularly since none of its kind had been attempted before
and the current malaria campaign had been floundering. See “Smallpox: Dispelling the Myths,” Bulletin of the
World Health Organization, 86, no. 12, 2008. It is also worth noting that the U.S. alone spent $150 million in 1967
and 1968 to mitigate the spread of smallpox within the U.S. Youde, Biopolitical Surveillance, 75.
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need collaborative partners to focus on eradicating and controlling the spread of infectious
disease. These responsibilities, however, extend beyond research, to call on these institutions
to work for social change.74 Medical research, in the case of smallpox and the present case of
Ebola, demonstrates one way change might come about.
Although global infectious disease remains a pertinent issue, many Western and
high-income countries have opted, instead, to focus research efforts on discovering cures for
chronic diseases facing individuals. The rise of research on chronic disease became a focus
of high-income countries by the 1960s. One of the first priorities that the NIH addressed on
a large-scale clinical trial was hypertension. While today many are aware of and treated for
hypertension on a daily basis, it was once not thought of as a serious threat to health. The
VA study demonstrated that it was in fact a real health concern that benefited from
treatment.
VA Hypertension Study
Though evidence of hypertension existed as far back as 2600 BCE, measuring of
blood pressure only became a consistent medical practice within the last century.75 One of
the earliest references—around the second or third century BCE—to high blood pressure
came from the Chinese medical textbook, Yellow Emperor’s Classic of Internal Medicine. Early
Chinese research identified too much salt in foods as a factor that contributed to increase
blood pressures. Other descriptions described dangerous blood pressure as “firm, rapid, and

The 2014-15 Ebola outbreak will be revisited in more detail in Chapter Four (p.172), and the role of potential
collaborative solutions, particularly as they pertain to the Catholic university, will be explored in Chapter Five
(p.222).
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large…” These descriptions offered by Chinese-medicine, however, lacked the capabilities
76

to prove their hypothesis. However, life insurance companies, not physician researchers, led
the way in studying the associations between hypertension and mortality.
In the early 1900s, life insurance companies in the United States began to take
concerted interest in discovering why and how their clients were dying. Their inquiries led
them to conduct clinically relevant research into the health concerns of those with high
blood pressure.77 The research consistently showed a higher mortality rate with those who
had higher blood pressure. Despite the evidence, however, hypertension was dismissed
frequently as a cause for concern in the medical community. In 1912, Sir William Osler, a
foundational figure in medical educational, dismissed high blood pressure as a medical
problem and advised against its treatment. He stated, “The extra pressure is a necessity-as
purely a mechanical affair as in any great irrigation system with old encrusted mains and
weedy channels. Get it out of your heads, if possible, that the high press is the primary
feature, and particularly the feature to treat.” 78 While Osler saw high blood pressure as
natural, others regarded it as a potential health risk and began treating it through surgical
interventions. Surgery, however, was often seen as a last resort and gave way to less invasive
pharmacological remedies. With the shift to pharmacological treatments, clinical trials were
needed to confirm if treatment would decrease a patient’s blood pressure.
By the 1940s, James Shannon stood at the forefront of establishing standards for
clinical research beginning with the development of anti-malarial drugs, which had
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unforeseen effects on hypertension research. One of the key drugs that Shannon and his
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research team used was chloroquine. However, through the research process it was noted
that some malarial strains were resistant to chloroquine and that an alternative or
complementary drug was needed to ensure its success. The supplement drug, pentaquine,
came to have a significant role not only in the treatment of malaria, but also as an initial
treatment for hypertension.
By the end of the decade, Shannon became the lead researcher at the National Heart
Institute and brought a familiar colleague with him, Edward Freis. Freis had already given
pentaquine to 17 patients with moderate to severe hypertension, and after several days of
treatment their supine blood pressure—taken when the person is lying down, which allows
blood to flow more easily throughout the body—fell between 10% to 40% below baseline.80
This immediate drop lowered their risk of heart attack, stroke, and heart failure. Though
pentaquine came with some debilitating side effects, it demonstrated an initial benefit of
treating patients with high blood pressure, while simultaneously underscoring the need for
more research.
In 1964, Edward Freis continued his research by conducting an unprecedented
collaborative study between 17 VA hospitals, utilizing a previously untried methodological
approach to clinical research. Given the skepticism about the need to treat high blood
pressure at all, any study undertaken had to demonstrate, without bias, a clear benefit for
treating patients. In order to achieve unbiased results, Freis coordinated a multi-site
randomized double-blind placebo-controlled study. In this type of study, multiple VA
Thomas J. Kennedy, “James Augustine Shannon, August 9, 1904-may 20, 1994,” Biographical Memoirs National Academy of Sciences 75 (1998), 357.
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41

treatment and who received the “placebo” or non-therapeutic treatment. Both groups were
selected at random, and were not deliberately chosen by any particular criteria. This type of
research, and on such a large scale, had never been tried before. Yet, neither the size nor
scope of the study was as impressive as the results that forced important changes in clinical
practice.
The results of the VA study demonstrated the effectiveness of a drug combination of
thiazide diuretic, reserpine, and hydralazine at lowering blood pressure.81 In total, 523
patients were enrolled and randomized into a treatment group and a control group. After 18
months of treatment, the study of the placebo group had to be stopped because of the
disparity that existed in the morbidity and mortality outcomes. Freis reported the following:
Four of the 70 patients in the control group died as a result of cardiovascular
complications as compared to none in the 73 treated patients…17 patients in the
control group developed non-fatal complications, such as the malignant phase of
hypertension, severe congestive heart failure, cerebral hemorrhage, or disabling
cerebral thrombosis… an additional 6 control patients developed non-terminating
events, including mild congestive heart failure, myocardial infarction, and nondisabling strokes…over the period of follow-up the incidence of cardiovascular
complications was 27 in the placebo group versus only one in the treated group...19
deaths due to cardiovascular causes had occurred in the control group versus 8 in the
treated group. The most frequent cause of death was either myocardial infarction or
sudden cardiac arrest…11 occurred in the control group and 6 in the treated group.
Stroke was the next most common…eight in the placebo group versus only one in
the treated group….56 (28.9 percent) of the control group developed cardiovascular
complications during the trial, compared to 22 (11.8 percent) of the treated group.82
Freis’ observations demonstrated a clear benefit to those in the treatment group, and the
consequences for those not being treated were so equally clear and dangerous that the trial
81 U.S. National Library of Medicine, “The Edward D. Freis Papers,”
http://profiles.nlm.nih.gov/ps/retrieve/Narrative/XF/p-nid/155 (accessed January 2, 2015); Laragh,
Hypertension : Pathophysiology, Diagnosis, and Management. The following description draws on Freis’s own narrative
of the case in an historical essay as well as the summary of the VA study compiled by the National Library of
Medicine.
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had to be stopped. The results pointed to a conclusive link between mitigating the effects of
hypertension through treatment and positive health outcomes. The conclusiveness of the
study led to increased funding from the NIH for developing safer and more effective drugs,
setting in motion a series of initiatives for further improvements in the treatment of
hypertension.
Over the next three decades, hypertension research continued to build on Freis’ VA
study through clinical research aimed at controlling hypertension, reducing mortality, and
increasing nutritional intervention. After 30 years of exclusive focus on pharmacological
treatments, more studies began to explore the effectiveness of reducing hypertension in
patients through a combination of therapeutic drugs with nutritional and hygienic
intervention. More recent focus has centered on studying the combined effects of other
diseases, such as those suffering with hypertension and diabetes.83 While much progress has
been made in anti-hypertension research, Freis’ study distinguished itself as the first to
address treatment options for high blood pressure by utilizing a new type of clinical research.
Perhaps more prominently, his work demonstrated the potential of a collaborative project by
coordinating the research and staff of 17 VA hospitals. Both the new methodological
approach and the participation of multiple hospitals contributed to a process that tried to
eliminate bias, which proved fundamental for a study surrounded by so much skepticism.
Freis’ research on hypertension, which has now become a global health challenge,
has allowed for research to continue in low and middle-income countries.84 However,
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chronic disease, such as hypertension, in lower income countries is often experienced along
side infectious diseases. In these areas, infectious disease remains a more persistent health
threat.85 One of the more prominent diseases faced in low-income countries is malaria,
which ironically played a crucial role in the story of hypertension research. While there are
treatment protocols in place, malaria still remains a global problem that has defied traditional
therapeutic remedies. To this end, alternative approaches to searching for anti-malarial
treatments and cures have been undertaken with promising discoveries surfacing through
synthetic biology.
Synthetic Biology
As breakthroughs in chemistry saw the deconstruction of molecules and geneticists
were able to observe entire strands of DNA, synthetic biologists focused on isolating genes
and reconfiguring molecules in order to study the effects of their interaction in a newly
created environment.86 The breakthroughs in chemistry, genetics, and biology throughout
the 1960-1990s provided the foundation for the development of synthetic biology in the
early 2000s.87 Two of the key elements necessary for synthetic biology to function rely on the
building blocks of biology and systems biology. Biology focuses on the micro level by
studying life through its functions, structures, developmental stages, environment, species,
etc. In contrast, systems biology operates on the macro level, organizing the vast diversity of
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biological study into a “quantitative understanding of natural biological systems.” This
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quantitative understanding creates opportunities for deeper knowledge about the way in
which particular biological processes function as a unit. For synthetic biology, it is important
to have the biological understanding of how these units function and to be able to both
break down and rebuild them.
The reconstruction and deconstruction of biological units requires engaging with
principles of engineering and biotechnology in order to create phenomena that do not exist
naturally. In terms of deconstruction, synthetic biology uses available biotechnologies to
break down existing biological entities into distinct and unique properties that do not
otherwise exist independently in the natural world. An example of deconstruction would be
the unraveling biological life by breaking it down to minimal set of genes that when
separated can be utilized in artificially creating simple and manageable structures. Likewise,
the constructive nature of synthetic biology requires the technological capabilities to
reconstruct the previously deconstructed biological bits.
Isolating a genome of one organism and, constructively, inserting that isolated
genome into the cellular properties of a completely distinct, albeit related, organism creates a
new entity by utilizing biotechnology and bioengineering.89 First, a new entity is created
because the cellular properties of isolated genome A do not exist as a part of organism B. In
this complex processes, it is the combination of biotechnology, engineering, coupled with an
understanding of biology, and systems biology that make these developments possible. In
this light, one can see how synthetic biology inherently functions interdisciplinarily.
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Furthermore, while its interdisciplinary nature is unique, what truly sets synthetic biology
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apart is the creation of new biological phenomenon or phenomena with the potential for a
variety of applications as indicated by patenting trends pertinent to synthetic biology.
Since the early 2000’s, patents for synthetic biology developments have been on the
rise. While more time will be spent on the function of patents in Chapter Four, for now
suffice it to say that a steady increase in patents indicates a certain level of scientific
innovation and prioritization of a particular type of research with the potential for generating
an economic return on investment. The U.S. has shown the most success for patenting
innovations related to synthetic biology. A recent survey indicated that the U.S. is
responsible for approximately 45% of the global patents in synthetic biology from 19902010.90 Synthetic biology patents with potential application in the area of medicine constitute
a small percentage, 13.8%, of the overall percentage of patents held. Most of these patents
are filed for by businesses, followed by universities and colleges, individuals, and research
institutions.91 The focus of these patents for medical research centers on both treatment for
and understanding of disease mechanisms. Currently, one of the efforts in synthetic biology
research that holds the potential to have significant consequences for global health is the
work being done on artemisinin, used in the creation of antimalarial drugs.92

90 Davy van Doren, Stefan Koenigstein, and Thomas Reiss, “The Development of Synthetic Biology: a Patent
Analysis,” Systems and Synthetic Biology, 2013, vol. 7, no. 4: 209-220. The language in the literature uses synthetic
biology and synbio interchangeably.
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Doren, et. al., ““The Development of Synthetic Biology: a Patent Analysis,” 213.

92 Anne E. Osbourn, Paul E O’Maille, Susan J. Rosser, Keith Lindsey, “Synthetic Biology,” New Phytologist 196,
no. 3 (2012), 673. In this example, rather than turning to artemisinin one could also look at In 2012 in Bristol,
UK, Northwestern University (Chicago, USA) professor Sam Stupp presented strategies in which chemical
structures were capable of signaling the mechanisms necessary for tissue growth, which hold “enormous
potential for the formation of human tissues and organs in regenerative medicine and for the development of
cell-like micro scale objects that can be targeted for therapeutic purposes (e.g. artery repair, drug delivery).”
Stupp’s research is an example of the constructive and applicative nature of synthetic biology to medical
research.
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The WHO estimates that 3.4 billion people are at risk of contracting malaria, and in
2013 the disease was responsible for close to 600,000 deaths, most of whom were African
children.93 African children are the most vulnerable population for contracting malaria, and
despite reducing mortality rates by 58% since 2000, one child in Africa dies each minute as a
result of the disease.94 Given malaria’s disproportionate inclination to infect persons living in
low and middle-income countries in the global south and the limited resources for research
on the disease within these areas, taking up malaria research addresses an unjust disparity in
research and disease burden that affects the global south. Yet, the possibilities of eradicating
or controlling malaria are often cited as being too costly due to drug resistant strains.
Drug resistant strains of malaria are typically treated with artemisinin-based
combination therapies (ACTs); however, acquiring artemisinin naturally is a costly and laborintensive process. To harvest the necessary artemisinin-base begins with its extraction from
dried leaves of the herb a. annua, a sweet wormwood plant found in Asia and East Africa. In
order to produce five kilograms of artemisinin, 1000 kilograms of dried leaves have to be
planted and cultivated from approximately 17,000 hectares (ha) or 42,000 acres of land.95
While recent efforts at increasing the total acreage have begun, the global yield falls far
below the global demand. This has led Jay Keasling, and others conducting research in
synthetic biology, to explore the possibilities of producing the precursor to artemisinin,
artemisinic acid.

93 World Health Organization, “Malaria,” http://www.who.int/mediacentre/factsheets/fs094/en/, December
2014, (accessed April 3, 2015).
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95 Victoria Hale, et al., “Microbially Derived Artemisinin: A Biotechnology Solution to the Global Problem of
Access to Affordable Antimalarial Drugs,” American Journal of Tropical Medicine and Hygiene 77, no. 6 (2007), 198.

Keasling’s research looks to construct a new metabolic pathway that allows for the
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possibility of producing the artemisinic acid necessary for ACTs. He and his team at the
University of California-Berkeley developed a biosynthetic pathway that consists of bacteria,
yeast, and the plant’s own gene, to identify the specific genes that initiate a annua’s
production of artemisinic acid. The bacteria, yeast, and genes were placed into a “bacterial
chassis,” an instrument capable of synthesizing a plentiful supply of “isoprenoid precursors”
that do not typically function outside of the biological acid producing process in the a annua.
Through the synthesizing process, researchers were able to identify a single-gene that
catalyzed the three oxidation steps necessary to produce artemisinic acid. Though the
process detailed above is complex, it can be broken down in a way that demonstrates how all
of the parts work together to create this synthetic product. The biological part is the a annua.
The biotechnology used is both the chassis, which allows for the systematic deconstruction
of the genes to their microbial function, and the technology that enables the insertion of the
specific biosynthetic gene into this process of creating artemisinic acid. It is the
reproduction of the naturally occurring three-step oxidation that makes this a work of
synthetic biology.
The work of Keasling serves as one example, though an important one, of the
possibilities that basic science research holds for future breakthroughs in global health
research. While the focus on this particular endeavor is highly technical, its potential for
broad application could go a long way in addressing the injustices of malaria’s disease
burden. One challenge, however, is that this type of research is not cheap. Keasling’s work
has been made possible in part by a $53.3 million gift from the Bill and Melinda Gates
Foundation and the collaborative efforts of UC-Berkeley, the nonprofit organization PATH,
Amyris a leading synthetic biology innovator, and the France-based pharmaceutical company

Sanofi.

96

While successful collaboration is important and implementation of the project
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could provide ACT treatment to over 200 million malaria infected persons, Keasling and his
researchers have only been able to produce the artemisinic acid necessary for initial testing of
new ACT-based malaria treatments. Thus, uncertainty still surrounds this research, which
will be costly and in need of support without a guaranteed return on investment.
Nevertheless, the success of Keasling’s project reinforces a common theme
throughout the development of medical research in this third phase, which is the importance
of an interdisciplinary and institutionally collaborative approach. The example of malaria
research, requires the efforts of educational, pharmaceutical, biotechnology, private
foundations, and non-profits entities to put the research efforts of Keasling and his team
into practice. Without this collaborative approach global health challenges that unjustly
affect the lower income countries of the global south might continue to go unmet.
Conclusion
Medical research from the end of the nineteenth century to the present day has
balanced prioritizing the health needs of individuals against those of the larger community.
The definitions of medical research given by international institutes for research, described at
the beginning of the chapter, articulate the wide range of values operative when considering
the rationale behind investing in medical research. The U.S., U.K., and France each
emphasize the importance of health research focuses on economic returns and technological
innovation. In contrast, India’s Council for Medical Research places a higher value on
research that demonstrated clear public health benefits with little value focused on the
technological or economic contribution of research. A low-tech public health approach was
96 Robert Sanders, “Launch of Antimalarial Drug a Triumph for UC Berkeley, Synthetic Biology,”
http://newscenter.berkeley.edu/2013/04/11/launch-of-antimalarial-drug-a-triumph-for-uc-berkeley-syntheticbiology/, April 11, 2013, (accessed April 2, 2015).
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characteristic of the first period of research highlighted by John Snow, Robert Koch, and the
multiple sanitary commissions, where efforts centered on improving the health of the
international community. The goal of improving public health served both the interests of
the community in which research was being conducted, but also held political and economic
importance for those communities.
The second phase of research, from the early 1900s into the 1950s, was characterized
by focusing on the health of particular communities. The efforts of the yellow fever
experiments of the Rockefeller Foundation centered on communities in South America
upon the opening of the Panama Canal, in order to ensure that yellow fever did not easily
spread through the new trade routes. Perhaps initially unexpected, yellow fever research
came to provide a great benefit to the war efforts by enabling the vaccination of some six
million U.S. and U.K. military personnel, contrasted with only 60,000 Brazilians. This
disparity in benefits of research is one that will continue to be raised throughout the
dissertation and highlights the importance social justice when considering research ethics.
Research ethics—the focus of the next chapter—has more traditionally focused on
protecting the rights of research subjects. While the protection of research subjects has been
vital, particularly during the periods when the rights of certain minority groups have been
ignored, research ethics should also be concerned with social ethics issues. One such
concern should aim to ensure that research efforts do not become too narrowly focused on
one particular group, neglecting more urgent health needs of other groups. It is the
temptation to focus on particular health needs of individuals and particular groups over
others that proves endemic to the examples in the second phase of research development.
However, the examples from the third phase of the development of medical research
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indicates ways in which a balance might be struck between addressing public and individual
health needs.
The efforts in synthetic biology signal the type of basic science research needed to
address increasingly more complex global health challenges. The smallpox eradication efforts
demonstrated the potential that large-scale research and public health efforts can have
through institutional collaborations. Collaboration was at the heart of Freis’s successful
hypertension studies between the VA hospitals. While at the time hypertension was only
emerging as a U.S. problem, the research that has developed from Freis’s work proved
foundational to addressing the global problem of heart disease related to high blood
pressure. This third period, in particular, demonstrated the importance of institutional and
interdisciplinary collaboration, which would not have occurred without financial and
intellectual investments in a variety of public and private entities.
This First Chapter has drawn attention to the multiplicity of players that have
contributed, and continue to contribute, to the progress and priorities of medical research.
While examples from the final phase focused on medical research that specifically addresses
global health challenges, these challenges often go neglected. In fact, as will be outlined in
more detail in Chapter Four, the most urgent health needs of people in low-income
countries tend to be under researched compared to the health needs in high-income
countries.
Estimates indicate that 90% of the medical research conducted, stands to benefit
only 10% of the global population.97 This unjust disparity indicates that the current state of
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research priorities needs to be reevaluated if global health needs of the majority of the world
are to be addressed. While research ethics, the focus of the next chapter, offers a way of
protecting the rights of research subjects, it fails to address the social inequities within the
practice of research itself. Thus, after considering the important role of research ethics—
despite its limitations—Chapter Three will argue that an epistemological shift of medical
research is needed in order to consider more seriously the health needs of the “poor
majority” that often go neglected.

CHAPTER TWO
THE CODIFCATION OF RESEARCH ETHICS
Introduction
In the midst of the medical research innovations from the middle of the Nineteenth
Century to the current technological practices of the Twenty-first Century, human subjects
begin to play an increasingly important role in the process of conducting research. The
paradigmatic examples in the previous chapter trace the development of medical research,
but paralleling these developments were questions about the ethics of research and the rights
of research subjects. These debates reach a crescendo after the Holocaust with the
development of the Nuremberg Code.
The code, while responding to the use of unethical and illegal practices against
Jewish prisoners, draws upon prior unethical practices of research. The previous legal cases
raise questions pertaining to research perpetrated against prisoners and prostitutes, who were
frequently enrolled as unknowing or uninformed participants in scientific research. However,
even after the condemnation of Nazi research at the Nuremberg trial, violations of the rights
of research subjects continues to occur. The continuance of unethical research practices
results in the development of guidelines aiming to prevent the unethical and illegal conduct
of medical research.1

Jenny Hazelgrove, “British Research Ethics After the Second World War: The Controversy at the British
Postgraduate Medical School, Hammersmith Hospital,” in Twentieth Century Ethics of Human Subjects Research:
Historical Perspectives on Values, Practices, and Regulations, ed. Volker Roelcke and Giovanni Maio (Stuttgart: Franz
Steiner Verlag, 2004), 181.
1
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The Nuremberg Code, followed by Declaration of Helsinki (1964), and the
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Belmont Report (1978), establish necessary ethical foundations intended to guide research
on human subjects. In one way or another, each of these international codes takes up ethical
and legal questions arising from medical research practices that reflect social questions of the
day. Despite the complex social and ethical questions surrounding the origins of these
documents, the implementation of normative guidelines foster only a minimum ethical
requirement protecting individual rights or the urging the physician to take responsibility to
do no harm. Therefore, regulations guiding the ethical conduct of research concentrates on
the individual participants, at the expense of the socio-ethical questions that surround the
origins of the documents.
The social and historical context provides a necessary dialectic for developing a
research ethic capable of responding to question of individual and social ethics for research.
Without this dialectic, research ethics functions more as a formulaic checklist of do’s and
don’ts. While a checklist proves beneficial, it cannot be the sole consideration when
evaluating the ethics of a research study. Moreover, the parameters of the ethical conduct of
research have to consider the social contexts in which research takes place.
This chapter emphasizes the importance of the socio-historic contexts in which these
foundational international documents took shape, a nuance that becomes minimized in their
practical application to research.. It does so in the hope of reconsidering discussions around
both medical research and research ethics within a framework of social ethics. Part one
explores the Nuremberg Code, which is often considered to be the first document detailing
the ethics of human experimentation. The Nuremberg Code served as a reflection and

2

codification of already established ethical norms that the Nazis simply disregarded. Even
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after the issuance of the Nuremberg code, researchers were slow to fully adopt some of its
key elements. In part, this was due to the historical events surrounding Nuremberg, which
made the code difficult to translate to “normal” settings of research. Thus, shortly after
Nuremberg, in 1954, the doctors of the World Medical Association (WMA) began their own
conversations to develop ethical guidelines for the practice of research.
The Declaration of Helsinki, finalized in 1964, is the second set of guidelines
explored in this chapter and draws from both the Nuremberg Code and the Declaration of
Human Rights, promulgated in 1948. Despite Nuremberg, the Declaration of Human
Rights, and Helsinki, research practices in the U.S. still made it necessary for another
normative document targeted at U.S. researchers. The third section of this chapter focuses
on the Belmont Report.
The Belmont Report, more than Nuremberg or Helsinki, remains foundational to
the U.S. approach to questions concerning the ethical conduct of research but, like the
others, cannot be appreciated fully outside of the context in which it develops. Its
development came on the heals of Tuskegee syphilis experiments, in which the rights of
vulnerable research subjects due to racism and poverty began to take on increasing import. I
conclude this chapter with a brief look at global bioethics, an area of research that has
become important over the last decade.
Global bioethics addresses questions of population health, distributive justice, and
vulnerable populations. All of these topics addressed by global health, are in someway
representative of concerns expressed in Nuremberg, Helsinki and Belmont that have been
2 Michael Grodin, “Historical Origins of the Nuremberg Code,” in The Nazi Doctors and the Nuremberg Code:
Human Rights in Human Experimentation, ed. George Annas and Michael Grodin (New York: Oxford University
Press, 1992), 125.

lost. I suggest that some of the concerns expressed by global bioethicists signal the
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importance of an epistemological shift for both medical research and research ethics, a topic
reserved for Chapter Three. While some of the richness of these international and national
guidelines for research ethics have faded over time, their influence on the development of
research ethics, broadly speaking, cannot be underestimated.
The Nuremberg Code
An Established Precedent
The Nuremberg Code, while frequently viewed as the first document that established
an ethical and legal precedent for conducting research on human subjects, drew upon two
key cases of research misconduct that laid the groundwork for a legal case against the Nazi
doctors. The first of these came about in 1898 when a case was brought against Albert
Nessier, a professor of dermatology and venereology at the University of Breslau in
Germany.3 Nessier’s study set out to analyze the success of a vaccine for preventing the
spread of syphilis. In order to study the vaccine, he enrolled patients who had been admitted
to the university hospital. He utilized patients admitted with syphilis and several others who
did not have the disease. For those who did not have syphilis, and in the interest of finding a
preventive method, “he injected cell free serum from patients with syphilis into patients who
were admitted for other medical conditions.”4 He would then test his vaccine on the patients
recently injected with the disease, which frequently failed to prevent the contraction of the
disease. While this would be reason enough to challenge the research, the unique aspect of
his study was that the majority of his research subjects, who did not have syphilis prior to
George Annas and Michael Grodin, “Introduction,” in The Nazi Doctors and the Nuremberg Code: Human Rights
and the Nuremberg Code, ed. George Annas and Michael Grodin (New York: Oxford University Press, 1992), 6.
3

4 Jochen Vollman and Rolf Winau, “Informed Consent in Human Experimentation before the Nuremberg
Code.” British Medical Journal (International Edition) 313, no. 7070 (1996), 1444.

their hospital admission, were prostitutes. Nessier specifically chose his subjects because
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he felt that these women had a higher potential of contracting syphilis of their own accord.
In his trial, despite it being untrue, he claimed that these women must have contracted the
disease by other means. Nessier was brought to trial and fined because he had ignored the
Prussian directive on informed consent issued in 1891, which was designed to protect
potentially vulnerable research subjects.
In 1891, the interior minister of Prussia issued a directive in response to questions
regarding the forced inoculation of prisoners against tuberculosis, which stated that it should
not be done against the patient’s will.5 The directive proved significant in the Nessier case
and influenced Nuremberg for a couple of reasons. First, the Prussian Code concerned the
rights of the imprisoned to refuse treatment. In this way, a precedent had been established
for protecting the right to refuse participation in an experiment or to receive treatment.
Equally significant was the extension of rights to those thought to have less worth in society.
Secondly, the Prussian Code established the legal responsibility of the medical personnel
conducting the treatment, or experiment, to obtain consent.6 Thus, when Nessier was
brought to trial for not obtaining informed consent, his conduct was not only unethical, but
also illegal.7 Discussions surrounding the importance of informed consent and the ethical
conduct of research did not end with Nessier.

5
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Ibid, 1446.

7 Ibid, 1445. Nessier offered as a defense that the women did not contract syphilis from the injection, but
rather from their line of work. The court, furthermore, was less concerned with the scientific risk involved and
held an exclusive concern on the lack of consent on the part of the patients at the hospital. A further
complication can be deduced that these patients sought treatment at the hospital with the expectation of any
injections aimed at improving their health and not involved in a research. An important ethical conversation
that continues to evolve is the relationship between medical treatment and medical research, and the overlap
that exists in certain instances.

In 1928, the German journal Ethik began publishing a series of essays on the
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ethics of human subjects research. The authors exchanged ideas and methods for conducting
research on human beings in a way that minimized harm.8 One physician stated,
“experiments by which patients may be harmed, however, I consider to be completely
inadmissible and have never tolerated them in my clinic.”9 This counter-argument
considered the potential of limiting scientific progress. Another commentator posited, “No
law and no supervision, no matter how strict will prevent ‘human experiment’…”10 At least
in practice, it seemed that harming one’s patients, who were often research subjects, was out
of the question for some but common practice for others. Further commentaries in the
issues of the late 1920s raised topics of vulnerable subjects, with a particular emphasis on
children and the physician’s obligation to “do no harm.”11 It was particularly the harm
brought to children that forced the issue, resulting in publishing guidelines for research by
the Reich Minister of the Interior.
In 1931, the Reich Interior Minister issued guidelines on “medical experiments”
intended to curb abuses in human subjects research stemming from a failed experiment
involving research on children. These guidelines were issued partly in response to a 1930
experiment that resulted in the death of 75 children in Lubeck, Germany. The Lubeck study
focused on developing a vaccine for children against tuberculosis.12 The Reich Circular, the
8 Andreas Frewer, “Debates on Human Experimentation in Weimar and Early Nazi Germany as Reflected in
the Journal ‘Ethik’ (1922-1938) and its Context,” in Twentieth Century Ethics of Human Subjects Research: Historical
Perspectives on Values, Practices, and Regulations, ed. Volker Roelcke and Giovanni Maio (Stuttgart: Franz Steiner
Verlag, 2004), 138-141.
9
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name of the guidelines, attempted to balance the public’s interest in research for
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developing a vaccine for TB or syphilis with the protection of the rights of the research
subjects. In both instances, it was the rights of the subjects that rightly gained legal
protection. While there was support for experimentation to discover cures and improve
patient care, this research required consent from a patient capable of considering the risks
and understanding the process of the experimentation.13 Informed consent, the distinction
between therapeutic and non-therapeutic research, and research on vulnerable groups, all
proved foundational to the development of the Nuremberg Code.14
The Trial
The Nuremberg Trial resulted in the prosecution of 23 Nazi physician defendants
charged with human rights violations that, in part, stemmed from scientific experimentation
on human subjects. Some of these experiments had a therapeutic purpose and focused on
diseases like malaria, tuberculosis, and typhoid. Other experiments, however, reproduced
and then attempted to treat the ill-effects that soldiers suffered in the midst of war: high
altitude, extreme cold, pressure change, poisoning, and a variety of war wounds. The legal
defense argued that during times of war survival was dependent on the knowledge acquired
during these experiments and “extreme circumstances demand extreme action.”15 The
experiments, they argued, were further justified by the fact that the research subjects were
already prisoners. They considered research on this population to be an acceptable practice
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14 Ibid. While the Nazis ignored most of these guidelines, they did outlaw cruelty to animals. Grodin noted, “if
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moreover, that no legal or ethical code had been established to guide research and that the
Nessier case and Reich Circular proved ambiguous in the midst of war. The defense
challenged that legal precedent had been established, and the gravity of the experiments
proved too much to ignore. Two of the cases cited by the prosecution highlighted the Nazi
perspective on therapeutic research, one on infectious disease and the other on treating war
wounds.
In his opening statement, U.S. prosecutor Telford Taylor described two experiments
that attempted to test vaccines and treatments to be used for Nazi soldiers. The first
experiments lasted between February 1942 and April 1945, in which over 1200 involuntary
research subjects were given malaria and treated with various drugs to test its efficacy. Dr.
Klaus Schilling led these experiments, which led to countless deaths.17 The second set of
experiments took place at Sachsenhausen and Natzweiler concentration camps. Grawitz and
Himmler, two of the physicians on trial, described the need to inject humans with germs and
diseases from animals—not the revers. Brandt, another of the physicians on trial, stated, “In
order to enlarge our knowledge, so far based only on inoculation of animals with germs
taken from humans it would be necessary to reverse the procedure and inoculate human
beings with germs cultivated in animals. Casualties must be anticipated.”18 This statement
was reflective of the guidelines instituted by Hitler that placed restrictions on research
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prohibiting cruelty to animals. However, these provisions did not extend to human
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beings.19.
Taylor and his team, which included two U.S. physicians Leo Alexander and Andrew
Ivy, outlined the known history of research ethics in the prosecution of the defendants.
Alexander and Ivy, who played a significant role in the development of the American
Medical Association’s (AMA) code of ethics, both presented research guidelines compiled
from key thinkers in medicine and medical ethics. They drew upon the thought of
Hippocrates—though he never references research explicitly—Thomas Percival (17401804), William Beaumont (1785-1853), and Claude Bernard (1813-1878). Each of these
thinkers established the ethical necessity of receiving consent from patients and ensuring
that no harm was done. Beaumont noted the importance of securing consent from patients,
emphasizing that experiments should be discontinued if any stress was brought about for the
research subject.20 His French colleague, Claude Bernard, also cautioned that scientific
advancement should not be placed ahead of the benefit of the patient or research subject.21
However, when a benefit could be derived for the patient, Bernard felt that physicians had a
duty and right to perform an experiment in order to save a life, cure, or positively impact a

19 Hazelgrove, “The Old Faith and the New Science,” 110. Prior to the trial, the U.S. prosecutors gathered a
group of international representatives at the Pasteur Institute in July 1946 to discuss the medical experiments
for which the Nazi doctors were being prosecuted. At the table were representatives from the U.S., Britain, and
France, all of whom together formed the first International Scientific Committee to collectively examine
informed consent. While the lack of consent was the least egregious ethical violation, legally it proved an
important precedent. Lack of consent, doing harm to one’s patients, and killing in the name of science
provided some of the key items that prosecutor Telford Taylor focused on at the Nuremberg Trial, but these
items resulted from conversations at the Pasteur Institute.
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patient’s health. More broadly, Thomas Percival, in his book Medical Ethics, argued that
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while research itself was rooted in the public good, all research should be undertaken only
after extensive conversation with other colleagues regarding the nature of the case and
potential benefits and burdens that could come about from its undertaking.23 Thus, the
prosecution’s use of Percival, Bernard, and Beaumont highlighted three important aspects of
medical research that emphasized the tension between individual rights and obligations and
the social dynamic of research.
Ivy and Alexander’s articulation of the ethical norms for research emphasized: 1) the
rights of research subjects and patients; 2) the responsibility of the researcher to do no harm;
and 3) the social nature of research, which included a consultative process to weigh the
benefits and burdens of research beyond its impact on the subject. Ivy’s understanding of
research ethics appeared in the Journal of the American Medical Association (JAMA), while
Alexander submitted his argument as a memorandum to the United States Chief of Council
for War Crimes.24 Their essays not only provided information on the Nuremberg Trial to
those in the U.S., but also described the framework for the ethical conduct of research to the
medical and legal community.
In drawing together this diversity of thinkers, Alexander and Ivy established key
components of research ethics, including: informed consent; the necessity of balancing the
burden or risk of research against its potential benefit for the patient; the importance of
research that promotes the common good—or as Alexander referenced it, “humanitarian
22
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benefit”—and the importance of dialogue about the experiments that cite the common
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good as a rationale for its pursuit. Their guidelines, coupled with those issued by the Reich
Interior Ministry in 1931, and the Prussian code of 1900, supplied the prosecution with
ample evidence that the Nazi experiments were outside the boundaries of established legal
and ethical norms for research. However, the Nuremberg Code, while incorporating many of
these norms when it was issued, failed to initiate a broad impact on the practice of medical
research.
Impact of the Nuremberg Code (1949)
When the dust had finally settled on the Nuremberg trial, the testimony of 85
witnesses had been heard, resulting in 11,538 pages of transcript that laid groundwork for
the ethical and legal parameters for human subjects research. Though the trial was about far
more than research ethics, the arguments of the prosecution at the trial established a
normative foundation for research ethics. The code itself incorporated much of Ivy and
Alexander’s testimony, including the importance of informed consent, researcher
responsibility, balancing of risks and benefits, and establishing human benefit as a standard
for ethical research. However, the atrocities of the experiments made it difficult for other
researchers to relate to the ethical violations of the Nazi doctors. In many instances the code
simply could not break free from the context in which it developed.
Few researchers, even those who were also violating the rights of their research
subjects as described in the Code, saw their experiments as unethical or illegal because of its
relationship to the Shoah. 25 In many ways, the single most important takeaway that
researchers considered following the Nuremberg Code was informed consent, which was
25 Pappworth and Beecher, whose works are described below, serve as important reminders that while the
research conducted by other may not have been as illegal or unethical as the Nazi research, unethical and/or
illegal research was still ongoing after Nuremberg.

only the first point of the code and, given the other violations of human rights, was the
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least obvious grievance against the Nazis. While informed consent was, and is, crucial to
ethical research practices, the document emphasized equally that research ought to offer a
benefit to humanity and, when possible, to the research subject directly. The socio-ethical
considerations within the code have become somewhat muted over time, though they prove
fundamental to the legacy of the document and essential to the function of research ethics
overall. 26
Beyond informed consent, the first point of the code, the remaining nine focus on
the tension between the individual responsibilities and rights within the research process and
the social aim of research itself. Thus, the second and third directives underscore that
research should anticipate its potential to “yield fruitful results for the good of society.” The
26 “The Nuremberg Code.” Health and Human Services, http://www.hhs.gov/ohrp/archive/nurcode.html
(accessed May 25, 2014). 1. The voluntary consent of the human subject is absolutely essential. This means
that the person involved should have legal capacity to give consent; should be so situated as to be able to
exercise free power of choice, without the intervention of any element of force, fraud, deceit, duress, overreaching, or other ulterior form of constraint or coercion; and should have sufficient knowledge and
comprehension of the elements of the subject matter involved, as to enable him to make an understanding and
enlightened decision. This latter element requires that, before the acceptance of an affirmative decision by the
experimental subject, there should be made known to him the nature, duration, and purpose of the experiment;
the method and means by which it is to be conducted; all inconveniences and hazards reasonably to be
expected; and the effects upon his health or person, which may possibly come from his participation in the
experiment. The duty and responsibility for ascertaining the quality of the consent rests upon each individual
who initiates, directs or engages in the experiment. It is a personal duty and responsibility, which may not be
delegated to another with impunity. 2. The experiment should be such as to yield fruitful results for the good of
society, unprocurable by other methods or means of study, and not random and unnecessary in nature. 3. The
experiment should be so designed and based on the results of animal experimentation and a knowledge of the
natural history of the disease or other problem under study, that the anticipated results will justify the
performance of the experiment. 4. The experiment should be so conducted as to avoid all unnecessary physical
and mental suffering and injury. 5. No experiment should be conducted, where there is an a priori reason to
believe that death or disabling injury will occur; except, perhaps, in those experiments where the experimental
physicians also serve as subjects. 6. The degree of risk to be taken should never exceed that determined by the
humanitarian importance of the problem to be solved by the experiment. 7. Proper preparations should be
made and adequate facilities provided to protect the experimental subject against even remote possibilities of
injury, disability, or death. 8. The experiment should be conducted only by scientifically qualified persons. The
highest degree of skill and care should be required through all stages of the experiment of those who conduct
or engage in the experiment. 9. During the course of the experiment, the human subject should be at liberty to
bring the experiment to an end, if he has reached the physical or mental state, where continuation of the
experiment seemed to him to be impossible. 10. During the course of the experiment, the scientist in charge
must be prepared to terminate the experiment at any stage, if he has probable cause to believe, in the exercise
of the good faith, superior skill and careful judgment required of him, that a continuation of the experiment is
likely to result in injury, disability, or death to the experimental subject.

onus for this responsibility does not fall exclusively on the researcher, but extends to the
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research community as a whole. This is a crucial point in the Nuremberg Code that becomes
lost over time, but is worth reconsidering.
Nuremberg’s lasting norm for the ethical conduct of research rested on ensuring the
protection of the research subject. However, Nuremberg also suggests that the research
community as a whole should affirm whether a research experiment has public value. It is
the responsibility of the research community to ensure that research stands to benefit the
society; presumably this protection extends to the majority of human beings suffering from
poor health conditions. However, institutional policies, not just international guidelines, need
to reinforce this notion.27 Ultimately, the historical context from which Nuremberg
developed limited its reception, but failures to adopt the Nuremberg code as a political and
institutional standard undercut its potential reception, as well. Given the limitedness of its
reception and the continuance of unethical research practices, the Nuremberg Code gave
way to other ethical guidelines to guide research.
The Declaration of Helsinki
Preparing the Declaration
Between 1949-1952, the WMA established a permanent committee on medical ethics
that concerned itself with violation of human rights within the medical community. After
Nuremberg and the United Nations (UN) Declaration of Human Rights in 1948, there was
an emphasis placed on the importance of protecting rights globally. Though the rights of
research subjects were never explicitly included in the UN Declaration, the WMA saw these

27

In Chapter Four and Five, I will give examples of how universities in particular have failed to do this for the
majority of human beings who are most susceptible to poor health conditions.

topics intimately connected. After several years of conversations at the WMA, which first
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convened in 1946, formal discussions of guidelines for research ethics began.28
In 1953, the ethical questions that arose about the use of human subjects in research
generated dialogue both within the WMA and the ethics committees of its member nations.
Among the member nation delegates was Paul Cibrie of France. Cibrie served as the chair of
the WMA’s medical ethics committee responsible for leading the inquiry around human
subjects research.29 By 1954, Cibrie’s committee developed a formal document, largely
reflective of his previous work in France, that highlighted important distinctions between
research conducted on healthy subjects versus research conducted on sick subjects.
Beginning in France and continuing through his work at the WMA, Cibrie concluded that
physicians had both a right and duty to conduct experiments on human subjects, but only if
they were informed volunteers who capable of accepting or rejecting interventions.30 While
the Nuremberg Code generally emphasized the necessity of fully informed consent—raising
questions about research on children, mentally disabled, and the imprisoned—the WMA
committee nuanced these parameters to include provisions for parents and guardians to
consent when the subject was unable.
The 1954 document stated that individuals should understand the nature of the
experiment, the rationale behind it, and the risk posed to the research subject. In the event
that the patient or subject were unable to make an informed decision “consent should be

28 Richard E. Ashcroft, “The Declaration of Helsinki,” in The Oxford Textbook for Research Ethics, eds. Ezekiel J.
Emanuel, et al. (2008: Oxford University Press, 2008), 141.

Susan E. Lederer, “Research without Borders: The Origins of the Declaration of Helsinki,” in Twentieth
Century Ethics of Human Subjects Research: Historical Perspectives on Values, Practices, and Regulations, ed. Volker
Roelcke and Giovanni Maio (Stuttgart: Franz Steiner Verlag, 2004), 199.
29

30
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obtained from the individual who is legally responsible for the individual.” Additionally,
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questions concerned whether sick persons in need of treatment could offer consent,
particularly when the therapeutic benefit was unknown. In many ways, the working
documents of the WMA between 1954 and 1959 focused on identifying particular groups of
persons for whom consenting to participate in a research study might be either
compromised or impossible. In part, these efforts reinforced the focus on informed consent
within the research community. Yet, the work on “compromised” subjects, led to the
identification of research subject populations that could be taken advantage of more easily.
In 1959, Hugh Clegg assumed the responsibilities of the WMA’s ethics committee
and began building on Cibrie’s 1954 document by identifying groups whose ability to
consent voluntarily was in question. The first group Clegg considered were medical students.
Medical students were frequently used to study the side effects of the medication. The
second focused on research with already sick persons regarding the possibility of using
preventive inoculations on certain persons, while having an uninoculated control group
which would remain untreated. The third group focused on research involving hospital
patients and their ability to distinguish between research and clinical treatment. The fourth
focused on those participating in controlled therapeutic trials of a new drug, while the fifth
took into account the use of prisoners or the institutionalized in controlled prophylactic or
therapeutic trials.32 The identification of these groups signaled the importance of considering
ethical issues beyond those pertaining to the researcher and research subject.

31 George Annas, “Mengele’s Birthmark: The Nuremberg Code in United States Courts.” The Journal of
Contemporary Health Law and Policy 7 (1991), 25.
32
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In September of 1960, after considerable debate about how to address the issues
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of these populations, Clegg and the committee considered simply adopting the Nuremberg
Code as the standard guide for research. However, the group “found it necessary to draft a
code which could serve at least as a guide to doctors working in different conditions and in
different countries.”33 The working group demonstrated concern not only about the
vulnerability of particular groups, but also enabled successful implementation of realistic
guidelines for physician researchers in diverse working contexts. Given the reality that many
physician-researchers ignored the ethical guidelines of Nuremberg, the WMA’s attempt to
re-contextualize ethical guidelines for research proved important, and so they circulated a
draft for discussion in 1962.34
The publication of the 1962 “Draft Code of Ethics on Human Experimentation” in
the British Medical Journal allowed for peers to review the document that had been devised
after years of conversation. The document was divided into three sub-headings: General
Principles and Definitions, Experiments for the Benefit of the Patient, and Experiments
Conducted Solely for the Acquisition of Knowledge. This working document essentially
summarized the efforts of Clegg’s and Cibrie’s committees by detailing the practice of
informed consent and identifying groups whose ability to consent voluntarily could be
compromised. While the first section defined an experiment as “an act whereby the
investigator deliberately changes the internal or external environment in order to observe the
effects of such a change;” the second point clarified the conditions under which an

33
34

Ibid., 206.
“Draft Code of Ethics on Human Experimentation.” British Medical Journal 2, no. 5312 (1962), 1119.
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experiment could take place. Here one saw the efforts of the WMA to re-contextualize
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the guidelines for research ethics and informed consent outside of Nuremberg’s shadow.
In order for a research study to begin, the risks had to be explained in order to
obtain consent from the research subject or his/her proxy. Research subjects had to
demonstrate that they understood they could withdraw from the study at any time and that
the researcher conducting the experiment was qualified.36 The latter two sections on the
Helsinki draft of 1962, focused on clarifying the ethical standards of research when applied
to the immediate benefit of persons versus research undertaken with the primary objective
of furthering scientific or medical knowledge.
In the case of experimentation for the direct benefit of a patient, it was important to
maintain the patient’s trust and have completed sufficient tests in a laboratory or on animals
prior to human experimentation. However, “the doctor should be free to perform an
experiment for the first time if in his judgment it offers the only hope of saving or alleviating
pain and suffering” but only after consent had been obtained.37 If the research would not be
of direct benefit to patients on whom the research was being conducted, then extra caution
should be utilized to ensure that the subject had the “mental, physical, and legal state as to
be able to exercise fully his power of choice.”38 Here, the discussions of Clegg and his
committee proved of particular importance for those who have a limited ability to consent.
In many ways, this section affirmed the Nuremberg Code’s inclusion of restrictions
involving prisoners of war or civilians detained because of a military invasions or political
35
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reasons, but Helsinki re-framed the guideline in an effort to distance from Nuremberg and
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extended protections to other vulnerable groups.
The Declaration of Helsinki (1964)
The 1964 Declaration of Helsinki on the ethics of human experimentation matured
from its 1962 draft into a more linguistically precise document that the WMA adopted at its
eighteenth meeting. While the document maintained the three-fold structure of the previous
draft, a key change shifted the language of “experimentation” to the term “clinical research.”
The use of clinical research again signaled a move away from the use of “experimentation”
in the Nuremberg Code, and represented another effort to establish itself as a distinct
document that took a more medical and research focus than its precursor.39 The document
explicitly referenced its own International Code of Medical Ethics, which aligned itself
specifically with all doctors involved in clinical research.40 Helsinki emphasized both the
researcher’s obligation to uphold the right to health and well-being and the rights of the
research subject’s to informed consent.
The Declaration’s three sections reflected the themes of informed consent by
distinguishing between consent for therapeutic and non-therapeutic clinical research.
Though these themes had been reflected in the 1962 draft, the language became more
precise in the official declaration. Therapeutic research was defined as caring for a sick
patient “if in his judgment it offers hope of saving life, re-establishing health, or alleviating
suffering.”41 This can be contrasted with the purpose of non-therapeutic research, which
enhanced the understanding of scientific knowledge as its true aim. In this case, the research
39
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subject does not stand to benefit from the investigation directly. In both instances,
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however, the doctor continued to have the obligation to “remain the protector of life and
health of that person on whom clinical research is being carried out.”42 This obligation
extended to research subjects with a limited ability to consent directly to participating in a
study. The idea of consent being granted from a person other than the research subject
represented an important development, but one that placed additional responsibilities and
formalities for the researchers to address.
Constructed by physicians and, at the time, for physician-researchers, the document
was framed from the outset with the intention of guiding responsible research. Thus, the
“Basic Principles” focused specifically on the obligations that the researcher undertook. The
research must be rooted in standard moral and scientific practices and established fact. The
researcher should be qualified to conduct the scientific study and it should be carried out “in
proportion to the inherent risk to the subject.”43 The burden to assess the risk, and benefit in
therapeutic research, was placed squarely on the physician. This was particularly true when
the “personality of the subject...is to be altered by drugs or experimental procedure.”44 While
consideration of whether to participate or not rested with the decision-making capacity of an
individual or her surrogate, the primary onus placed on the researcher was deciding whether
a research project ought to be pursued or not. One of the critiques, though lasting influences
of the document was its emphasis on the responsibility of the researcher to lead experiments
rooted in the promotion of health and well-being. While Declaration of Helsinki has seen
several revisions, its connection with the promotion of health and well-being has remained a
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constant. Subsequent revisions, however, continue to revisit new challenges in the ethical
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conduct of research that have influenced the way in which countries, as well as international
organizations, have articulated their own guidelines for research.
Helsinki’s Impact
Since its original pinning, the Declaration of Helsinki has undergone seven revisions
of varying degrees, as well as issuing two notes of clarification in 2002 and 2004. The latest
revision took place in October 2013 at the 64th General Assembly of the WMA held in
Brazil, while the first revision occurred at the WMA’s meeting in Tokyo in 1975. The
consistent revisions of the document continue to address ongoing developments within the
landscape of research ethics. The constant updates signals the importance of creating a
document that reflects the context in which research and research ethics is practiced.
The 1975 Tokyo revision emphasizes the context by further developing the
protection of research subjects by arguing that their interest should always prevail over those
of science and society.45 In an effort to institutionalize this practice, this revision centered on
the necessity of forming committees to review of research studies by an institutional review
board (IRB) or research ethics committees. By emphasizing the importance of IRBs, the
1975 revision pointed to the importance of institutional practices focused on maintaining
responsible research. Through local control of research initiatives IRBs can identify more
easily potentially vulnerable research subjects and questionable research practices on the
local level.
A second impact of the Helsinki revision came from Edinburgh in 2000. The
protection of research participants continued to be a primary focus of the document. In this
version, these protections were tied explicitly to the health and human rights, which
45
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represented new language for the document itself and more explicitly acknowledging the
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origins in the internationalization of human rights following World War II. The 2000
revision included the importance of recognizing the economic status of particular groups as
a potential source of a research subject’s vulnerability. A group that became a central focus
in this document, were vulnerable research populations that reflected concerns for those
suffering from HIV/AIDS. It stated, “research risks are justified only ‘if there is a reasonable
likelihood that the populations in which the research is carried out stand to benefit from the
results of the research.”46 . These particular concerns are specifically addressed in paragraph
30, and recommended against the use of placebo control trials in vulnerable populations,
which are standard in the development phase of a new drug.47 This proved to be one of the
more controversial revisions, and one that caused the U.S. to drop references to Helsinki
beyond its 1989 revision.48 The guidance on the use of placebo-controlled trials was
reiterated in the latest revision, 2013, and included that extra consideration should given to
ensure that vulnerable groups receive a “fair level of additional benefits.”
A final impact generated from the Helsinki declaration has been the international
influence of the document itself. The importance of Helsinki can best be attributed to the
emphasis placed on the development of guidelines that address the changing reality in which
research is conducted. The Declaration contributed greatly to the development of other
international documents produced by the World Health Organization (WHO), Council for
46
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the International Organizations of Medical Sciences (CIOMS), and also countries that
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have established their own ethical standards for research.
A representative, though not exhaustive, list of countries that have referenced the
Declaration in developing their national standards for research includes: Australia, Belgium,
Brazil, China, Germany, India, Israel, Japan, New Zealand, Norway, Switzerland, Uganda,
United Kingdom, United States, and South Africa.49 In addition to its influence on national
policies, the Declaration continued to make contributions to the development of standards
within research and particularly the research ethics focused on lower income countries. The
focus of the CIOMS/WHO guidelines draw on Helsinki to describe:
how the ethical principles that should guide the conduct of biomedical research
involving human subjects, as set forth in the Declaration of Helsinki, could be
effectively applied, particularly in developing countries, given their socioeconomic
circumstances, laws and regulations, and executive and administrative
arrangements.50
The introduction to the CIOMS guidelines explicitly referenced Helsinki and further
contextualized the document’s concerns about research conducted in low and lower-middle
income countries. The further revisions of both Helsinki and the CIOMS guidelines, in
many ways, have led to increased efforts within the area of global bioethics—considered in
the final section of this chapter—that promotes the ethical conduct of research in a way that
more justly considers the needs of the communities in which it works.
Helsinki has proven important in constructing ethical research guidelines that take
seriously the social context and impact of research can have on health and well-being of
both persons and communities. The initial document and subsequent revisions draw
Juhana Idanpaan-Heikkila and Sev. E.Fluss, “Revised CIOMS International Ethical Guidelines for
Biomedical Research,” Journal of Commercial Biotechnology 10, no. 2 (2003), 140.
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attention to the reality of vulnerable persons and populations due to disease and socio-
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economic factors. While the document has been well received in most parts of the world, it
has seen limited reception in the United States, appearing neither in the Common Rule nor
the Food and Drug Administration’s guidelines for research since its elimination in after
1989. Despite its omission from the FDA guidelines, Helsinki provides an important
reference point for the discussions regarding the ethical conduct of research and the
protection of human subjects when they began in the U.S. through the work of the National
Commission for the Protection of Human Subjects (National Commission).
The Belmont Report
Concerns Before the Report
The circumstances that led to the creation of the National Commission, and the
subsequent Belmont Report, stemmed from developments in the U.S. that brought attention
to unethical and/or illegal research practices following the increased funding of research
between World War I and II. As shown in Chapter One, the period surrounding the World
Wars led to necessary innovations in medical research that continued after the the Second
World War. In the years following the Wars, research funding from the U.S. National
Institute for Health (NIH) increased from $700,000 in 1945 to over $36 million by 1955.
Within 20 years, funding had increased to an astonishing $436 million dollars that resulted in
11,000 grant awards, one-third of which required experiments to be conducted on human
beings.51 Included in this study were some of the catalysts for the ethical reform of research
brought about by the National Commission, Willowbrook, Tuskegee, and a lesser known
Rothman, Strangers at the Bedside, 53-54; Henry K. Beecher, “Ethics and Clinical Research,” New England
Journal of Medicine 274, no. 24 (1966), 36. In five years, the funding would cross the one billion dollar mark.
Chapter Four (p.149) will revisit the increased funding for research and describe the confluence of factors
between the U.S. government, Academia, and the Pharmaceutical Industries that contributed to the “golden
age” of research.
51
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syphilis study conducted over several years in Guatemala. Given increasing concern
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about the responsible conduct of research internationally and the growth in research
domestically, James Shannon, who directed the NIH and worked closely with Dr. Freis
during his VA anti-hypertensive studies, sought to implement changes to ensure the ethical
conduct of research.
In 1964, Shannon formed a committee through the NIH Division of Research
Facilities and Resources to review ethical issues in human experimentation. In developing
their guidelines, the committee drew from the Livingston Report that critiqued the
guidelines of Helsinki and Nuremberg because they placed too much responsibility on the
researcher. Shannon’s NIH group, taking into consideration the previous critiques, proposed
that research protocols should be reviewed by outside committees so as to alleviate some of
the burden placed on researchers. Of secondary importance, however, was the self-interest
of the NIH, which did not want to assume responsibility for potentially inhibiting the
development of future research.53

52 While Willowbrook and Tuskegee, both of which are discussed below (p. 75), the Guatemala research study
has only come to light in the past few years. The Guatemala study drew from children, prisoners, soldiers, and
sex workers as their research subjects. The research team attempted to infect prisoners and soldiers without
syphilis by using sex workers. This was because it was known that the disease was not easily injected into
research subjects, from the Terre Haute, IN prisoner study, described in the opening section of the President’s
Commission for Bioethics Report. While the report details the history—Charlene Galarneau, “‘Ever Vigilant’ in
‘Ethically Impossible’: Structural Injustice and Responsibility in PHS Research in Guatemala,” Hastings Center
Report 43, no. 3 (2013): 36-45—points to the socio-political dimension to this study that built on U.S.
Guatemala relations, deliberately targeted vulnerable populations, and involved Guatemalan physicians who
had worked with members of the U.S. research team as collaborators for this projects. In short, the Guatemala
experiment, along with Tuskegee and Willowbrook, point to the complexity of the practice of medical research.
Unethical research does not just take place at the hands of researchers, but necessarily involves other
institutions willing to support a particular research undertaking. Presidential Commission for the Study of
Bioethical Issues, “‘Ethically Impossible’: STD Research in Guatemala from 1946 to 1948,” Washington, D.C.:
Presidents Commission for the Study of Bioethical Issues (2011),
http://bioethics.gov/sites/default/files/Ethically-Impossible_PCSBI.pdf, (accessed: May 1, 2015).
53 Ruth R Faden, Tom Beauchamp, and Nancy King, A History and Theory of Informed Consent (New York:
Oxford University Press, 1986), 207.; Anderson, Public Participation in Human Research, 28-29.

The group arrived at the decision to empower local ethics committees to oversee
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and approve institutional research initiatives to more evenly distribute the responsibility and
commitment to ethical research to a wider group.54 These local ethics committees charged
with evaluating research were referred to as Institutional Review Boards (IRB), instituting a
practice called for in the 1975 revision of the Helsinki Declaration. The utilization of IRBs
could not have been better timed given the concurrent release of two exposés of unethical
and/or illegal research practices in the U.K. and U.S.
Maurice Pappworth and Henry Beecher raised important issues surrounding the
nature of research ethics and the need to protect the rights of research subjects by calling
attention to unethical and/or illegal research in the U.S. and U.K. Pappworth, from the
U.K., highlighted these questionable studies in both a 1962 essay and 1967 book. Beecher, a
U.S. physician, exposed his concerns about ethically questionable research in a 1966 essay
published in the New England Journal of Medicine. 55 While Beecher has frequently received
more credit for his essay, Pappworth’s efforts should not be overlooked.56
Both Pappworth and Beecher highlighted unethical research that targeted vulnerable
populations, failed to obtain informed consent, and engaged in practices that not only
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Allan Gaw, “Exposing Unethical Human Research: The Transatlantic Correspondence of Beecher and
Pappworth.” Annals Intern Medicine 156, no. 2 (2012): 150-155. This recent article points the dialogue that
developed, and dissolved, between Beecher and Pappworth. Their obvious common concern for research
ethics led to correspondence between the two. However, both took different positions with how the research
should both be exposed and corrective measures. Pappworth was of the opinion that the research projects and
researchers should be made public. Beecher, however, perhaps being considered more of an insider when it
came to research had higher hopes of his research colleagues. In their correspondence Beecher thought that
simply raising the awareness of the ethical issues surrounded these projects would be sufficient to curbing their
practices. When Pappworth continually pushed and challenged Beecher on these issues, Beecher seemed to be
the one to discontinue the dialogue. Though Pappworth’s work came first, Beecher’s became the more often
cited source.
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offered no benefit, but deliberately brought harm to patients. In a 1990 retrospective,
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Pappworth described one study in which 43 diabetic patients were induced into a diabetic
coma by having their insulin deliberately withheld. Once in the coma, the researchers
biopsied liver and kidney samples in order to better observe the effects of the coma on these
organs.57 In his New England Journal of Medicine piece, Beecher’s 22 post-war research studies
drew attention to unethical research practices out of concern that “bad ethics would
undercut the pursuit of good science, and the result would be widespread ignorance and oldfashioned quackery.”58 Though Beecher recognized the complexity of research and that
properly obtaining informed consent was laden with difficulties, he found it imperative to
the practice of research. One of the more infamous studies that both Beecher and
Pappworth included in their retrospectives was the Willowbrook Study.
Willowbrook was an intuition for mentally handicap children in Staten Island, NY
where Saul Krugman led a study trying to understand and mitigate a strand of hepatitis that
chronically affected the health of the residents. Beecher described the experiment, which
began in the mid-1950s, as a “study directed toward determining the period of infectivity of
infectious hepatitis…carried out in an institution for mentally defective children in which a
mild form of hepatitis was endemic.”59 At the time, Krugman estimated that 40-50 patients
per every 1000 would contract the disease annually. By injecting them with a mild form of
the disease, Krugman hoped that the residents would develop a resistance to more potent
hepatitis strains. The residents were unable to consent as minors, but also because of their
diminished cognitive function that made them unable to understand the risks or benefits of
57
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the study. In keeping up with the norms of proxy consent, however, Krugman did acquire
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consent from the children’s parents or guardians, the caveat being that parents were under
the impression that the school would close if the hepatitis problem was not controlled.
Pappworth argued that this constituted a form of coercion because parents thought that
participation could help them keep the school open.
A second concern raised by Beecher and Pappworth focused on the deliberate
infection of individuals without therapeutic or prophylactic indications. Beecher charged,
“There is no right to risk an injury to one person for the benefit of others.”60 Pappworth
likewise argued that therapuetic benefit should be a prerequisite for any research done with
children. 61 Moreover, both men raised the objection that these children appeared to be
targets for questionable research because they were vulnerable and “devalued” members of
society.62 In other words, this type of experiment would not have been able to be conducted
on other non-institutionalized children or children of more advanced cognition. The fact
that this research targeted marginalized members of society has led some to refer to
Willowbrook as the “Pediatric Tuskegee.”63
“The Tuskegee Study of Untreated Syphilis in the Negro Male,” came to be the
example of unethical research practices in the U.S. The study targeted a marginalized
population, lacked any therapeutic benefit, and never informed the research subjects that
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they were participating in a study. The study itself, however, was very clear in its aim. The
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study would focus on black males with syphilis and observe, without intervention, the
natural progression of syphilis if left untreated.
The study began in 1932, and received repeated approval by the Alabama Health
Department. At that time, no cure existed for syphilis, though there were varying treatment
options. None of these options were extended to those used in the study.64 By 1945,
penicillin had emerged as an effective treatment for patients with syphilis, but these research
subjects were barred from receiving the treatment or seeking medical attention outside of the
medical exams provided as participants in the study.65 From 1945 until the conclusion of the
study in 1972—predicted originally to last only six months to a year— patients continued to
suffer from painful procedures and the ill-effects of the disease while a medical treatment
existed.66
In that time over 399 African-American men with syphilis were enrolled
unknowingly in the study aimed at understanding the effects of the disease on black males.
However, none of these men consented to participate in an “experiment.” Rather, they
believed they were receiving treatment for “bad blood.”67 In addition to the 399 men with
syphilis, an additional 201 men without syphilis were also recruited to serve as a control
group. It has been estimated that 100 men died as a direct result from the study. However,
64 James H. Jones, “The Tuskegee Syphilis Experiment,” in The Oxford Textbook for Research Ethics, ed. Ezekiel J.
Emanuel et al. (New York: Oxford University Press, 2008), 90.
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once the study was brought to light—though not by Beecher or Pappworth, but rather by
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a story by Jena Heller from the Associated Press—a special commission led by Edward
Kennedy closed the study. Kennedy then began pushing for national reforms for the
conduct of research. In 1974, the National Commission was established, beginning a
national conversation about the ethics of research that resulted in the development of the
Belmont Report.
The Belmont Report (1978)
The National Commission first convened in December of 1974 and concluded with
its 43rd meeting on September 8, 1978. The task of the Commission was to develop
guidelines for the ethical conduct of research involving human beings. In 1976, the
commission requested several leading scholars to contribute essays in philosophy and ethics
to be incorporated as a part of the ongoing conversation for constructing guiding principles
of research.68 Two essayists prominently influenced the position of the Commission on the
ethics of research, though neither were a part of the commission initially.
The essay by H. Tristam Engelhardt, a physician and philosopher, crystalized the
aims of the commission by distilling the ethics of research into translatable principles that
explored the breadth of research practices into a coherent and accessible format. He
described his principles as: “respect for persons as free moral agents, concern to support the
best interests of human subjects in research, intent to assure that the use of human subjects
of experimentation will on the sum redound to benefit society.”69 Engelhardt points, like
68 National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research,
Appendix, the Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research
Washington, DC,(1978).
69 Albert R. Jonsen, “On the Origins and Future of the Belmont Report,” in Belmont Revisited: Ethical Principle for
Research with Human Subjects, eds. James Childress, Eric M. Meslin, and Harold T. Shapiro, (Washington, D.C.:
Georgetown University Press, 2005), 4.

many of the other documents before, distilled the ethics of research into goals of
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protecting research subjects in pursuing only research that would benefit society. What the
commission found lacking in Engelhardt’s essay, however, was an articulation of the role
justice played in research ethics.
Thomas Beauchamp—who was not a member of the national commission, but
eventually wrote the Belmont Report—penned an essay, “Distributive Justice and Morally
Relevant Differences,” highlighting not only the importance of justice in establishing
ethically appropriate volunteers for research, but also for determining whom should benefit
from the fruits of research itself. Beauchamp’s essay was the only essay the Commission
considered that referenced justice as related to the importance of selecting research subjects.
Though not explicitly expressed, the just-selection of subjects was rooted in a concern for
vulnerable research subjects. Secondly, a particular nuance of his essay—ultimately lost in
the practical application of the Commission’s report—emphasized distributive justice. With
the focus on distributing the fruits of research as an explicit goal of the commission,
research ethics took on a social dimension that proved important for the structure of the
document itself, even if limited in the document’s reception.
The National Commission’s Belmont Report settled on three principles as the
bedrock of ethical research: respect for persons, beneficence, and justice.70 Though the
report itself did not mandate specific regulatory recommendations, it did advise that the
overall construction and utilization of these three principles be adopted in their entirety as a
guide for all research endeavors. The document was divided into three parts. Part A offered

70 Thomas Beauchamp, “The Origins and Evolution of the Belmont Report,” in Belmont Revisited: Ethical Principles
for Research with Human Subjects, ed. James Childress, Eric M. Meslin, and Harold T. Shapiro (Washington, D.C.:
Georgetown University Press, 2005), 12. The Belmont Principles differed, in many ways, from what Childress
and were up to in Principles. His account of the origins and his role in both documents is quite illuminating.

important clarifications about the boundaries of medical practice and research, while parts
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B and C, which constituted the substance of the document, explained the principles and
their application.
Given that the practice of medicine and medical research can and do occur together,
it was often challenging for patients and research subjects to distinguish between the two.
Thus, the commission offered a working definition of both medical practice and medical
research. It defined practice as, “interventions that are designed solely to enhance the wellbeing of an individual patient or client and that have a reasonable expectation of success.
The purpose of medical or behavioral practice is to provide diagnosis, preventative treatment
or therapy to particular individuals.”71 In medical practice, the purpose was always to be
focused on the health and well-being of a specific individual. Research, however, “designates
an activity designed to test an hypothesis, permit conclusions to be drawn, and thereby to
develop or contribute to generalizable knowledge…is usually described in a form a protocol
that sets forth an objective and a set of procedures designed to reach that objective.”72 In
contrast to medical practice, medical research functioned more objectively, placing an
emphasis on generalizable knowledge with the potential to benefit society. The remainder of
the document focused on describing ways that the Belmont principles could guide the ethical
practice of medical research.
The principles—respect for persons, beneficence, and justice—established an
accessible way to articulate the ethical values at stake when conducting research. While the
content and conversation surrounding the development of the principles was academically

71 Department of Health, Education, and Welfare, Ethical Principles and Guidelines for the Protection of Human
Subjects Research: The Belmont Report, (1979).
72
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robust, the descriptions incorporated into the document had to be intelligible and
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applicable to a wider audience. In an effort to achieve this, principles were broken up into
two sections. The first, section (part B) defined the principles and part C discussed their
application.
The first principle, “respect for persons,” found practical application in informed
consent. Respect for persons articulated that autonomous choices were not to be overridden
or disrespected, and “that persons who are not adequately autonomous be protected by the
consent of an authorized third party likely to appreciate their circumstances and who will
look after their best interest.”73 This principle also included the requirement that researchers
ensure that the research participants have comprehended the information they had been
given about the study. Here the burden of responsibility was placed on the researcher, which
was particularly important with subjects who had diminished autonomy. The committee,
moreover, wanted to ensure respect for persons and noted three possible applications: 1)
ensuring that participants understood the information pertaining to their participation in the
study; 2) that the individual knew their participation was voluntary and could withdraw at
any time; and 3) that the subject comprehended the risks/benefits of the study. In the
process of obtaining consent, the researcher had to take into account the well being of the
research subjects, which formed the bedrock of the second principle, beneficence.
The Hippocratic ideal of “do not harm” provided the minimal aim of the principle
of beneficence.74 The importance here was that the possible benefits were to be maximized
73 Thomas Beauchamp, “The Belmont Report,” in The Oxford Textbook of Clinical Research Ethics, ed. Ezekiel J.
Emanuel et al. (New York: Oxford University Press, 2008), 151.
74 Thomas Beauchamp and James Childress, Principles of Biomedical Ethics, 6th ed. (New York & Oxford: Oxford
University Press, 2009). It is important here to distinguish the work of Beauchamp and Childress from the
efforts of the National Commission. Though both adopted a principles-based approach, Beauchamp and
Childress were already into the drafting of their own influential principle-based document Principles for Biomedical
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while minimizing harm. Furthermore, these risks and benefits were to be systematically,

84

not arbitrarily, presented to the individual and also considered by an IRB. In this way,
beneficence extended beyond the responsibility of individual investigators to their subjects
and more broadly to representatives of the community—local, institutional, and scientific.
The Belmont Report empowered IRB committees to weigh the benefit and risk that a
proposed study posed to society at large. They were “obliged to recognize the longer term
benefits and risks that may result from the improvement of knowledge and from the
development of novel medical, psychotherapeutic, and social procedures.”76 The intent of
the principle of beneficence was to take into account the need for application of the
principle within the social context of research in which both individual participants and
potential beneficiaries are affected. It was the final principle of justice that sought to balance
more deeply the effects of research and its impact on society.
The principle of justice focused on both the selection of research subjects and the
distribution of post-research results by more broadly considering those who ought to receive
benefits of research versus those forced to bear its burden. The report required fair
distribution of both burdens and benefits of research with special levels of protection for
vulnerable and disadvantaged parties. Included in the principle of justice, developed from
Beauchamp’s original essay, was concern over the competition that existed for benefits of
research. This competition has only increased since the early 1980’s. While research
continues to be heavily funded, it has been funded disproportionately for a small minority of
Ethics. Beauchamp, in Belmont Revisited, notes his disagreement with the away in which the principles were
articulated in the Belmont Report, which in many ways differed from what Childress and he were up to in
Principles. On this point in particular, Beauchamp and Childress described the principle of non-maleficence as
distinct from that of beneficence used in the report.
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the population’s health. Given the scarcity of certain benefits, it was, and continues to be,
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important to ensure that resources developed from research receive just-distribution.
Reflecting on the description of the principle of justice in the document, Beauchamp
described his concern as follows:
The over utilization of readily available, often compromised, segments of the U.S.
population was a matter of deep moral concern to the National Commission. The
theme of justice and proper selection of research participants was the Belmont Report’s
way of saying that because medical research is a social enterprise for the public good,
it must be accomplished in a broadly inclusive and participatory way.77
The social dynamic of research aimed at benefit of the public good demonstrates the
principle’s emphasis on both the inclusivity of research, particularly concerning the benefits
and burdens of research, but also the importance of public participation in shaping research
as a social enterprise.
Belmont’s Impact
The Belmont Report established a framework for an expansive discussion of the
ethics of research from both an individual and social perspective, which laid the foundation
for the U.S. Common Rule. The U.S. Common Rule outlines the federal regulations that
guide the conduct of research in the U.S. The clearest expression of the report’s enduring
impact was its inclusion as the foundation for revisions to the 1981 Code of Federal
Regulation 45 part 46 (45 CFR part 46), later known as the Common Rule. 45 CFR part 46
was originally published in 1974 as a part of the National Research Act, and was revised
initially in 1981 and again in 1991. A third revision of the Common Rule began in 2013 in an
effort to reflect the changes that have taken place in the conduct of research since 1991.
Despite these revisions, the core of the document remains rooted in the initial principles of
the Belmont Report.
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The Common Rule places significant emphasis on instructive guidelines for the
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practice of IRBs and other departments within the federal government.78 45 CFR part 46 is
into four parts, subparts A-D. Subpart A, which is the part of the regulations referred to as
the Common Rule, establishes necessary provisions in order to protect human subjects by
providing key definitions and descriptions of the requirements for the composition and
operation of an IRB. One key stipulation in subpart A contains important guidance
regarding the conduct of research outside the U.S. In these instances, the Common Rule
should be used unless stricter regulations existed in the country in which the research was
being conducted. While subpart A defined the parameters of the regulation of research
involving human subjects, subparts B, C, and, D detail additional regulations for the
protection of vulnerable population. Subpart B concerns, pregnant women, human fetuses,
and neonates, subpart C, prisoners, and subpart D, children. Noticeably absent from these
descriptive guidelines however, is explicit reference to any of the Belmont principles. While
legal regulations prove to be fundamental to the protection of human subjects in research,
ensuring compliance with them waters down the robust personal and social implications for
research ethics that were foundational to the Belmont Report. The National Commission’s
conversations that resulted in 45 CFR part 46 focus on implementing a minimum standard
for protecting the rights of research subjects lacks the fullness to which the Belmont
principles aspired.

78 15 U.S. federal departments abide by the Common Rule. Included in this list are: the Departments of
Agriculture, Energy, Commerce, Housing and Urban Development (HUD), Justice, Defense, Education,
Veterans Affairs (VA), Health and Human Services (HHS), and Transportation, the National Aeronautics and
Space Administration (NASA), Consumer Product Safety Commission, Agency for International Development
(USAID), Environmental Protection Agency (EPA), and National Science Foundation. Additionally, though
not articulated in the Common Rule regulations, the Central Intelligence Agency, Department of Homeland
Security, and the Social Security Administration also are in compliance.

Lost in the application of the Belmont principles and their role in the formation of
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the Common Rule is the broader social considerations of research, foundational to the
origins of the document. In a retrospective volume recounting the development of the
Belmont Report, Karen Lebacqz criticizes the lack of the social dimension and the simple
application of complex principles. Lebacqz, one of the original members of the National
Commission, argues that the vagueness of the principles allows for reinterpretations that
elude the depth of their original meanings. Of particular concern for her is the emphasis
placed on respect for persons. “First, respect for persons became interpreted solely in the
language of respect for autonomy. Second, autonomy itself became interpreted in restricted
ways.”79 The principle shifts its focus to center on a person’s opinion and the need to respect
their desire to refrain from pursuing, or deciding to pursue, certain choices and/or activities.
A further contributing factor that influences the reception of Belmont are Beauchamp and
Childress’s own distinct principle-based ethic.
In Tom Beauchamp and James Childress’s, The Principles of Biomedical Ethics, respect
for autonomy serves as one of the foundational principles for bioethics. Though Beauchamp
notes that the Belmont principles differ greatly from his and Childress’s approach, and
emphasize equally the importance of beneficence and justice. Nevertheless, respect for
persons has translated into autonomy and continues to rule the day. Lebacqz laments:
As respect for persons is reduced to autonomy and autonomy to self-determination
or freedom of choice, the logical outcome is that the broad ranging principle of
respect for persons is then truncated into the rule of ‘informed consent.’ The only
question we ask is whether one consented to medical interventions or use of
technologies. Any question as to whether such interventions or technologies are right

79 Karen Lebacqz, “We Sure are Older but are we Wiser,” in Belmont Revisited: Ethical Principles for Research with
Human Subjects, ed. James Childress, Eric M. Meslin, and Harold T. Shapiro (Washington, D.C.: Georgetown
University Press, 2005), 100.

is utterly lost.
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The social dynamic of the human person and the Belmont principles can become lost.
Moreover, when the principles themselves are reduced, as Yesley surmises, to informed
consent, weighing of individual risk/benefit, and the selection of research subjects, the
scientific endeavor itself loses its social context. Yet, it is precisely the social context from
which illegal and unethical violations of the rights of human subjects arose, not only in the
U.S., but globally.
In an application of the Belmont principles, it is worth considering the broader social
contexts that bear on the way in which the regulatory efforts are applied. While broader
applications, and in some instances expansion, of the principles have begun in newer areas
of bioethical inquiry, such as global bioethics, a broader framework capable of keeping the
focus on the social dimension of research in tension with the regulatory protections of
individual human rights research proves crucial. Global bioethics is an area of ethical inquiry
that has developed over the last two decades and focuses on the role of research, health, and
human flourishing.
Global Bioethics
Global bioethics concerns itself with three areas: 1) the discourse pertaining to
international research; 2) the importance of benefit sharing and protection that promotes
human existence and flourishing; 3) the cognizance of participation in global community or
world moral community.81 These categories are interconnected and raise the awareness of
one’s mutual participation in the construction of a global community. The concept of global
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bioethics originated in 1988 with Van Rensselaer Potter, a U.S. oncologist whose work in
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bioethics focused on human survival and flourishing. Potter’s influential text Global Bioethics,
which has been more influential outside of the U.S., serves as a follow-up to his 1971
Bioethics: Bridge to the Future.82 His earlier argument, nevertheless, laid the groundwork for
considering global bioethics as a field that linked humanitarian values with the disciplines of
science and medicine. Potter integrates concerns about the development of society and care
for the environment as constitutive issues for bioethics to address. His global approach to
bioethics, however, has been rarely taken up by U.S. bioethicists, until recently.83
The groundwork Potter laid in global bioethics has increasingly become a subject of
interest within current trends in bioethics, reflecting on bioethics as a discipline at the
intersection of science and human values in a socio-political context. Daniel Wikler and Dan
Brock describe global bioethics as taking a “birds-eye” view of bioethics, moving beyond the
particularly individual focus of bioethics, instead settling on issues of justice and politics of
health.84 With a more comprehensive approach to bioethics, questions regarding global
preparedness for the spread of infections disease, distributive justice, and practices that
promote or limit positive health come into focus.85 This broader perspective de-centers
autonomy as the dominant bellwether for bioethics and lends itself to consider the the

82 Peter J, Whitehouse, “The Rebirth of Bioethics: Extending the Original Formulations of Van Rensselaer
Potter,” American Journal of Bioethics 3, no. 4 (2003), 26-31. Whitehouse particularly mentions Albert Jonsen and
Tristam Engelhardt’s accounts of bioethics. Henk A. M. ten Have, “Potter’s Notion of Bioethics,” Kennedy
Institute of Ethics Journal 22, no. 1 (2012), 61.
83 H. Tristram Engelhardt, Global Bioethics: The Collapse of Consensus. (Salem, MA: M & M Scrivener Press, 2006).
Engelhardt stands as one of the critics of any normative approach to global bioethics. He argues that the
diversity of approaches, while enriching the global dialogue within bioethics, makes it difficult to develop
consensus around bioethical issues.
84 Ronald M. Green, Aine Donovan, and Steven Jauss, eds., Global Bioethics (Oxford: Oxford University Press,
2008), 16.
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intersection of bioethics and justice.
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Eric Meslin and Ruth Macklin have distinguished themselves as two of the leading
figures taking up issues of justice related to research in a global context. For Macklin and
Meslin, justice functions as the lynchpin to debates concerning medical research and its
distribution. Macklin argues that concerns regarding global bioethics come at the intersection
of questions about global justice and research ethics. She raises the importance of the
particular question of reducing the gap between health status and life expectancy between
the rich and the poor.87 With respect to ensuring justice between the rich and the poor,
questions of justice have to be raised at a policy level in order to address, not only the health
gap between the rich and the poor, but also the research gap.
The research gap, discussed in greater detail in Chapter Four, refers to the disparity
in research in which 90% of research stands to benefit only 10% of the population.88 Eric
Meslin argues that concern over the research gap needs to be addressed from the “bottomup.” Meslin characterizes Macklin’s approach to justice as global bioethics “from above” or a
“top down.” In contrast, he proposes that the issues of justice in global bioethics focus on
capacity building and collaboration with those communities that lack the ability to participate
and govern their own research practices. Meslin describes the approach taken by Indiana
University’s Medical School in building its own hospital, developing an exchange program
for training medical students, and helping to support a local IRB in the Rift Valley in
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Eldoret, Kenya as an example of an approach from below. Meslin’s approach in many
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ways echoes the approach of this dissertation.
While Meslin and Macklin rightly highlight justice as the place to consider challenges
in global research ethics, these considerations have to be done in conjunction with
collaborative partners and from the experience and place of those that suffer injustices.
Thus, it is not only important that collaboration occurs with communities of need, but that
the projects developed truly reflect their needs, and not those of an outside institution—a
challenging task. Therefore, even a preconceived notion of justice can prove difficult to
reconcile with the experience of injustices within local communities. In order to address this
important distinction, I turn to the perspective of liberation theology, in which questions of
justice begin with experiences of injustice.
Conclusion
The Nuremberg Code, Declaration of Helsinki, and Belmont Report develop as a
result of illegal and/or unethical practices in medical research from particular socio-historic
contexts. These contexts provide a basis for the content of these documents. To interpret
and implement these documents as regulatory requirements absent of a consideration of the
communities from which they developed undervalues their importance for research ethics.
The narrative of individuals and the communities that were victimized in the process of
research form the foundation of each of these documents. Ezekiel Emanuel has been an
outspoken critic of both the revisions of the Declaration of Helsinki and the Belmont
Report in large part because of their inadequate consideration of communities. He articulates
the importance of incorporating “respect for communities” as a key component of ethical
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research. Yet, respect does not go far enough, and global bioethics articulates more
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clearly the challenge as one rooted in justice.
For global bioethics, justice allows for a social ethics approach to burdens of disease,
standard of and access to care, foreign research practices, and the development of bioethics
internationally. Global bioethics highlights the increasingly global impact of medical
research, which has become lost particularly in many of the international documents. While
the applicative dimensions of Nuremberg, Helsinki, and Belmont remain essential for the
protection of individual rights included in research ethics, emphasizing the current injustices
within research practices proves necessary. “[A] broader understanding of justice would
require looking not simply at the selection of research subjects but at entire systems and
structures and how they distribute power and privilege.”91 While this approach inevitably
creates new challenges and potential obstacles for research and research ethics, it would also
promote a more serious consideration of the social dynamics of the practice of research
itself. The next chapter proposes that increased consideration of justice within the practice
of medical research, however, will require an epistemological reframing of the task of
medical research itself.
Chapter Three draws on the work of Ignacio Ellacuría who provides important
insights as a philosopher, theologian, and university president. As a former university
president, Ellacuría readily acknowledged the important role that research plays for
institutions, insofar as that research remains grounded in historical reality. For Ellacuría,
90 Emanuel Weijer, “Ethics. Protecting Communities in Biomedical Research.” Science 289, no. 5482 (2000);
Green, Donovan, and Jauss, Global Bioethics, 352; Sirkku Hellsten, “Global Bioethics: Utopia Or Reality,”
Developing World Bioethics 8, no. 2 (2008), 70.; Henk A. M. ten Have, “Global Bioethics and Communitarianism,”
Theoretical Medicine and Bioethics 32, no. 5 (2011), 315.; Van Rensselaer Potter, Global Bioethics; Joseph Millum and
Ezekiel J. Emanuel, eds., Global Justice and Bioethics (New York: Oxford, 2012), 315.
91

Lebacqz, We Sure are Older but are we Wiser, 107

historical reality comprises the object of philosophy by considering “history’s actors,
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authors, editors, players, and parts of all the parts that make up reality.”92 The ethics of
research, rooted in reality, maintains the importance of protecting the rights of human
subjects, but in a way that remains cognizant of those who benefit and bear the burdens of
research. By attending to issues such as participation, power, economics, culture, and
politics, one can better account for the complexity of ensuring a consideration of the social
and ethical conduct of research.

92 Kevin F. Burke, The Ground Beneath the Cross: The Theology of Ignacio Ellacuría (Washington, D.C.: Georgetown
University Press, 2000).
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CHAPTER THREE
LIBERATING MEDICAL RESEARCH
Introduction
The historical development of research ethics has centered on the protection of the
individual rights of the research subjects without considering adequately the social context in
which research develops. Thus, the horizon of research and research ethics has concentrated
its efforts on preservation and protection, rather than prospectively addressing any social
inequalities created by the practice of research itself. By considering more seriously social
questions within research ethics, a greater awareness of the social injustices present within
medical research emerge. In this chapter, I argue that an epistemological shift proves
necessary in order to recognize the injustices present within the practice of medical research.
While the current epistemology of medical research centers on the development of new
objective knowledge, it fails to adequately consider the research needs for the majority of the
world. Recasting medical research from the epistemological lens of liberation theology
requires the reimagining of medical research in concert with the needs of the poor.
The epistemological importance of a preferential option for the poor, foundational
to a liberationist and Catholic approach, requires an agenda capable of addressing the
structural injustices of medical research. Before addressing the structural inequalities, the
focus of Chapter Four, it proves necessary to articulate what it means to address the practice
of medical research from the perspective of the poor. In describing this process, I follow the
thought of philosopher, theologian and university president Ignacio Ellacuría.
!
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The chapter will develop, first, by considering the person and thought of Ignacio

Ellacuría, followed by the influence of his mentor and collaborator Xavier Zubiri, a
twentieth century Spanish philosopher. Section three reflects on Ellacuría’s anthropological
vision, which understands the human person through the Zubirian term, reality animal. With
this anthropological foundation, the fourth section will explore Ellacuría’s three-fold
understanding of intellection as a praxis-based encounter with historical reality. It is this
praxis-based encounter that not only informs the task of human intellection, but also the
tasks of socio-historic institutions, e.g. university-based medical research. The final section of
this chapter, then, takes up the Ellacuría’s understanding of the university as an institution
positioned to confront the social injustices that exist in reality and begins to move towards
transforming that reality. Drawing upon the thought of Ellacuría, the Catholic university,
given its prioritization of the poor and commitment to justice, should be a place from which
the socio-ethical and theological dimension of medical research is considered.
Why Ellacuría?
Ellacuría was a Spanish-born Jesuit priest who spent most of his professional life
living and working in San Salvador, El Salvador. Up until his death, on November 16, 1989,
Ellacuría served as the president and rector of the University of Central America. On that illfated night, he and five other Jesuits, the cook for the seminary, Elba Ramos, and her
daughter, Celina, were all murdered by a government death squad, a special group of military
personnel trained for assassinations. While the details and political motivations have been
well documented elsewhere, what holds significance for the purposes of this dissertation is

!
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Ellacuría’s influence as the president of the UCA.1 Buttressed by his philosophical and
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theological vision, Ellacuría urged the Catholic universities, and in particular his own,
address the injustices present in historical reality.
Key Terms
“Historical reality,” a term frequently utilized by Ellacuría to describe the world as a
presently experienced, complex, and deliberate construction that results from choices made
in the past, are currently being made, and will continue to be made in the future. While this
may seem simplistic—historical action creates the present reality—historical reality
necessitates not just a deeper exploration of the present reality and the injustices present
within it, but also of one’s individual and collective role in creating these injustices.
Reflecting on historical reality reveals that the minority of persons have utilized their power
in a way that has created a reality in which the majority have limited access to resources and
a diminished capacity to participate in shaping historical reality. Thus, they are subjected to
participate in a reality neither of their own choosing, nor one in which they have they have
the capacity to alter. Ellacuría references the term frequently in his philosophical, theological,
and political writings, and is interested not only in how historical reality is understood, but
how it can be transformed from the perspective of the “poor majority.”
From the perspective of the poor majority, i.e. the majority of human beings unable
to fully participating in construction of historical reality, injustices become more readily
visible. The poor majority includes human beings that suffer from illness, premature death,
and lack the opportunities to participate in the political and economic construction of
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Robert Lassalle-Klein, Blood and Ink: Ignacio Ellacuría, Jon Sobrino, and the Jesuit Martyrs of the University of Central
America (Maryknoll, NY: Orbis Books, 2014), xvii-xxii; Kevin F. Burke, The Ground Beneath the Cross: The Theology
of Ignacio Ellacuría (Washington, D.C.: Georgetown University Press, 2000); Teresa Whitfield, Paying the Price:
Ignacio Ellacuría and the Murdered Jesuits of El Salvador (Philadelphia: Temple University Press, 1994).
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society. For Ellacuría, the poor majority has both a political and theologically function.
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Politically, they force reflection on the structures that perpetuate disparities and
inequalities and look for avenues through which to transform them. Theologically, Ellacuría
argues the poor call attention to God’s revelation in scripture as taking place through those
who are rejected in history. He gives particular attention to the Exodus account, Isaiah’s
suffering servant, and, finally, to the person of Jesus. More will be said about the theological
function of the poor majority in fourth section of this chapter (p. 114) when discussing
Ellacuría’s epistemology, but it bears mentioning here, because it is his epistemological
framework that framed his political and theological vision as the president of the University
of Central America (UCA) in the midst of civil war in El Salvador.
Social Projection and the UCA
The history of El Salvador resulted in stark divisions between the economically and
politically rich and poor. Ellacuría saw the task of the Catholic university to project the
Salvadoran reality in the university’s tasks of teaching, research, and service. “Social
projection” at the university argues that these university practices should study and reflect
upon the reality—socio-economic, political, theological, philosophical, etc.—in a way that
sets out to transform it in favor of the poor majority. One of his efforts at social projection
of the Salvadoran reality was a series of dialogues established by the UCA to discuss, in a
neutral setting, the challenges of living in a war-torn country. Rather than joining sides with
the right-winged government or the left-leaning FMLN (Frente Farabundo Martí para la
Liberación Nacional), Ellacuría proposed a third force by sponsoring a series of dialogues at
the university between the poor majority and the wealthy minority about the realities of El
Salvador.
!
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Through this third way not only did the poor majority find a voice, but the wealthy

minority also began to hear their voice. Lassalle-Klein notes, “Ellacuría stresses that this
third force is not a political organization but a social one, and he links it to an emerging
theme in Catholic Social Teaching, namely, social organization and civil society as an
important means through which individuals’ interests can be defended against oppressive
state power.”2 While any university could hold these talks, Ellacuría sees it as the unique task
of Catholic universities to serve as places that promote social movements that allow greater
inclusion of the poor in society.
The UCA promotes the participation of the poor and the social projection of reality
through academic writing in university-run journals, to students through course instruction,
and as a guide for the university’s research agenda. Ellacuría argues that the Christian
university serves as a place that ought to engage in the practice of social projection, a process
that takes on the injustices present in reality and works to transform these injustices present
in society. The university has a responsibility to take up these concerns as their own,
prioritizing the poor as constitutive to their institutional priorities, actions, and practices.
For medical research, the epistemic shift requires the gathering of information to
improve health, but to gather information aimed at improving the health of those who are
most likely to have poor health. This reprioritization would require a research agenda to shift
from one that has focused increasingly on individual health to one that focuses on the health
of the public. Prioritizing the poor offers an epistemological corrective for research and
research ethics by drawing attention to the majority of humanity that is excluded from
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receiving the benefits of medical research. Moreover, the epistemological shift calls Catholic
universities engaged in medical research to take up that practice from the place of the poor.
The Catholic university, like other institutions of higher education, has become
entangled in the social structure of medical research that tends to benefit a select few rather
than a suffering majority. Though liberation theologians and philosophers have taken up the
option for the poor as the ethical lens through which historical actions should be considered,
science and research has always prided itself on objective and neutral perspective.
Nevertheless, the research decisions are not made from a place of neutrality and, in fact, this
false impression has contributed to the disparities in health which medical research aspires to
address. While these tasks are not explicitly theological, they are deeply theologal.
The theologal is a term that Ellacuría develops along with his mentor Xavier Zubiri
to describe the “God dimension” of reality.3 The theologal dimension of reality is allencompassing and the choices made within history participate, in some way, in that ultimate
sense of reality. Ellacuría’s utilization of the term theologal is borrowed from his mentor
Xavier Zubiri, and is described in more depth below (p. 100-101). While the theologal
grounds the thought of both Ellacuría and Zubiri, Zubiri’s influence extends beyond that
and affects the way in which Ellacuría understands a wide variety of topics, in particular, his
understanding of human intellection and the role of science.
Zubiri’s Influence on Ellacuría
For Ellacuría, no mentor had greater influence on his thinking than that of the
Spanish philosopher Xavier Zubiri. Zubiri’s philosophy came to be understood as a
phenomenology of “fundamental reality” that develops through his encounters with some of
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the great scientific, mathematic, and philosophical minds of his day: Einstein, Schrödinger,
Zermelo, Jaeger, and Plank. Immersed in their world, Zubiri starts grappling with new ways
of envisioning the philosophy of science. While Zubiri’s understanding of science is
important to understanding the function of medical research, ultimately his understanding
does not differ from his description of human intellection. For Zubiri, the notion of
intellection is a process that functions both rational and sentientiently and greatly shapes
Ellacuría’s own thinking. For Zubiri, and Ellacuría, all knowledge is situated within particular
space and time. This understanding leads to Zubiri’s critical stance towards the epistemology
that guides science.
Zubiri on Science
Zubiri’s critique of scientific knowing counters science’s claim of neutrality and
objectivity as the highest form of intellectual pursuits. The privileged status of scientific
thinking, while having its origins in the Enlightenment, becomes synonymous with Francis
Bacon’s articulation of the scientific enterprise. For Bacon, science functions as way to
constantly improve upon the condition in which humanity finds itself.4 Scientific
experiments allow for a deeper understanding about the material world in which human
beings exist. Bacon’s method of improving knowledge centers on an evidence-based process
that increases scientific understanding through “progressive stages of certainty.”5 Medical
research, and medicine in general, tends to operate within this perspective. Thus, the more
research conducted and applied to the improvement of medicine, the more progress is
achieved. Jeffrey Bishop, a physician and philosopher, reflects on Bacon’s scientific
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epistemology and cautions,“medicine tends to perpetuate a certain naïve understanding of its
progress. Namely, we are moving to more and better knowledge and we will be able to
deploy new technologies to assist in bettering the human condition.”6 This imperative for
research and improvement can still be seen in the efforts within biotechnology and genetic
innovations of today.
In the scientific efforts at the beginning of the 20th century through to the present
day, there has been an increased shift toward reasoning rooted in materialism. “Science,”
Bishop argues, moves single-mindedly, without regard for sentient life.”7 In disregarding the
sentient and intellectual nature of human beings, the science of medicine effectively reduces
life to notions of cause and effect. Thus, the more information accumulated the better
chance of understanding, and controlling, the cause of disease through treatment. Research
understood in this sense, however, centers on control, not knowledge. For Zubiri, the
knowledge derived from scientific inquiry was not about control, but rather about deepening
an understanding of the pluriformity of reality.
Zubiri did not understand science as an isolated and objective discipline that
operates separate from reality. Instead, Zubiri argued that acquiring knowledge both
contributes to and shapes reality. Zubiri’s corrective to a Baconian understanding posits a
non-materialism that perceives reality thorough the senses and reason. “While we do directly
perceive reality, we do not do so in an absolute, detached sense envisioned by classical
science.”8 Thus, scientific knowing represents only one of the necessary pieces for
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comprehending reality. While scientific understanding represents an important piece of the
puzzle, it does not represent the highest form of knowledge. It is science, coupled with other
disciplines, like philosophy, that benefit from and need each other to more deeply
understand the infinitely open reality in which they exist. Zubiri’s philosophy came to more
seriously consider the limitedness of all forms of human knowing, including philosophy and
science. It is the limited perspective of intellectual disciplines, however, that makes research
fundamental to understanding reality.
Zubiri describes research as an investigation of reality by seeking the precise and
detailed constitution of reality. “To research is to dedicate oneself to the true reality…this
force consists in configuring and conforming our mind according to the demonstration of
reality and to offer that which is seen for others.”9 However, Zubiri notes, not unlike Bacon,
that given the openness of reality research functions as an infinite task of observation and
communication of that which is seen. Though, in contrast to Bacon, the results of the
research are always situated, partial, and pluriform. The pluriformity of reality exists, “not
only because things have many distinct properties, but also for the reason that from my
perspective there is always something deeper: because that which is open is its own proper
character of reality.”10 It is scientific task that takes up the study of reality in itself, as it is
seen and experienced materially, while philosophy works cooperatively with science to reflect
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on the reality experienced, “there is always something deeper” to explore. For both Zubiri
and Ellacuría, within reality lies a constitutive and inaccessible dynamic that they describe as
the theologal dimension of reality.
The Theologal Dimension of Reality
Zubiri posits that the theologal dimension of reality imbues and forms the
fundament of reality itself. It is important to underscore that the theologal not be confused
with the theological. Zubiri does not intend to offer proofs for God’s existence, nor to place
God “on top of” reality. Instead, the theologal conveys the endless desire for human beings
to know more and discover “something deeper.” Zubiri posits it is God, not the God of
theology, but the God of reality that drives the endless task to know more about reality. The
totality of reality, however, is not increasingly understood through the advances and control
achieved through science, nor the musings of philosophy. However, both philosophic and
scientific inquiry together can lead to a deeper understanding of reality, but not exhaust it.
The theologal power of the real is that which propels and compels human beings
forward, to discover more, with the expectation that the more one comprehends reality, the
more aware one should become of power one has to shape reality itself.
Reality is a “more,” but not one that is in addition to a thing, but rather a ‘more’ in
the thing itself. That is why in being with “this reality,” where I am is in “reality.”
Likewise, it is because of that “which this reality” can impose on me that it adopts a
form in “reality.” It is not a question of concepts, but of a physical character of the
power of the real.11
The emphasis Zubiri places on the shaping of reality comes to influence Ellacuría’s own
thinking and the importance of human actions that shape history. Thus, reflecting on one’s
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actions and understanding the reality in which those actions occur are fundamental to the
sentient and intellectual function of the human knowing.
Sentient Intelligence
Zubiri refers to sentient intelligence as the process of human intellection in which
one is always interpreting, understanding, and acting from a particular perspective and out of
a set of experiences that make sensitive impressions on the intellect. This impression,
however, is only experienced contextually and partially. The impression, while contextual,
sentient, and partial, remains infinitely open to the possibility of other realities and to a
deeper understanding of one’s own personal reality. In an example used by Zubiri, he argues
that one cannot isolate a piece of reality, e.g. the color red, without at the same time
considering a multiplicity of factors being present within that experience. Moreover, one has
to recognize that the impression “I” have when seeing “red” might be different than “your”
impression, but neither renders the other less “real.” It worth noting that Zubiri does not
equate the “real” with truth; thus, one can have a false perception of reality by not taking
into account other valid experiences from different places. Continuing with his example of
color, while a person who is colorblind experiences “red” differently than a person without
color-blindness, it does not render either experience less real, even if the scientific reality of
their experience of red does not match the material properties of the color red.12
Comparatively, science offers material insights into reality, though the knowledge acquired is
only partial. By uniting the senses and the intellect Zubiri demonstrates his efforts to
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philosophical thought in an effort to counter what he describes as the “logification of
intelligence.”
Zubiri observed a similar trend in western philosophy, similar to Baconian science, in
which the intellective process tends to be reduced to a rational function that only needs to
be understood through reason isolated from the senses. He describes the logification of
intelligence as the process through which intellection becomes rooted in reason alone and
reduces the senses to the interpretation of sense data. “This form of intellection comes to
function formally as a faculty of affirmation in a way that neither reality, nor the beings of
things would be accessible to human beings without this modality of intelligence
characterized by logos and reason.”13 Reason only allows for an interpretation of reality in
itself and reality makes an impression that is at once sensitive and rational. This sensitive and
rational impression of reality, however, makes the whole of reality present, not just what is
most immediate. Reality in its totality, though formally present in the intellective process,
cannot be reduced to a purely rational function, as science is wont to do.14
Through sentient intelligence, science takes on the role of deepening the knowledge of
reality as it is materially, while philosophy searches for the meaning of reality in its totality. It
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is the “of its ownness” of intramundane reality that functions as the object of philosophy,
and science proves a necessary complement to the philosophical task through the
exploration of reality that is perceptually—intellectively and sensitively—present “in itself.”
Moving toward the real that exists outside the perception of sensible qualities. Every
quality is perceived not only in and of itself as such and such a quality, but also as a
pointing toward. The reality of the qualities that are only in the perception is exactly
what constitutes their radical insufficiency as moments of the real. They are real, but
they are really insufficient. In their insufficiency, however, these
qualities…are…pointing toward the real that is outside the perception. Indeed, this is
what gives rise to science.15
For Zubiri, science and scientific research functions as a mode of more deeply reflecting on
reality as it is experienced. However, the reflection on perceived reality does not exhaust
reality, an understanding that was not lost on Ellacuría.
The theologal dimension of reality, sentient intelligence, and the role of science serve
as three aspects of Zubiri’s thought that Ellacuría embraced. The influence of Zubiri on
science can be seen in Ellacuría’s role as president of the UCA and the way in which he
spoke of the importance of research, along with service and teaching as the means by which
the university reflected reality. It is the term reality, however, from which Ellacuría began to
build on the work of Zubiri. For Ellacuría, Zubiri’s notion of reality did not sufficiently
describe the praxical dimension of reality in which human actions continually give shape to
reality as it is experienced. The next section describes Ellacuría’s understanding of reality and
the role of human beings in shaping that reality.
From Intramundane to Historical Reality
Ellacuría nuances Zubiri’s description of intramundane reality by describing the
object of philosophy as historical reality. Historical reality, as briefly mentioned in the
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introduction, is a unified and global understanding of all “real things,” which constitute a
physical and dynamic unity through which all things come to be through one another and, in
one way or another, constitute the interdependent structure of the real.16 Ellacuría’s notion
of historical reality is not merely a theoretical exploration of historical circumstances, nor is it
simply the sequential retelling of historical events and occurrences, though it includes these
components. Kevin Burke notes that Ellacuría’s definition of historical reality refers:
to the field, sphere, or area of reality that serves as reality’s realm of ultimate
realization, and to the unity underlying the various historical happenings, the
contents of realization…It emerges through the totality of history’s actors, authors,
editors, auditors, all the players, all the parts, the audience, the stage, and every other
aspect of cosmic theater, but the unity as such is not imposed by any of these.17
Insofar as reality is made up of a diversity of historical players and places, a key distinction
develops between Ellacuría’s description of historical reality and Zubiri’s intramundane
reality.
The Importance of Praxis
The key distinction between historical reality and intramundane reality rests on
Ellacuría’s emphasis on the praxical dimension of reality. In this way, Ellacuría nuances the
Zubirian focus on the apprehension of reality through sentient intelligence. For Ellacuría,
one comes to know in order to transform. Intramundane reality does not emphasize strongly
enough the fact that, through human action in reality, human beings make history and shape
historical reality. Thus, Ellacuría gives particular attention not only to human thought, but
also human actions as the grounds through which historical reality—i.e. the pluriformity of
conditions, contexts, and circumstances—is experienced and transformed by human beings.
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Ellacuría describes human beings as reality animals—a description borrowed from

Zubiri—who operate through both social and individual dimensions in which historical
reality comes to be realized. Ellacuría describes the human person as a distinct kind of
creature that remains open to the immediate reality in which she is situated but aware that
other realities are simultaneously present and shape the experience of one’s particular reality.
Human beings, like animals, are immersed in situations and are “subjects to” all that
situations require of them.18 However, human beings also have the capacity and
responsibility to transcend the particularities of their circumstances and recognize the reality
of others. For Ellacuría, it is the fact that human action alters historical reality that marks an
evolution from Zubiri’s notion of intramundane reality and emphasizes the fundamentally
ethical dimension of the human person.
Ellacuría argues that historical reality is “of itself,” and that reality’s “of itselfness” is,
in part, a result of human actions that lead to the construction of reality as it is. This reality is
reflective of both one’s own actions and the actions of others, which jointly shape a unified
reality for one’s self and other selves. In this way, the ethical construction of historical reality
necessarily moves beyond the individual experience, because that particular experience,
though holding on to a dimension of reality “itself,” is a reality that is conterminously shaped
by and with others. Thus, reality as it is experienced is a function of a dialectic between one’s
self and other selves, both of whom give shape to the experienced historical reality.
Historical reality then is “co-real,” meaning that each of these experiences or encounters can
only be understood as real with others, “because the reality of the others forms part of my
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own reality.” This co-construction of reality takes place through options and decisions
made by oneself and others by responding to options as presented naturally, in the midst of
conditions that have been commonly constructed.20
The Biological Fundament of Ethics
Ellacuría reflects on what is “common” to humanity as a biological fundament that
provides the most basic commonality amongst human beings. Thus, what is most common
to human beings is biological in nature and does not necessarily pertain to a community or
society.21 Rather, the construction of communities and societies evolves from deliberate
human choices, which have the capacity to foster a sense of community and to form justsocieties that allow for the equal participation of all its members, or not.
It may strike one as odd that Ellacuría grounds ethics in biology, however, this move
is deliberate and not intended to argue some “ethics gene” inherent in human beings.
Ellacuría argues that injustices can be seen where people continually lose their lives at a
disproportionate rate than is biologically necessary. In this way, the biological fundament
takes a socio-ethical position that calls one’s attention to the perspective of people who, as
Gustavo Gutiérrez says, “die before their time.” The biological fundament, moreover,
requires critique of systems or structures that perpetuate this injustice.22
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By calling attention to this socio-ethical position, Ellacuría raises the possibility that

choices made by particular people tend to have more influence on the shape of history than
the choices of others. It is the disparity in loss of life between high-income and low-income
countries that Ellacuría points to as demonstrative of unjust social arrangements. Thus, in
order to correct these injustices, greater attention needs to be focused on those places in
society in which people die, not of natural causes, but because of unjust structures. For
Ellacuría:
Society and history, above all, are not able to be (ser) what human beings decide;
what society and history are going to be depends on the structuring of real and
complex factors following the structure of law, but also between these factors, how
we see them in their place, they have there proper place (puesto), their own position
(posición), what human beings do and want to do.23
Thus, Ellacuría’s initial socio-ethical question is not, what ought one do, but rather, where
ought one begin to think about what one ought to do. It is the place from which one enters
into a praxis-based encounter with reality that proves crucial to Ellacuría’s philosophical and
theological method.
A Praxis-Based Encounter with Reality
Ellacuría’s three-fold praxical encounter with reality and its particular impact on
theology is described in a 1975 address that develops his philosophical foundations of a
Latin American theology. Ellacuría argues that if intellection is a process that is
simultaneously sentient and rational, then, “Every reading, every interpretation is motivated
by interests, be they existential or social. The important thing is realizing what this interest is
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and how this interest conditions our way of approaching and comprehending reality.” The
way in which one uncovers the motivations for particular interpretations of reality is rooted
both in the hermeneutic through which one interprets reality and also the process by which
one engages it.
Ellacuría offers a three-fold method of engaging with reality that argues the human
person comes to understand, interpret, and take responsibly for historical reality through a
praxis-based encounter that begins from the place of the poor. While there are three aspects
to his method, these should not be seen as sequential developments. Rather, each of these
components functions as a spiral and proves necessary for responsibly encountering reality
as it is, in order to shape it as it ought to be. This process, however, does not stop with finite
conclusions. Once one acts, the reality in which one has acted is now transformed to some
degree. Therefore, the entire process begins again from a new point and within a new reality.
In order to act responsibly, according to Ellacuría, one must realize the weight of reality (el
hacerse cargo de la realidad); shoulder the weight of reality (el cargar con la realidad); and take
charge of the weight of reality (el encargarse de la realidad).25 Ellacuría’s methodology is
designed not as an intellective move to observe, judge, and act from a third party standpoint,
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continually being co-constructed.
Realizing the Weight of Reality
“Realizing the weight of reality” means being present to it formally. In other words,
realizing reality’s weight is more than a rational or cognitive task; it is a task that requires an
active mediation.26 Jose González Faus emphasizes, “Realizing the weight of reality involves
a conception of knowing more profound than the mere objective accumulation of data.
Spanish expressions such as ¡ahora me hago cargo! (Now I get it!) or hazte cargo (you must
understand) allude to a comprehension which goes far beyond mere objective knowing and
links knowing and empathy.”27 These type of expressions point not just to the intellectual
grasping of a concept, e.g. an algebraic equation, but to an owning of the concept so much
so that it becomes a part of one’s identity. Therefore, the knowledge becomes one’s own and
is literally “taken on.” By realizing reality, one comes to understand one’s own participation
in the shaping of reality as it is. In the midst of realizing reality, one has to bear responsibility
for a historical reality in which the majority is poor and vulnerable. Upon realizing the weight
of reality, one is confronted with an ethical responsibility within a commonly shared reality.
Shouldering the Weight of Reality
El cargar con la realidad, could be literally translated as “loaded with reality,” which
gives the physical sense of what Ellacuría intends to convey. As one recognizes the role of
reality to be an inherently ethical role, the question then shifts to how one should “shoulder
the weight of reality.” As reality imposes itself on the reality animal, one necessarily has to
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decide how to act and react within the environment. The fundamentally ethical character of
intelligence “has not been given to us so that we could evade our real commitments, but
rather to take upon ourselves what things really are and what they really demand.”28 It is in
this aspect of his methodology that the place from which one encounters reality shapes how
one acts.
Making an option regarding the place—not necessarily a physically location but more
of an intellective/ethical locus—from which one acts is important. Theologically, Ellacuría
describes an ethical place as that which is “most likely to inspire a living faith in Jesus and a
corresponding praxis of discipleship (the praxis-oriented dimension), and the place most apt
to stimulate a lively, authentic theological understanding of faith (the noetic dimension).”29
Ellacuría describes the place from which human beings, of faith and no faith, should opt to
act is from the place of the poor.
Ellacuría describes the poor as:
the vast bulk of humanity whose standard of living is such that they can scarcely
satisfy their most basic needs; this majority whose material standard does not permit
them sufficient human development, who do not have access in an equitable way to
the resources now available to humanity and who are marginalized in relations to
elite minorities who…dispose of the greater part of available resources for their own
immediate benefit; and those majorities whose dispossession is not due to natural
law or personal or group laziness, but rather to historic social arrangements that have
relegated them to situations in which they not only lack, but are deprived of, what
they should have, whether because of exploitation in the strict sense or because they
have been hindered indirectly from enjoying the fruits of either their labor or their
political initiative.30
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Thus, this is not a unique subset of the population, but the collective of individuals that
comprise the majority of persons within historical reality. He argues, moreover, that the poor
are poor because, “The rich have dispossessed the poor from what was theirs…if the poor
are impoverished, the rich are the poverty-makers; if the poor are dispossessed, the rich are
the possessors; if the poor are the oppressed and repressed, then the rich are the oppressors
and repressors…”31 The disparity between the rich and the poor is present, too, in medical
research.
In the last chapter, I referenced the research gap in which 90% of medical research
benefits only 10% of the population. In large part, these disparities stem from the
institutions that establish the research agenda—high-income resource rich nations or high
powered economically solvent pharmaceutical industry—whose priorities primarily focus on
how to yield an economic return on investment.32 However, for Catholic universities, while
economics cannot be dismissed, they cannot occupy the central concern of what research
opportunities to pursue. Insofar as medical research at Catholic universities reflects the
national funding priorities that do not benefit the poor majority, an issue addressed in
Chapter Four, then these institutions participate in the dispossession of the poor as Ellacuría
rightly points out. The importance of place, highlighted in the ethical dimension of
Ellacuría’s epistemology, is helpful in framing the ethical problem, however, it does not
readily identify a solution. Thus, from the place of the poor one not only has to interpret and
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understand, but ultimately one has to take responsibility for the transformation of historical
reality.
Taking Charge of the Weight of Reality
The final dimension of Ellacuría’s methodology focuses on “taking charge of the
weight of reality” (el encargarse de la realidad) by engaging in responsible action that considers
more broadly one’s responsibility not only to oneself, but also for and with others. For
Ellacuría, it is the praxical character of intelligence that proves necessary for human
intellection to become a completed process. The “praxical character of intelligence…only
fulfills its function, including its character of knowing reality and comprehending its
meaning, when it assumes as its burden doing something real.”33 In other words, what takes
place in human intellection only comes to fruition when one takes charge of reality in a way
that leads to an active transformation of that reality to make it more “real,” meaning more
human(e). The only way to shape reality, however, requires “engaging, remembering, and
ultimately undoing its terrible negativity. In a word, it demands conversion, a conversion of
the human heart and a conversion in historical reality.”34 The conversion of the human
person starts with taking the poor majority as the heuristic through which one interprets and
critiques reality, thus, opening oneself to a praxis-based engagement with reality that “comes
from and returns to the configuring of a specific social structure.”35 Thus, there is a need to
take seriously the praxical responsibility one has in shaping social structures grounded in the
theologal dimension of reality.
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The Theologal Dimension of Reality (Reprised)
In the theologal dimension that Zubiri develops and Ellacuría takes up, God does

not exist above or along side of historical reality, but rather God’s transcendence takes place
in and through reality.36 Thus, there are not two realities—God’s and humanity’s—but a
single historical reality that God and humanity share. Ellacuría points to the story of God’s
revelation in the Exodus story, Isaiah’s suffering servant, and finally through the life, death,
resurrection of Jesus. God’s transcendence comes to be made known, not by taking
something away, but rather by pushing something forward. In the Exodus account, Moses
leads God’s people from captivity and oppression to the Promised Land. In Isaiah, while the
suffering servant, “has bourne our infirmities and carried our diseases…wounded for our
transgressions, crushed for our iniquities” (Is. 53:4-5), the servant also serves as a light to the
nations “that [God’s] salvation may reach the end of the earth” (Is. 42:6, 49:6).37 While not
superseding the suffering servant, through continuing the story of God’s revelation in and
through those who suffer, Jesus’ suffering and death emerges as the central Christian
narrative through whom God comes to be known most fully. It is through the oppressed
and marginalized and in the person of Jesus that demonstrates most fully God’s presence in
history.
Thus this fundamental article of faith does not refer to God alone, to a God apart
from human history, nor even to a God who gives meaning to individual life and
whose fullness is projected beyond history. On the contrary, it is from and in history
itself that God becomes present as the fundamental and foundational religious event,
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not only not separated from the sociopolitical processes but established and re-lived
in that process.38

Here Ellacuría calls attention to the structural transformation implied through God’s action
in history in which captives are freed, the suffering serve as a light to the nations, and the
dead are raised.
Utopia and Prophetism
In one of Ellacuría’s final essays, he argues that the God’s action in history takes on
both a utopic and prophetic function that must remain dialectically in tension.39 He argues,
“The Christian utopia can only be constructed from propheticism, and the Christian
propheticism must take into account the necessity and the characteristics of the Christian
utopia.”40 Propheticism in this sense does not mean simply a critique of the structures, but it
is a critique that calls for structural change, change that is more in line with the utopic vision
of God’s kingdom. The dialectic between prophetism and utopia “gives present reality to
what is formally an historical possibility…”41 The formal and historical possibilities are made
known because of God’s transcendence in and through history and have been revealed most
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in Latin America,” in Towards a Society that Serves its People: The Intellectual Contribution of El Salvador´s Murdered
Jesuits [Utopia y profestismo en Latino America], ed. John J. Hassett and Hugh Lacey, trans. S. J. James
Brockmann (Washington, D.C.: Georgetown University Press, 1991d), 44-90.; James Matthew Ashley, A
Grammar of Justice : The Legacy of Ignacio Ellacuría, 2014), 7-56. The latest translation presented in A Grammar of
Justice, alters Brockman’s translation from “prophesy” to “propheticism,” an infrequently used word, but on
Ashley and Burke thought better conveyed the structural change called for with the Spanish word profetismo. In
their introductory comments they state: “Propheticism implies something beyond the discrete word or act of
prophecy it refers to an integrated and integrating vision, a structuring principle, a way of life.” I follow their
lead in translating profetismo as propheticism.
40 Ellacuría, “Utopía Y Profetismo Desde América Latina: Un Ensayo Concreto de Soteriología Histórica,”
142. La utopía Cristiana sólo puede ser construida desde el profetismo y el profetismo cristiano debe tomar en cuenta la necesidad y
las características de la utopía Cristiana. Follows Ashley and Burke translation.
41

!

Ibid. Actualizarlo significa…dar realidad actual a lo que formalmente es una posibilidad histórica…”!

118
!
fully in those who suffer on the margins of society. He argues that the place from which
theology most authentically develops should be set by the historical reality of the people of
God, most fully witnessed in the poor and marginalized as the continuation of the
incarnation of the crucified Jesus in history.42
Ellacuría and his contemporary, Jon Sobrino, note the historical suffering of the
majority of the world today functions as the historical sign of Jesus’ continued crucifixion in
history. The “crucified people” represent the result of the deliberate choice and freedom for
human beings to choose against God. “This crucifixion results from historical decisions,
actions, traditions, and structures and represents, in Ellacuría’s view, the most urgent and
theologically dense of all the contemporary signs of the times.”43 The crucified people,
continue to make the crucified Christ present in history, also making present the reality of
his, and their, ultimate resurrection. Thus, the crucified people push forward within the
present reality a utopic vision in need of actualization.
Catholic universities participate in this propheticism in a particular way by taking up
this Christian utopic vision that prioritizes the poor. This vision calls attention to the
injustices that exist in the world, and works towards reform of those structures. Ellacuría
saw this as a vital role that universities could and should play. For Ellacuría, the Catholic
university functions as a mission-based institution striving to embody the Christian utopic
vision rooted in an option for the poor. This perspective on the role of the Catholic
university proves fundamental to his leadership of the UCA and continually calls for action
in the midst of an unjust reality.
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Ellacuría and the University
In the immediate years preceding his assassination, Ignacio Ellacuría served as an

important public figure in El Salvador as the president and rector at the UCA. In his time
there as both a professor and administrator, his philosophy and theology of liberation
reflected the way in which he viewed the function of the university. While he wrote only a
few essays on the topic of the university, his inquiries led him to reimagine its role as an
institution that addressed social injustices, and the injustices in El Salvador at the time were
plentiful. Faced with that reality, he argued that a Catholic university, like the UCA, should
undertake social projection (proyecion social) as its fundamental task.44
Social Projection
Social projection conveys that all components of the university—faculty, students,
staff, teaching, service initiatives, and research, etc.—ought to reflect the socio-historical
reality in which the university operates. The work of the university, then, goes against the
“ivory tower” or disengaged notion of the university, arguing that it should reflect and aim
to transform the social context in which the university exists. “Social projection understands
itself here as a function that puts the totality of the university, although through its parts, in
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44 Adolfo Nicholas, S.J., “Depth, Universality, and Shared Ministry: Challenges to Jesuit Higher Education
Today,” (presented at Networking Jesuit Higher Education: Shaping the Future for a Humane, Just, Sustainable
Globe, Mexico City, April 23, 2010) http://www.sjweb.info/documents/ansj/ 100423_Mexico%20City_
Higher%20Education%20Today_ENG.pdf; Brad Hinze, “The Tasks of Theology in the Proyecto Social of the
University's Mission” Horizons. 39, no.2 (2012): 282-309; Dean Brackley, “Higher Standards for Higher
Education: The Christian University and Solidarity,” address delivered at Creighton University (Omaha, NE),
November 4, 1999, http://onlineministries.creighton.edu/Collaborative
Ministry/brackley.html. The term social projection has increasingly been influential on reflecting on the way in
which Jesuit universities themselves operate. While Ellacuría uses the term “Christian” university, he is
speaking more specifically about Catholic universities and his thought has been most frequently been
incorporated into the thinking of Jesuit universities. Referencing the above description, if it is faith in Jesus that
lay at the foundation of the action of these institutions, then it is faith in Jesus who continually targeted his
mission to the poor and marginalized of society. Given this foundation in Jesus, rather than the institutional
churches themselves. my argument in particular is addressed to Catholic universities, which already exist as part
of an organized and unified network through which international projects and policies play an important role,
especially when considering issues of global health.

!

!
direct relationship with social forces and processes.”45 While each of the parts of the
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university, departments, academic disciplines, students, etc. have their particular roles to play,
these develop most effectively and beneficially through relationships with those persons and
institutions outside of the university itself and amongst the community in which it operates.
Rather than using the university’s teaching, education, and service for self-promotion
and/or aggrandizement, these tasks, which are fundamental to the university, should most
clearly reflect the needs and concerns facing historical reality. “[Social] Projection
operationalizes the contribution to the creation, modification, and configuration of the
collective conscience in its totalitizing structural dimension or partial structural dimension.”46
David Gandolfo comments that the university as social projection must insert itself
effectively in society. In so doing, the university recognizes its responsibility by allowing the
needs of society to penetrate and permeate the university “determining its curriculum and
research agendas.”47 Therefore, the university projects reality on to reality by being
reflective—the intake of data for processing—and projective—identifying solutions,
critiques, and working to provide the necessary resources in order to transform the unjust
immediate reality.
Thus, social projection functions representatively of the social situation and,
additionally, strives to transform that same situation as needed. The university’s method of
social projection, however, remains focused on the central tasks of the university. Teaching,
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research, and service rooted in social projection aims at the transformation of society beyond
educating students for a profession, providing instead, an education that addresses the
complexities and injustices of reality. At the time, Ellacuría argued, “the UCA needs to look,
to offer, and to support universitarily the process conducive to more justice, freedom, and
solidarity in El Salvador and Central America.”48 It is this emphasis that points to the
political function of the university, a function that holds up the poor majority as the horizon
for university action.
University Politics
Structuring the university’s activity from the place of the poor majority and striving
to transform the injustices of the present reality makes the university political. The politics of
the university does not mean explicit support for a political party, but the political task of the
university results from engaging and confronting political structures that creates an unjust
situation for the majority.49
The university is in and of itself, a reality that moves within the camp of social forces
and that, in the abstract, is able to prescind from this political environment of state
power, even though not from the environment of social classes, nevertheless, here is
where the state converts into a sustainer of social structures that are fundamentally
unjust and irrational and constitute themselves as a validator on the part of society
against the other, this is, in favor of one social class, here the university necessarily
enters the conflict as a social force, it is here where the university puts itself on the
side of truth and justice.50
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The university’s political task emerges in its recognition as an institution that operates as a
counter-structure to unjust structures. While this does not mean siding with a political party,
it does requires that the university honestly reflects on, critiques, and offers solutions for the
injustices present within its context. One way in which it critiques injustices stems from
Ellacuría’s epistemology.
Ellacuría holds that all knowledge is derived from a particular perspective and from
experiences. Therefore, he encourages the UCA, and implicitly other Catholic universities, to
readily call out any “pretense of scientific neutrality and professionalism that negates
‘interestedness and ideologizationally,’ the political reality of the university in order to make
it, surreptitiously, a political instrument at the service of the dominate structure, which may
or may not conflict with society.” 51 Rather than encouraging objectivity in its research
practices, which does not exist, Ellacuría challenges the university to embrace this lack of
“disinterestedness” and to embrace an ideology that explicitly prioritizes justice for the poor.
Thus, while engaging the community through the public and private interests of business
and government therein, the university must be conscious and vigilant in its mission to
socially project reality in a way that prioritizes justice for those who have none. An explicit
focus on justice from the perspective of the poor requires an epistemological shift that
emphasizes the theological mission of the Catholic university.
Theological Mission
The option for the poor captures both an epistemological insight and theologically
shapes how the Catholic university realizes, shoulders, and takes charge of reality. The
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Christian inspiration of the university necessitates engagement in activities that foster the
continuation of the actions of Jesus in history. Yet, there is certainly a counter-cultural
dimension to Jesus’ mission, which was preached in a particular way to the marginalized—
the economically poor and the social outcasts, including those who were ill.
Epistemologically, for Christians knowing changes with the experience of Jesus in history.
God is understood as human, not one of privilege, but one who was marginalized. Jesus did
not live a long life, but rather one cut short by dying an innocent death. His mission was one
of inclusion that challenged existing social structures. The Catholic university participates in
the continuation of this theological mission by consciously embodying an option for the
poor.
A university is a Christian university when its horizon is the people of the very poor
who are demanding their liberation and struggling for it. [Thus, it is] a university
whose fundamental commitment is to change both structures and persons with a
view towards a growing solidarity; a university which is willing to engage in
dangerous struggle on behalf of justice; a university whose inspiration for making
ethical judgments of situations and solutions and for the means to use in moving
from such situations to solutions is the inspiration of the gospel. It is also—some of
us believe—the different university that our country needs.52
Thus, the way in which Ellacuría frames the Catholic-nature of the university does not rest
on a doctrinal assent, but on the commitment of a praxis that engages the world as Jesus did,
by making an option for the poor. Making this option, however, will narrow the focus of
how the Catholic university goes about its tasks of teaching, service, and research.53
Teaching, research, and service that take the poor majority as the horizon of its
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minimally avoiding common harm.54 In a brief essay, Ellacuría argues that the common
good offers a formal and abstract horizon that attempts to shape one’s actions. However, it
is difficult to agree on the exact characteristics that make up the common good, which
Ellacuría argues is not the sum of all individual goods. Thus, he proposes that a focus on the
common harm might generate some consensus on morally responsible actions.
He describes the common harm as those actions that result in harm to the majority
of persons.55 While the common good can be defined inversely, it still remains somewhat
nebulous as to how to construct the common good, particularly in the midst of unjust
situations. Thus, in educating against the common harm, the UCA aims to develop initiatives
that worked against “the structural oppression of the majority of Salvadoran people, the
UCA should look, offer, and support universitarily the process conducive to more justice,
freedom, and solidarity in El Salvador and Central America.”56 Yet, the way in which this is
to be done is not uniform, but rather is a dynamic process that works interdisciplinarily
through the activities of the university by beginning with the experiences of those who suffer
injustices. Beginning with experiences of injustice requires that scientific and medical
research be reimagined in order to address the needs of those who suffer most.
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Research and the University
Research prioritizes the objective pursuit of knowledge by more deeply

understanding reality and discovering new ways of engaging it. One of the potential pitfalls
of research is its tendency to understand itself as an isolated and neutral task, devoid of
interests, aside from scientific progress. An argument for objectivity proves particularly
challenging in the pursuit of research that explicitly strives for technological or scientific
advancements that fails to address the immediate needs of the present reality. Research for
advancement becomes, in essence, a “race to stay ahead,” rather than socially projected
research. Ellacuría notes:
other research agencies are so far ahead of us in this respect we can never catch
them. Rather, it would be a kind of research that can help resolve the huge problems
of a national reality whose chief defining feature [now] is the existence of popular
majorities who see their fundamental human rights violated and a blockade of the
potential pattern towards a life emerging from the true cultural and political selfdetermination.57
For medical research, Ellacuría’s insight is important to consider. University funding for
medical research at Catholic universities is limited. Insofar as Catholic universities attempt to
keep up with the Harvard’s, Oxfords, and Freiburgs, there success will often fail to address
the “big problems” in need of addressing, like malaria, TB, Ebola, etc.58 Ellacuría’s challenge
requires that research focus on addressing “huge problems” that violate the rights of
individuals and communities and inhibit full participation in society both culturally and
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politically. Positively asserted, then, medical research has a responsibility to target those
places where a lack of health restricts a person’s ability to flourish. Ellacuría describes
research that allows for greater participation in the shaping of historical reality as humanized
and historicized research.
Humanization, Hominization, and Historicization
Humanized research strives for outcomes that allow for greater participation and
flourishing of human beings, which becomes historicized in and through human praxis. In
short, Ellacuría’s notion of humanized research is rooted in the biological fundament of
ethics, namely, that research should promote biological possibility of participation in history
(hominization). By this he does not mean biological enhancement or a constant perfection of
human beings, but simply research that sustains life where life is most often threatened,
amongst the poor. Research for biological sustenance, hominization, represents the baseline
criteria for ethical research. Ellacuría argues, however, for a move beyond “hominzied”
research in pursuing the humanization of research.
The humanization of research allows for the historicization of fewer injustices that
limit human persons from greater participation in the actualization and shaping of historical
reality. “Humanization of the species presents itself as an ethical corrective and
prolongation of the biological process of hominization. Humanization has to be conceived,
then, as a process that optionally and projectively, continues and prolongs the biological
process of hominization.”59 The process of humanization, therefore is not separated
completely from hominization. The goal of humanized research, however, is not the
postponing of death, and instead, humanized research allows for those who have historically
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been limited from participating in historical reality a better opportunity to shape the reality in
which they live. The verification of the success or failure of humanized research takes place
through the historicization .
The historicization of research requires some verification of the fuller participation
of those who have been dispossessed by history is realized. The historicization of research
takes place through the increased ability of human persons to “make history from nature and
with nature…and educes the determinative influence of human praxis upon historical
reality.”60 With respect to medical research, greater attention needs to be paid to measures
such as Quality Adjusted Life Years (QALYs) and Disability Adjusted Life Years (DALYs).
These quantitative public health measures, described in greater detail in the next chapter,
give tangible content by which to measure research’s historicization. For Ellacuría,
humanized and historicized research is socially responsible research that allows for human
flourishing for those whose lives unjustly end before their time.61
While human existence is not all about biological life, it constitutes the first of
human rights, a right that is not always realized.62 Often, this inability to realize this basic
right to life can be limited by the technological capacity to deliver what is necessary to
further human life. This is certainly true in many areas of the world in which not only
medical technology is limited due to a variety of factors, but also basic necessities such as
access to healthy foods, clean water, or health care remains unavailable to the majority. Thus,
historicization and humanization of research, particularly medical research, cannot be
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needs.
The Role of Technology
Technology and scientific advancements form a creative potential in the world that
has resulted in both the ability to sustain itself against environmental threat and a desire to
seek absolute control over that same environment.63 While both technology and science have
been used in positive and transformative ways, Ellacuría notes that technology itself has
been utilized increasingly as an instrument of control over the physical world that has
resulted in the domination of the other. “Domination, above all, of the physical nature, by
the knowledge of its laws and potentialities; domination of other human beings, but
managing its disabilities and desires; domination of people, those that appear impotent
before those that hold the power of technology.”64 Recalling the historical examples of
medical research, the positive uses and the abuses of emerging research technologies can be
seen throughout.
In particular, the juxtaposition of the development of the yellow fever or small pox
vaccines with that of the global eugenic practices of the early 1900s reveals a stark contrast in
the use of technology. While the vaccine programs sought control of a disease that was
disproportionately affecting large groups of people, eugenics research sought to manipulate
and control human beings by using technology that enabled certain lives to be valued more
than others. Thus, it was not about enhancing participation in the construction of historical
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63 Ignacio Ellacuría, “Tecnología apropriada,” Escritos Filosóficos. Vol. 3, (San Salvador, El Salvador: UCA
Editores, 2001): 234.

Ibid., 235, Dominación, ante todo, de la naturaleza física, médiate el conocimiento de sus leyes y potencialidades; dominación de
los otros hombres, médiate el manejo de su debilidades y apetencias; dominación de los pueblos, que se bien impotentes ante quienes
detentan el perdió técnico.
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reality, but rather further restricting this participation. Today, though perhaps less

129

maliciously, the vast majority of human beings who have limited access to benefits of
technological advancements in medicine tend to be those economically disadvantaged in the
two-thirds world. Thus, an ethical approach to the use and distribution of the benefits of
research ought to be considered. This is particularly important because greater access to
these technologies correlates with greater participation in the co-construction of historical
reality.
Just-Research
For Ellacuría, just-research confronts and takes responsibility for reality by
addressing the fundamental necessities of the poor majority, a responsibility that can be
easily be lost in the technological and financial scope of medical research. Technology and
research holds the power to “create a humane or inhumane world, it can be an oppressor or
a liberator, it can construct or destroy.” 65 Without historicizing the use of technology, its
potential impact on greater participation of the majority in the development of historical
reality can be lost. He argues, “A technology taken as a whole, that produces bad effects for
the majority of humanity or that simply does not put their resources towards resolving the
fundamental necessities for the majority of humanity is a bad technology.”66 If Christian
universities continue to engage in medical research, then it is a theological, ethical, and
epistemological imperative that this engagement prioritizes an option for the poor.
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65 Ellacuría, “Tecnología,” 240. La técnica puede hacer un mundo humano o inhumano, puede ser opresora o liberadora,
puede construir o destruir, puede ocultar o revelar.

Ellacuría, “Tecnología,” 248. Una tecnología que, tomada en su conjunto, produjera males profundos a la mayoría de los
hombre o que simplemente no pusiera su recursos actuales a resolver las necesidades fundamentales a la mayoría de la humanidad,
es una tecnología mala.
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The university, in taking up social projection of reality as a fundamental task, has the

option of focusing on the needs of the poor majority, or not. Ellacuría argues that the
Christian university is in a unique place to choose to focus on the needs of the poor and
vulnerable. “The university can best offer a scope for action in basic ways for political and
structural change and begin to organize appropriate techniques for dealing with an
independent voice; provide a number of upright professionals working for deep rapid
change primarily in education and public sector; serve as a voice for the voiceless; provide
immediate help to neediest through social outreach.”67 Essentially, the teaching, research,
and service that takes place at universities has the opportunity to transform the way in which
students, faculty, and staff contemplate issues of justice and how they can confront the
injustices in society. While I will explore examples of just-research more comprehensively in
Chapter Five, Ellacuría lays the groundwork for a just-research agenda that targets both
preventive and curative research that stands to benefit those who consistently and unjustly
bear the global burden of disease.
Advancing a global medical research agenda necessitates intentional and local
collaborations with institutions outside the Catholic university who hold a shared sense of
the mission of social projection. “Whether the new mission of the university is carried out,
however, will depend primarily on what it is prepared to do in its own proper sphere of
activity. The university must embody and implement its professed dedication to changing
social structures in its threefold functions of teaching, research, and social outreach.”68 Given
the limited control institutions have over available grants for investigations that aim at social
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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Ellacuría, “Is a Different Kind of University Possible?” 197-198.
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transformation of the poor majority, this socially projected task presents unique challenges
that I will address in the next chapter. However, despite these challenges, Ellacuría’s vision
of a Catholic university—in particular his emphasis on social projection and the
historicization of humanized research—offers valuable insights from which certain
parameters can be established that allow for a more socially responsible approach to medical
research.69
Towards Socially Responsible Medical Research
Medical research functions as multi-disciplinary endeavor that requires the input of
biologists, chemists, businesses, governmental and non-governmental agencies. At times,
however, the most important people in medical research, the people affected by disease,
remain excluded. Thus, developing a socially responsible and socially projected research
agenda requires an emphasis on working with those in need of the benefits of medical
research and against the very structures limit research on these diseases. For Catholic
universities, in following Ellacuría’s liberationist approach, this necessarily considers research
that promotes health and humanization globally.
Given that universities themselves are a part of a global network of institutions
throughout low, middle, and high-income countries, it is important that global issues are
reflected in their research agenda. 70 If Catholic universities were to project that reality in
their research agendas, tangible repercussions would develop that would affect the way in
which research priorities and methods were established. Building on Ellacuría’s insights as a
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69 In addition to the challenges that one might pose to Ellacuría’s approach, examples will be given of instances
of medical research project that demonstrate the possibility of a different approaches to medical research.

This in fact was one of the key points of Fr. Adolfo Nicholas’s, Superior General of the Jesuits, address in
Mexico City in 2010. He argued that there is increased competition amongst Jesuit universities and that the
globalization of the world has not resulted in more collaboration, but rather increased isolation amongst
institutions.
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university president, philosopher, and theologian the five theses below draw out implications
of his thought that would be reflected in the construction of a medical research agenda with
an option for the poor. These five theses provide the foundation from which the rest of this
dissertation will develop.
Thesis One
Medical research functions “communally” and shapes historical reality, which is unified and shared.
Ellacuría argues that what human beings share in “common” pertains to our
biological nature, which is concretely affected by the historical actions of human beings. As
the shapers of a unified historical reality in which all things come to be through one another,
human beings, in one way or another, constitute the interdependent structure of historical
reality. These unified historical actions undertaken by human beings, participate in the coconstruction of our commonly experienced reality. Medical research necessarily participates
in the formation of the “common,” but medical researchers, often believed to be acting
objectively making, can overlook the potential impact of research on society. Thus, medical
research’s impact on society happens accidentally rather than deliberately.
A deliberate and targeted approach to medical research more intentionally
participates in the development of research that aims to reflect research priorities that can
transform the interdependent historical reality in which it exists.71 If historical reality is a
unified reality, and human actions participate in the co-construction of that which is real,
then medical research necessarily shapes the commonly experienced historical reality, both
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71 While Ellacuría anticipated, perhaps sooner than others, the globalized world in which the university
operates, the “community” in which research is conducted necessarily includes the institutions immediate and
local community. However, given the internationalization of university collaborators, this “community-based”
approach would necessarily include the social projection of the local and global community, as applicable. This
opens up its own unique set of challenges and possibilities that will be taken up in chapter four.
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practice of medical research are faced with an epistemological option of choosing the place
from which they will engage this task. Within this understanding, place can function both as
a physical location and as the capacity for human beings to transcend one’s place and put
oneself in the place of another human being.
Thesis Two
Medical research from the place of the poor reflects the Christian university’s mission and should promote
research that allows for both homonization and humanization.
For Ellacuría and the perspective of liberation theology, it is the place of the poor—
understood as both a physical and intellectual place embodied by the socially, economically,
and biologically disadvantaged—that provides the most authentic ground from which
medical research ought to begin its inquiries. In many respects, the injustices and limitations
experienced by the poor disproportionately result in premature death and higher propensity
for contracting disease than those living in high-income countries. 72 Insofar as medical
research, at least at its most fundamental level, is about the promotion of human health then
it holds a minimum obligation to concentrate research efforts that allow for the hominization
of the human person.
The hominization of research provides the foundation upon which a person is more
fully able to participate in the construction of historical reality. At its most basic level,
medical research focused on allowing for biological development to continue proves
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
72 A contemporary of Ellacuría’s and one of the foundational figures of liberation theology, Gustavo Gutierrez,
defines the poor quite simply as those that die before their time. While this definition may raise questions,
when this definition is applied to notions of healthcare and medical research there are people to whom this
definition directly applies. More often than not they are correlate with Ellacuría’s socially and economically
based definition above, see n. 35.
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constitutive of human activity in history. Ellacuría’s emphasis on the place of the poor draws
attention to the socio-historic locations where unjust poverty and the burden of disease limit
the full participation of human beings in the co-construction of reality. Yet, the
homonization of research does not adequately address the injustices often suffered. Rather,
it is the humanization of research that proves most needed and serves as the goal of Catholic
medical research.
The humanization of medical research promotes investigations that allow for greater
participation of the poor majority who are de-humanized through a research process that
ignores their needs. If homonized research promotes life, humanized research works to
allow for the greater functioning of that life. 73 However, consideration of the exact research
endeavors needs to begin by considering de-humanized research, i.e. those practices that fail
to address the needs of the poor majority.74 If medical research does not foster the
possibility of, and not necessarily the realization of, greater participation of the poor in the
co-construction of historical reality, then this research fails to meet the standard of research
that should be conducted at Catholic universities.
Thesis Three
Historicized medical research works through social structures to understand and reflect back a research
agenda that is representative of reality.
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73 In Chapter Five, I describe Comparative Effectiveness Research (CER) as a type of research currently
supported by existing national funding structures that promotes improving quality health care outcomes by
focusing on disease prevention, diagnosis, and treatment. CER centers its efforts on community participation
in developing targets for research, as well as ensuring that the same community benefits from the research
undertaken.! !

An example of dehumanizing research practices are those that allow disease like Ebola and cholera to
continue to go under researched until arriving at a crisis point that is likely to impact Western, high-income
nations. I consider both of these examples of neglect in medical research in the next chapter, focusing explicitly
on the Ebola outbreak that started in 2014 and Haiti’s cholera epidemic that began in 2010.
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The historicization of medical research provides the verification of humanized

research through witnessing greater participation of populations that have statistically and
experientially failed to thrive. The task of historicization is a foundational component of the
university’s social projection. It is in and through the socially projected reality that the
university is better able to target its approach to research approach in a way that allows for
fuller participation of the poor majority in history. The historicization of research is not
validated by making “historical” breakthroughs in medical research, but rather through
participating in the development of new populations with whom to collaborate. Thus,
through the process of historicizing medical research, it is necessary to identify barriers to
humanized research and collaborators with whom overcoming these obstacles is possible.
Thesis Four
Medical research, which develops from sentient intelligence, should work cooperatively with other academic
disciplines, including theology and philosophy, to ensure that its interests and values address reality as it is
seen and experienced by others.
A tendency exists in medical research to pursue newer technologies and innovations
in a presumed objective and scientific way. However, if all intellection—inclusive of
scientific thought—is sentient and rational, then despite medical research’s attempts to be
objective, it operates within a particular and defined set of values, motivations, and interest.
Moreover, following Zubiri and Ellacuría, these values, motivations, and interests are not
necessarily intrinsic to medical research itself, but have been shaped by other historical actors
whose interests, motivations, and values co-construct the reality in which research takes
place. Therefore, those engaged in medical research must pay attention to the extrinsic
influences on the priorities established for research agendas by collaborating with other
!
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research, particularly, with the disciplines of theology and philosophy, broadens the
reflective nature of the research task and its foundation in the university’s mission with
respect to justice.
For liberation theology, questions of justice arise from stories and experiences of
injustice, presenting a unique set of concerns and values that can complement, challenge,
and/or affirm the task of medical research. Liberation theology and philosophy, in particular,
would be highly critical of medical research that appeared to be motivated by economic
incentives or that deliberately sought to benefit the wealthy majority who could pay for
treatments and medications, over the poor. By approaching medical research from the
perspective of liberation theology, an emphasis would be placed on validating the experience
of suffering and working with the poor in search of an alternative. It is here that other
academic disciplines prove necessary in an effort to reimagine medical research through the
lens of under-researched populations.
Thesis Five
Developing a research agenda focused on the poor majority functions as a necessary political task that leads to
both confrontation and collaboration with public and private institutions engaged in medical research.
A university-based medical research agenda developing from the place of the poor
occurs in an historicized way and necessarily turns to partners outside the university to serve
as collaborators. These collaborative partners prove fundamental in determining the
appropriateness of medical research within a particular population. In this way, it is not the
university grantees or the public/private grantors who establish the medical research agenda,
but rather those immersed with in the social reality of the poor majority. However, given the
!
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current process for funding research initiatives, humanized research aimed at addressing
social inequalities in health requires a targeted approach to pursuing grants currently
available in existing funding structures, but also with the flexibility and willingness to seek
alternative sources for funding.
Ensuring that a university’s research agenda takes the poor majority as the horizon of
its activity may require the partnering and dialoguing with institutions that do not necessarily
share the same mission. As will be explored in the final two chapters, academia and industry
have two different objectives—education and profit—and have historically been important
collaborators that have allowed for the development of both institutions. However, the
university’s task—guided by social projection—also operates within its own sphere of the
values, one of which is justice.
Just-research, then, works to create structures that can contribute to social change.
One strength of Ellacuría’s model for the university is its openness to dialogue with others
that elicits the stories and experiences of injustice in order to transform structures that
perpetuate its prevalence. By engaging the ideological other and remaining grounded in the
values and motivations at the heart of the Catholic university, potential collaborative
partners may emerge that advocate for a broader understanding of medical research that will
better enable and promote value-based research that takes the poor majority as the horizon.
While this liberated approach to medical research presents its own challenges and critiques,
in certain instances, examples of this type of research already exist. Before taking up these
examples in the concluding section of Chapter Five, I now turn to the injustices prevalent in
the practice of medical research itself.
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Conclusion
University-based medical research that meets the needs of the poor majority presents

a challenging task given the diverse actors that shape the research agenda. However,
Ellacuría’s philosophical and theological project provides a fundamental epistemological
shift from the scientific agenda that characterized the Enlightenment and Baconian science.75
The emphasis on expanding the horizons of science and developing new technologies
perpetuates a social practice that ignores those who suffer from the most acute forms of
health challenges that remain neglected. Through the socio-critical lens of liberation
theology, the injustices within this practice are unmasked when viewed from the perspective
of the poor.
For Catholic universities the option for the poor represents a normative foundation
from which to address issues of justice. While the universities articulate their commitment to
justice with respect to service and education, it remains unclear how justice shapes the
practice of medical research. In the next chapter I will describe the development of the social
practice of medical research and how it has emerged within academia as increasingly
economic driven task. The task of the Catholic university, explored in Chapter Five, centers
on how to be an institution that participates in the shaping of a more socially responsible
research agenda.!
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75 Bishop, The Anticipatory Corpse. Bishop takes up a genealogical approach, drawing on Foucault, to describe
the way in which the technologization of the body has generated a fundamental discord between the medical
approach to death and dying compared to one rooted in Christianity. What I want to do is similar, but using
medical research and the emphasis on the poor as an epistemic category by which to make a similar shift. Thus,
by maintaining a Baconian and technology perspective, one loses the context in which research is conducted
and who stands to benefit.

!

!

CHAPTER FOUR
RESEARCHING REALITY
Introduction
In this chapter, I follow Zubiri and Ellacuría’s claim that human intellection
functions simultaneously as a sentient and rational process to argue that science and medical
research, therefore, never operate as a purely neutral or objective practice. Scientific research,
like all other forms of human activity, both shape and are shaped by historical reality. Thus,
the context from which research one approaches medical research influences how it
develops and who benefits from those developments. In this chapter, I am particularly
concerned with socio-political values within the development of medical research, who has
benefited over time from the development of research, and, conversely, who did not. Finally,
I address the ways in which research can begin to recognize and advocate for those who
have been unjustly overlooked within the practice of medical research.
In his neo-Aristotelian ethics, Alasdair MacIntrye argues that all practices have a
social dynamic that must be established as a “good” activity. The good of a particular activity
both comes from and develops in relationship to social contexts. Within this activity, agreed
upon goods of particular practices emerge that prove constitutive of the human activity in
and of itself. Thus, a practice is:
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any coherent and complex form of socially established cooperative human activity
through which goods internal to that form of activity are realized in the course of
trying to achieve those standards of excellence which are appropriate to, and partially
definitive of that form of activity, with the result that human powers to achieve
excellence, and human conceptions of the ends and goods involved, are
systematically extended.1

Here, MacIntrye speaks to the cooperative nature of human practices and the inherent goods
particular to them. At the same time, these goods have to be identifiable and, through
“human powers,” are brought to fruition. In Chapter One, I addressed the notion of medical
research as a practice that at its most basic level concerns itself with the promotion of health.
In this chapter, I argue health has not always been seen as the goal of medical research.
Within the development of research funding, serious questions emerge whether the
improvement of health played as prominent of role as it should have in creating funding
structures for medical research.
A variety of factors influenced the development of funding practices for medical
research. These developments, however, should not be viewed as distinct from the goal of
medical research itself, serving instead as a complement to the process. Chief among these
developments has been the important relationship between industry and academia. Industry,
in this case, is understood as businesses whose primary aims are the buying, selling,
marketing, and development of goods able to be sold as they pertain to health. The first
section of this chapter focuses on the gradual development of the relationship of academia
with the pharmaceutical industry.
The origins of this collaboration in the U.S. center on developments both prior to,
and in the midst of, the World Wars. It was at this time that the U.S. government formed
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Alasdair C. MacIntyre, After Virtue: A Study in Moral Theory (Notre Dame, Ind.: University of Notre Dame
Press, 1981). 187. See also, MacIntyre, “Social Structures and their Threats to Moral Agency,” Philosophy, 74, no.
2, (1999), 311-29.
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collaborative relationships with universities. During the Wars, government, university, and
industry officials focused on developing wartime technology. However, at the conclusion of
the Wars, there was a desire to both continue the progress made in research and to find new
researchers capable of expanding these efforts to fields beyond wartime technology.
The second section of this chapter, then, describes the evolution of the collaborative
relationships between government, industry, and academia as essential to the way funding
structures were established for research, with economics becoming a key motivator of both.
The prioritization of economic gain influences the decision to pursue certain research
endeavors over others. These choices contribute to disparities between those who benefit
from medical research and those whose needs go unnoticed in the establishment of research
priorities.
The disparities in research manifest themselves between the diseases suffered by
persons from low and middle-income countries compared to those of high-income
countries. People living in low and middle income countries comprise the majority of
persons in the world who, incidentally, disproportionately bear the global burden of disease,
as measured by disability adjusted life years (DALY). DALYs serve as a statistical
measurement for the total number of life-years lost due to death and/or disability. Thus, in
order to create an agenda that aims to improve health, DALYs prove an important tool that
indicates the geographic location of those whom have the greatest unmet health needs. Yet,
despite knowing those who suffer the greatest burden of disease, relatively little has been
done to significantly close the research gap, which I will explore in section four. In fact, the
research efforts of high-income countries largely ignore the needs of these countries. One
need look no further than the most recent failures of the global management of the Ebola
!
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outbreak, which resulted, in part to insufficient attention to a disease that had confined itself
primarily to West Africa.
In section five, I turn to a commentary by Paul Farmer, physician, global health
expert, and medical anthropologist, on the recent Ebola outbreak. Farmer argues that
improving a population’s health begins with a health care delivery system, public health
infrastructure, and general readiness with developments from medical research to care for
the health of another human being.2 It was only when Ebola entered the Western world that
a bevy of concerned persons began to raise awareness about the need to research Ebola and
other global diseases that disproportionately target the poor majority.
The final two sections address the importance of raising awareness about diseases by
highlighting the role advocacy groups have played in altering the research agenda. One of the
primary successes of advocates, particularly within the HIV/AIDS movement, has been
their ability to communicate the stories of the patients to the general public. Too often, the
stories of the poor and marginalized go unheard. If medical research is going to be a practice
that improves health, then the stories of the “unhealthy” have to be heard. While advocacy
and narrative efforts are not cure-alls, they can impact the way in which research is
conducted.
The social practice of medical research functions as a complex and financially
incentivized collaboration that often undervalues the health needs of the majority of the
world. Yet, within this structure institutions have a responsibility to maintain the focus of
medical research on health. Advocacy efforts prove important to this process by speaking
for the research and health needs of those who unjustly bear the burden of curable and/or
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Paul Farmer, “Ebola,” London of Books, 36, no.20 (2014), 38-39, accessed: November 3, 2014,
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controllable diseases. While this chapter takes up the social challenges within medical
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research, the final chapter will draw examples of research practices that maintain a focus on
health and just-research practices that befit Catholic universities.
The Industry-Academia Collaboration
Policies adopted by the U.S. government fueled collaborative efforts between
academia and industry.3 As shown in Chapter One, during World War I and II, the
government had partnered with universities and industry officials to develop new
technologies for the immediate use in war. As the war drew to a close, it was realized that a
model had been established for generating new knowledge that, at the same time, provided
an economic stimulus for the U.S. The creation of new knowledge allowed for the
production of goods that could then be sold on the market. However, a challenge after the
war arose from the need to put new knowledge and products to non-wartime use.
While some health related research had been going on as part of the war efforts—
development of vaccines to be used in the geographical areas in which soldiers were fighting,
as described in Chapter One—the investments made by the government were minimal.
Post-war, the U.S. continued to invest in technology-based research but also expanded its
scientific research relating to health. The leader of this effort was Vannevar Bush, head of
the U.S. Office of Scientific Research and Development (OSRD) during and after World
War II.
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The focus of this chapter centers on U.S. based research practices because they are the largest funders of
government-based bio-medical research. Moreover, the intellectual property policies developed here are similar
to, and in certain cases established the model that many other high-income countries follow.
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Vannevar Bush and the Endless Frontier
Bush’s proposal to Roosevelt outlined the importance of the government’s post-war

investment in research through the education of soldiers who would serve as the next
generation of scientists, and emphasized the importance of continuing to fund universitybased research. On both fronts, the hope was that these efforts could lead to a source of
revenue for the U.S. economy through the production of new knowledge. Bush’s landmark
report, Science the Endless Frontier, signaled two important concerns that the nation faced
following the war’s conclusion. 4 The first highlighted the need to put soldiers to work
returning from war, and the second concerned continuing the economic dividends that the
U.S. reaped by investing heavily in scientific research during the war. While these
investments were primarily technology-based, Bush argued for new forms of research that
would invest in the public good, one of these goods being health. As Bush’s ideas began to
take form, the National Institute of Health started investing its research dollars into
universities and medical schools.
Medical schools and universities served as the ideal places to make investments in
scientific research because of their ability to serve as centers of education and their track
record of collaborating with government and industry.5 First, universities were able to meet
the need of educating returning soldiers for new jobs in scientific research. Bush
commented, “Many had begun their studies before they went to war. Others with capacity
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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Vannevar Bush, Science, the Endless Frontier: A Report to the President (Washington: U.S. Government, 1945).

5 Richard C. Atkinson and William Blanpied, “Research Universities: Core of the US Science and Technology
System.” Technology in Society 30 (2008): 30-4. Chief among these collaborations came from University of
Chicago, Columbia University, and Massachusetts Institute of Technology, all of made important contributions
to the development of the atomic bomb. Thus, not only were universities collaborating with government and
industry, they were doing so on some of the most top secret and significant developments—albeit a quite
sinister one—of the twentieth century.
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prospect of making up some of the deficit in scientific personnel is by salvaging scientific
talent from the generation in uniform.”6 Bush saw academia as playing the role of resupplying the scientific work force with returning soldiers for future research. Bush and
others, moreover, hoped that increasing the number of scientists at work in education held
potential for stimulating industrial development emerging from new innovations.
At this time, most of the health-related research centered on diseases that could be
contracted overseas during the war: yellow fever, typhus, malaria, and various sexually
transmitted diseases. The funding for this research came from a combination of private
investment, e.g. Rockefeller Institute, and public grants targeting academia and industry
researchers willing to participate in the war effort. The OSRD was working closely with both
industry and academia “to develop penicillin, synthetic antimalarial drugs, steroids, and
replacement blood products, the companies used their preexisting connections with
academic researchers to meet the wartime demands.”7 Thus, the collaborative relationship
Bush proposed was nothing new, but rather an attempt to expand the success generated
during the war effort.
Post-war research efforts shifted, however, to focus on cancer, cardiovascular, polio,
sexually transmitted diseases, e.g. syphilis, and the development of neurological drugs.8 While
Bush understood that scientific progress itself was not a “panacea for individual, social, and
economic ills,” it was essential for ensuring “health, prosperity, and security as a nation in
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the modern world.” As an example, research efforts around cancer engendered widespread
marketing campaigns and fundraising efforts, which helped to raise awareness about the
positive impact that research can have on the lives of Americans.10 In addition to generating
public support, the U.S. government saw investment in research as a way to emphasize the
importance of strong science behind the development of new drugs.
Scientific Support
The U.S. government’s emphasis on the basic sciences as the heart of a medical
education allowed for the strengthening of the regulations for new drugs with the support of
scientific data.11 Thus, universities with schools of medicine saw an influx of scientific
researchers and an opportunity to interrogate the questionable science behind many of the
drugs on the market in the early half of the twentieth century. One such case resulted in the
death of some 107 people following the consumption of a new drug Elixir Sulfanilamide.12
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Bush, Science, the Endless Frontier.

10 Ken Burns’s recent documentary utilizes the historical narrative of Siddhartha Mukherjee, The Emperor of All
Maladies: A Biography of Cancer, (New York: Scribner, 2010). The documentary is: Barak Goodman, director,
“Cancer: The Emperor of All Maladies,” PBS Video, March 30 – April 1, 2015,
http://www.pbs.org/kenburns/cancer-emperor-of-all-maladies/home/.
11 Abraham Flexner and Daniel Updike, Medical Education in the United States and Canada: A Report to the Carnegie
Foundation for the Advancement of Teaching (New York: Merrymount Press, 1910); Lawrence H. Diller, “100 Years
Later, the Flexner Report is Still Relevant,” Hastings Center Report 40, no. 5 (2010), 5.; Starr, The Social
Transformation of American Medicine, 118-126. By turning to medical schools, the government sought benefit from
the renewed emphasis on the basic sciences as the heart of a medical education. The influx of scientific
researchers in university and medical education would allow for the government to be more assured that the
scientific developments that could be applied would be more rigorously studied. The government’s concern
about the questionable science behind many of the drugs that were on the market in the early half of the 20th
century was reflected in the tightening of regulations controlling the selling and marketing of drugs. In short,
universities and medical schools came to serve as an important interchange between publicly funded research
and potential economic returns in an increasingly regulated drug industry.

Peter Temin, The Origin of Compulsory Drug Prescriptions (Cambridge, Mass.: Dept. of Economics, Massachusetts
Institute of Technology, 1978); Peter Temin, “The Origin of Compulsory Drug Prescriptions.” The Journal of
Law and Economics 22, no. 1 (1979), 91; Hany Marks, “Revisiting the Origins of Compulsory Drug
Prescriptions,” American Journal of Public Health 85, no. 1 (1995), 109.
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Though there were prior Food and Drug Administration regulations, the 1938 regulations
reinforced the importance of sound science behind the development of new drugs.
The regulation standards for the marketing and selling of drugs had come under
heightened scrutiny by the FDA through policy developments in 1906 and 1938. In 1906,
the “Pure, Food, and Drug Act” outlawed the use of false or misleading drug labels. In 1938,
the “Food, Drug, and Cosmetic Act” adjured these same companies to demonstrate the
safety of their products before the FDA approved them for marketing. Academic scientists
found their domain of expertise in demand on multiple fronts, as educators, as regulators,
and as innovators. From the government’s perspective, universities and medical schools
provided the space in which new discoveries could be made and the science behind the new
drug discoveries could be verified. Industry, given the increased regulations, likewise, needed
to partner with academia in order to comply with FDA guidelines. The drug industry knew
that it needed its products to be more scientifically sound, but additionally saw future
possibilities in collaborating with academic researchers.
Through the initial relationships between industry and academic institutions, the
drug companies ensured their products were up to FDA standards, which led to financial
arrangements with academic research centers. In detailing the history of industry and
academic partnerships, Tobbell described how one of Harvard University’s vice-presidents
courted a relationship with George Merck to “advance biomedical education and
research…”13 When this courtship succeeded, the money received did not have any
stipulation that Harvard would put it toward a particular research endeavor, but rather would
be used for the overall development of students and infrastructure. From the perspective of
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the industry, however, these relationships built up academic allies who could offer scientific
support for their products. Recognizing the need for collaborating with scientists, industry
officials, e.g. George Merck, Eli Lilly, reached out to universities to form partnerships.
As the possibilities of collaboration were realized between universities and industry
officials, the government increased funding for research, and the FDA increased regulations.
The tightening of regulations further strengthened the partnership between academia and
industry. By the late 1950s and early 1960’s the partnerships had grown to the point that
both academia and industry became leery of any “non-scientific” government influences for
fear that they would begin to dictate what they could research, exerting control beyond
regulations. “Academic physicians and the industry regarded the scientific weakness of the
FDA as a very real threat to the integrity of pharmaceutical innovation and to clinical
research, and thus to the public’s health.”14 The scientific weakness of the FDA, however,
did not stop them from tightening their regulations on newly developed drugs.
The 1962 FDA regulations allowed the FDA to take greater authority over the
testing, manufacturing, and marketing of drugs and served to solidify the relationship
between academia-industry. The increased regulations by the U.S. government strengthened
the relationship between and academic researchers and industry because industry officials
needed to ensure that their products could pass FDA regulations. While the details of this
arrangement lie beyond the scope of the argument, the nexus of relationships between
government, academia, and industry create a story in which all three entities mutually relied
on and influenced the others.
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The collaborations between the three players—industry, academia, and politics—

though complex, have shaped the way in which research has developed. The U.S. was
concerned with maintaining the collaborative research efforts that had made significant
contributions to the public good during the war efforts. Academia, facing a renewed
dedication to science and medical education, sought to collaborate with government and also
industry officials regarding the scientific aspect of drug development. Industry saw these
partnerships as opportunities to deepen the science behind their products, and also to
increase its marketability though allying with physician-researchers to explain the validity of
the product. This junction of collaborations, forecasted in Bush’s proposal, was solidified by
the hefty investments in research made by the NIH.
Funding Research
The NIH’s budget dramatically increased U.S. investment in health-related research
between 1945-1970. In 1947, NIH funding for research was slightly over four million
dollars. Within ten years, the total dollars invested would reach $100 million. In addition to
investing in research, the government also saw the need to develop the research
infrastructure of the NIH. Thus, the NIH saw its own budget—not just that portion used
for grant awards—expand from $8 million in 1947 to more than $1 billion by 1966. 15 This
significant public investment created jobs, and generated practical health benefits and
products that could be invested in by private industry in the hopes of making a return on
their investment. This period of research is often referred to as the “golden age” of research,
where the resources being invested were rapidly yielding new knowledge and financial gains
through grant-based initiatives.
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The Golden Age of Research
The NIH grant awards were intended to support research projects and any additional

costs incurred by the research institution itself. Howard Schachman, a researcher, professor,
and an influential figure in the development of grant review process, described the landscape
of research in the 1950s as modest. He held a $7,000 grant from the National Science
Foundation to help fund his research. Though he realized the possibility of other larger
grants, he was content with the one that he had.16 The grant offered support for his research
and provided minimal assistance for ancillary staff. “Graduate students in the early 1950s
were supported as teaching assistants or research assistants funded by small grants to faculty
members or departmental funds. A typical laboratory would have one or two graduate
students, a technician, and perhaps one postdoc, a far cry from the research group of
today.”17 In a short time, the size of a research team, which is today composed of multiple
graduate students, post-docs, and research assistants, the source of paying for those
researchers evolved from a university-incurred expense to one absorbed frequently by grant
awards.18
Grants were, and still are, awarded through a peer-review process that considers a
wide-range of factors: research design, purpose, experience of researcher/s, budgets, and
appropriate “fit” for the aims of the grants itself. Peer-review serves as the standard process
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281, no. 11 (2006), 6889; Nicole Kresge, Robert Simoni, and Robert Hill, “Innovations in Ultracentrifugation
and an Analysis of Aspartate Transcarbamoylase: The Work of Howard K. Schachman,” The Journal of Biological
Chemistry, 282, no. 21 (2007), e16.
17

Schachman, “From ‘Publish Or Perish’ to ‘Patent and Prosper.’” 6891

This represents an important distinction from today that will be described in a bit more detail below. The
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for determining grant awards. At NIH, the review process is divided into two levels. The
first review takes place with a team of “expert reviewers” who consider the scientific and
technical value of the projects. This is an appointed review board of individuals who have
expertise relevant to the proposed grant. The initial panel is responsible for scoring the
application from one to five—one being the top score and five the lowest—and compiling
comments from the grant reviewers. The grant and its score are passed on to the second
level of review.
The second level of review takes place with both public representatives and scientific
experts who are appointed to the NIH review council. They evaluate the project based on
seven core values of NIH peer review: expert assessment, transparency, impartiality, fairness,
confidentiality, integrity, and efficiency.20 While the 1-5 score is taken into account, the
priorities of the NIH, special projects, potential overlaps, and the “general fit” of research
needs are considered.
It is important to note that the research needs have been determined historically
from within the scientific research community, though different types of researchers are
represented—i.e. basic, epidemiologic, clinical, quantitative, and qualitative investigators—
their discipline is science. In this way, the focus of the research review process remains
rooted in an epistemology that views science as an objective practice. Yet, with the
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19 The process described here comes from NIH. Though NIH’s process functionally reflect the standard way in
which peer review takes place. Laura Bonetta, “Enhancing NIH Grant Peer Review: A Broader Perspective,”
Cell 135, no. 2 (2008), 201; Medical Research Council, “Our Mission,” Medical Research Council - United
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epistemological shift called for in the previous chapter, the transformative effects of research
on historical reality have to be viewed more broadly than their scientific impact.
As seen below, the impact of research decisions on poor and vulnerable populations
cannot be viewed as neutral. Therefore, the needs of the community in which the research is
intended to benefit needs to play a part in setting priorities for awardees.21 While this process
continues to be improved upon, it was not even on the radar of the award committee during
the research’s “golden age.”
During the research boom, grant applications in the 1960s and into the 1970s
enjoyed a near 60% success rate. This high success rate in grant awards allowed universities
to use research dollars for needs beyond the scope of the research process itself. The influx
of research dollars due to successful grant applications from university researchers led to the
allocation of that money to cover a host of costs that the university attributed to research.
These costs included construction costs for new buildings, administrative fees, graduate and
post graduate fellowships, and eventually faculty salaries. Research costs would eventually
be used to justify two or three months worth of salary, but this gradually led to “establishing
‘soft money’ faculty positions.”22
Soft Money
Soft money positions signify that the faculty-researcher is responsible for raising a
small to significant portion of one’s salary through grants. This is opposed to hard money
positions, in which the faculty member is guaranteed and accounted for in the university’s
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21 This review process can be contrasted with that of Comparative Effectiveness Research (CER) described in
the next chapter. CER grant review intentionally focuses on the input of the community that the research
intends to benefit.
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budget. Schachman notes that this has become common practice, particularly in medical
schools. He recalls that one institution in California has been allocated state funds for 30
full-time faculty salaries, and approximately 300 faculty members held those 30 slots. In the
case of this institution, faculty members are required to raise around 90% of their salary
from grant awards. With this type of system, universities were able to create much larger
science departments than before, thereby justifying the construction of new buildings and
research facilities to house their growing faculty. The researchers raising funds for their own
salaries, coupled with the construction of new campus buildings, however, leads to
discontent between university administrators and research faculty.
Given the amount of public funds used to support faculty time and construction of
research buildings in the 1970s, complaints surfaced about too little of the grant money
being used to support research. “Research scientists, faced with stringent budgets and with
ratings on their grants below the funding level, argued strenuously that indirect costs
amounting to billions of dollars annually, should be reduced markedly. In their view, the
money saved could then be used to support more research.”23 As more questions arose
about the university’s use of funds, so too did difficulties regarding the university’s ability to
cover “indirect costs” with grant money. While successful applications from the mid 19601970s were consistently near 60%, this figured dipped significantly in the 1980s and settled
closer to 20%.24 This shift can be attributed, in large part, to changing priorities within the
U.S. budget, which led universities to look for new sources for research funding.
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The economic benefit research afforded for universities increased throughout the

1960s only to level off at the dawn of a new decade, forcing universities to explore
alternative sources of funding for researchers. Paula Stephan noted two factors in particular:
the Vietnam War and the Mansfield Amendment. The 1969 Mansfield Amendment barred
any research that was not directly targeted for the benefit of military function, and therefore
restricted the use of government funds for university-based research.25 However the
government had not been the only entity investing in research throughout this “golden age.”
Universities’ own contributions “increased by 55 percent, and by contributions from all
other sources, which included philanthropic organizations, that grew by 68 percent.
Industry’s expenditures on academic research increased by almost 70 percent.”26 Thus, given
the multiple investors and competition for research dollars, universities had to find a way to
keep sources of revenue flowing in order to invest in new buildings, pay top researchers, and
continue the philanthropic investment, all while NIH funds had stalled. Nevertheless,
universities were determined to find ways to pay their researchers and generate some return
for the intellectual property being developed at their institutions.27 While there was much
debate about the patenting of research for industry purposes, universities themselves
remained disinterested in patenting rights until the mid 1970s.
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25 Paula Stephan, “The Endless Frontier: Reaping what Bush Sowed?” in The Changing Frontier: Rethinking Science
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Research, forthcoming), 2.
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27 Ibid. The number of institutions offering science PhDs almost tripled from 80 at the end of the war to 224
by 1974. This made acquiring grants most difficult, particularly as NIH investments slowed. Thus, with
hundreds of PhDs being produced each year, industry began to be able to pick off researchers and could also
pay much better than academia. Here one can see the convergence of science, business, politics, and education
affecting the way in which research is structured. While university researchers had to earn their soft-money
salaries, industry PhDs were guaranteed theirs.
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Patents and Current Research Funding
The slowing of NIH funds that emerged in the late 1970s and early 1980s, began to

shift the position of universities with respect to patenting rights. As funding sources began
to wane throughout the 1980s, universities sought other ways of maintaining the revenue
flow to which they had grown accustomed. Concurrently, research itself became a more
expensive undertaking, while pharmaceutical and newly emerging biotechnology companies
tended to reap the financial benefits.
While no one would doubt the importance of ensuring the quality and safety of a
drug, this comes at a cost. Significant resources, both financial and employee time, are
devoted to clinical trials. 28 This has been particularly true as researching targeted the defeat
of certain diseases, e.g. Nixon’s famous declaration of “war on cancer.” Therefore, not only
were universities engaged in basic science research, but medical campuses—institutions with
both a university and a hospital—were now more heavily engaged in expensive and timeconsuming clinical trials. While technological breakthroughs and a spike in resources
devoted to clinical trials led universities to seek alternative funding sources, it is was legal
action that allowed universities to patent their intellectual property.
Bayh-Dole and Diamond v. Chakrabarty
Two important events, the passage of the Bayh-Dole Act and the U.S. Supreme
Court ruling Diamond v. Chakrabarty, both in 1980, solidified efforts to allow for the patenting
of intellectual property derived from federal funds. The first of these developments, the
passage of the Bayh-Dole Act, offered an opportunity for researchers, their university, and
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established a uniform patent policy in which universities and other non-profit research
entities could “retain the title to inventions made under federally-funded research
programs.”30 This was a reversal of years of policy that allowed the government to retain the
intellectual property rights of developments that came from government funds. This
legislation was reinforced by another development, the Supreme Court ruling in Diamond v.
Chakrabarty.
The Diamond v. Chakrabarty ruling allowed for the patenting of a biologically
engineered microorganism that was designed to be able to break down crude-oil spills.31 The
consequences of this ruling were two-fold. Most importantly, it marked the first instance of
patenting a product derived from federal funds. Secondly, the patent was for a biologically
created organism. Thus, as biotechnology has become more sophisticated, the ability to
create biologically engineered organisms has continued to grow and patents increase. 32
While the Supreme Court ruling promoted a close 5-4 decision, it paved the way, along with
Bayh-Dole, for patenting of new biotechnology and the potential for generating a substantial
financial gain from those research endeavors.
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29 The act’s passage enabled greater collaboration with industry representatives and served as an instantaneous
model for way in which research was conducted globally. The move to be open to the commercialization of
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Today, patenting practices at universities and non-profit organizations have become

commonplace in the basic science research. The Association of University Technology
Managers, the association of managers that oversees technology transfers at universities,
serves as a gauge for the interaction between academia and industry. Since the passage of the
Bayh-Dole Act, Callahan notes that as of the early 2000s, “American universities now own
more patents than the twenty-five largest pharmaceutical and the biotechnology companies
put together.”33 Patenting rights generally allow the intellectual property holder to maintain
sole possession of the patent for 20 years from the time of application. This exclusive period
of ownership, has allowed American universities to develop more than 4,000 companies and,
according to AUTM survey data, has generated significant financial rewards, netting $36.8
billion in 2012 alone.34 Patenting, while not problematic in and of itself, does complicate the
motivations and values operating within research efforts, particularly as industry assumes
more and more control over the research and development of new drugs. This shift, both
within the university and industry engagement with research, has raised concerns within the
research community about the purity of research efforts and the challenges of doing research
in an environment with multiple interests and billions of dollars at play.35
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Conflicts of Interest
One approach to addressing emerging ethical questions between financial rewards,

patents, and the goal of medical research centered on the issue of conflicts of interest.
Conflicts of interest can arise for a variety of reasons, and when they do, they have been
shown to affect decisions that researchers make. Josephine Johnston, a researcher at the
Hastings Center, describes academic studies with financial ties to industry have tended to be
favorable to the sponsor of the research and holding back negative publications.36 While
financial conflicts can lead to disproportionately favorable outcomes in experiments, they
have also been shown to improve the likelihood of a drug’s approval.37
In a recent study, exclusive industry partnerships with researchers who serve on
regulatory boards, e.g. the FDA, tend to approve drugs at a 10% higher rate than those with
no financial ties or multiple ties to the sponsor and a competitor.38 This is not to say that
conflicts of interest cannot be balanced, however, it raises important questions regarding the
motivation of research approval and consequences of patenting. Moreover, conflicts of
interest raise questions regarding the validity of the approval process itself. In other words,
are new drugs simply being approved because they offer an opportunity for financial gain or
because of the health benefits they might bring? Questions regarding conflicts of interest
retain central importance and should continue to be investigated, as billions of dollars flood
the global research market.
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Global Investments
Global investment in research and development, taking place through both public

and private funding sources, reached over $1 trillion in 2014. Battelle, a company that tracks
the business aspects of innovation across various industries, estimates that about half of that
trillion is divided amongst basic science research and applied research throughout various
public and private research institutions.39 The United Nations Education, Scientific, and
Cultural Organization (UNESCO) derived close to the same figure as Battelle, with the U.S.
leading the way in investments for health related research totaling over $475 billion,
spending approximately 2.8% of its GDP on research.40 According to UNESCO, the
funding sources for research come from one of several categories: business enterprise,
government, higher education, private non-profit organizations, or “abroad.”41 Despite the
breadth of funding sources, the majority of investments in research and development come
from pharmaceutical and biotech industry re-investing their own money and utilizing their
own scientists in an effort to keep costs down.
The estimated cost of bringing a drug to market can be upwards of $1.5 billion and
take 15 years for approval. Most drugs, moreover, fail during the second and third phase
trials, after which significant investments have already been made in research. In short, the
ten leading pharmaceutical companies have spent over $58 billion on research and
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development activities in 2009. However, as Valverde points out supporting Marcia Angell’s
critique of the early 2000s, pharma companies exhaust “more time and resources on
generation, collation, and dissemination of medical information than it does on production
of medicine.”42 Thus, while R&D costs may be upwards of $1.5 billion there is debate about
whether this is the actual cost of research itself, or ancillary marketing and dissemination that
the companies deem necessary.
Marcia Angell, former editor of the New England Journal of Medicine, in addition to her
critique of what “counts” as Research and Development (R&D), has been equally critical of
industry’s proclivity to research primarily profitable drugs. She specifically highlights research
practices focused on the development of “me too drugs.” “Me too” research centers on the
development of new drugs to replace already serviceable pharmaceuticals in the market
place. The hope is to develop an alternative drug with different chemical properties that will
allow for the pharmaceutical company to hold a new patent on their product, regardless of
whether or not it is more effective than the product already on the market.43 Here the lines
between the health outcomes of research and the economics of research seem to switch
places, with financial gain serving as researchers true goal. While medical research can be forprofit, institutions of higher education and non-profit private investors, who account for
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around 40% of the total investment in R&D, need to ensure that their research focuses on
health outcomes over economic gain.44
Amongst the top ten research contributors, the United States, China, and Japan
account for over 50% of investments made into research, a small portion of which flows
through institutions of higher education.45 However, the question centers on what these
institutions are doing with the funds. China, for example, invests no money for research in
higher education, whereas the U.S. and Japan funnel a modest 10% through universities.
Brazil, also in the top-ten of global investors, devotes the most, around 40% of their total
research expenditures, India 4%, and the U.K. and France invest around 20% into
universities.46 In other words, globally, university-based research still plays a role in shaping
the landscape of, albeit not as significant as in the “golden age.” The question is how ought
universities use those resources at their disposal?
Established Priorities
If medical research is a practice, as proposed at the beginning of this chapter, and
there are internal goods to the practice, then one of those goods has to be the actual
improvement of people’s health. Yet, given the allocation of the NIH budget, it seems more
investments are being made on the potential impact on people’s health than more immediate
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needs. A look at the 2014 NIH “Estimates of Funding for Various Research, Condition, and
Disease Categories (RCDC)” notes that over $16 billion went to research pertaining to
Genetics ($7.3 billion), Biotechnologies ($5.7 billion), and Bioengineering ($3.3 billion).
These three categories, while having the potential of generating future benefits, offer little
immediate impact—particularly when considered in a global context. On the other hand, $14
billion—not an insignificant amount—was devoted to research for Women’s Health ($3
billion), Pediatric Research ($3 billion), HIV/AIDS ($2.9 billion), Cardiovascular ($1.9
billion) Nutrition ($1.5 billion), Orphan Drugs ($809 million), Stroke ($300 million),
Tuberculosis ($279 million), Infant mortality ($268 million), Malaria ($169 million), and
Malaria Vaccine ($36 million).47 In other words, $2 billion more went to three research
categories, as compared to the 11 categories that roughly correspond with priorities
recognized by the WHO and the United Nations (UN) Millennium Development Goals as
representing global health challenges. While genetic, biotechnologies, and bioengineering, no
doubt, hold scientific promise of improving health, they also yield a high return on
investment.48 Thus, it is unclear whether they are being prioritized for health or financial
gain. Moreover, given that cutting-edge research is not likely to be realized for the majority
of the world, ought high cost-high yield research be prioritized more than Women’s Health,
Pediatric care, or HIV/AIDS?
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Minding the Research Gap
When reflecting on the historical developments in medical research, the health

improvements experienced globally tend to originate in the Western world and to offer
greater benefit to persons from those countries. Although there are exceptions, such as the
previously mentioned smallpox, applied research typically leads to the development of new
medical treatments and interventions that center on the health of those who can afford these
developments. David Resnik argues the economics of research creates disparities in research
priorities. Disparities “exist because biomedical research on the health problems of the
developing world is neither financially lucrative nor politically popular. Although some
private foundations spend a great deal of money on the health problems of the developing
world, their contributions are not enough to close the gap.”49 In short, the global medical
research priorities, not just those of the U.S. described above, disproportionately improve
the health of particular persons, i.e. those who those of high-income countries. This blind
spot in establishing research priorities has resulted in a consistently unjust burden of disease
that affects the majority of humanity.
The “10/90 gap” is a phrase coined by the Global Forum for Health Research that
represents the disparities in medical research, in which 10% of the population benefit from
90% of the research conducted. Conversely, this means that 90% of the world’s population
receives only 10% of research’s benefit. These numbers were originally developed in the
early 2000s by a WHO working group that calculated an “estimated 93% of the world’s
burden of preventable mortality (measured as years of potential life lost) occurs in the
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developing world... [yet] only 5% [of research] was devoted specifically to health problems of
developing countries…”50 While these figures have been challenged, and by most
estimations decreased over the last two decades, the phrase stands as a symbolic point of
reference for the continued disparity and underfunding for research that benefits the those
bearing most of the global burden of diseases.51 Epidemiologic measurements of the global
burden of disease demonstrate geographically which populations bear the heaviest burden of
disease and serve as indicators of the need for improved medical care and treatment.
Burden of Disease
Measuring the burden of disease provides important information about who is
suffering from particular diseases, where they are located, and the estimated life lost There
are two measures frequently used in public health to estimate the number of life years lost
due to disease or premature death, QALY (quality adjusted life years) and DALY (disability
adjusted life years). QALY estimates the number of quality life years lived and is more
frequently used to establish a cost effectiveness strategy for investments in health. DALY,
which is the measurement used by the WHO, is calculated by adding the number of years
lived with a disability to the number of years lost due to premature death, based off of an
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51 While certain essays have been more dismissive of the continued use of the 10/90 gap for neglected diseases,
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countries. For an argument against the usefulness of the 10/90 gap, see “Diseases of Poverty and the 10/90
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ideal standard, i.e. years of living without disease and/or disability.52
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DALYs prove helpful when trying to trace the burden of disease on particular
populations. The highest concentration of DALYs is located in Sub-Saharan Africa with
Sierra Leone having the highest number of adjusted life years due to death or disability, over
117,000 years. The lowest number of years lost is in Singapore (14,354 years), followed by
Japan (15,700 years).53 A glance at the WHO numbers for morbidity and mortality indicate
that there are vast disparities in the communities who bear the global disease burden. While
research alone will not address the DALYs completely, they do serve as a focal point for
what diseases are pertinent to these areas and to consider the role research could play.
According to the WHO, the top ten causes of morbidity and mortality cut across
geographic and economic lines, but the number of deaths due to preventable diseases
primarily plague low-income countries.
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Figure 1. The 10 Leading Causes of Death in the World, 201254

Figure 2. The Top 10 Causes of Death in Low Income Countries, 2012
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Table 3. The Top 10 Causes of Death in Lower-Middle Income Countries, 2012

Table 4. The Top 10 Causes of Death in Upper-Middle Income Countries, 2012
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Table 5. The Top 10 Causes of Death in High Income Countries, 2012
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As can be seen in Figure 1, the leading causes of death globally are comparable between
those countries of varying economic status as seen in Figures 2-5. What proves significant
about these deaths, however, is the combination of preventable causes of death that appear
primarily in low-income countries and, to a lesser degree, in lower-middle income countries.
However, these preventable health-related deaths—diarrheal diseases, birth complications
(pre and post partum), and malnourishment—also appear alongside chronic diseases—TB,
diabetes, heart disease, etc. Preventable health complications presenting alongside increasing
numbers of chronic diseases result in higher incidence of death. As a country’s income level
increases the burden of disease related to public health causes and lack of access to health
care correlatively dissipate.
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“A Pathogenic Situation”
Paul Farmer notes—and the above statistics corroborate— these disparities

demonstrate a propensity for preventable, or at the least treatable, diseases to
disproportionately affect people living in low-income countries. He describes these
disparities as epidemiological in nature.
Most often, diseases themselves make a preferential option for the poor. Every
careful survey, across boundaries of time and space, shows us that the poor are
sicker than the non-poor. They’re at increased risk of dying prematurely, whether
from increased exposure to pathogens (including pathogenic situations) or from
decreased access to services—or as is most often the case, from both of these ‘risk
factors’ working together.55
What Farmer means by “pathogenic situations” is that the very conditions in which people
live, not just the disease pathogens, make individuals more susceptible to contagion. Farmer
highlights that, in this way, diseases tend to disproportionately affect persons who lack both
socio-economic and health resources. Analysis of the global morbidity and mortality
statistics for low and low-middle income countries demonstrates that they suffer unique
health circumstances that do not create problems for higher income countries who have
greater access to both economic and health resources. However, what also gains increased
clarity is that health problems of higher income countries—cancers, cardiovascular disease,
diabetes—are now beginning to afflict lower income countries. The introduction of chronic
diseases compounds the already unique challenges presented by high incidence of child
deaths from diarrhea, lower respiratory tract infections, and neonatal deaths in low-income
regions.
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Two recent examples that reflect the challenges of combining disease, poor health

infrastructures, and poverty are the continuing cholera epidemic in Haiti that began in 2010,
and the recent, 2014, Ebola virus disease (EVD) spread in three West African countries,
both of which exemplify Farmer’s analysis. These situations, while illustrating the
importance of sound public health and health care delivery systems working together, also
highlight the necessity of having adequate medical research develop from all areas: clinical,
epidemiologic, and basic, to address emerging needs. Moreover, these case studies point to
the continued complexities of under-researched diseases that exist primarily in low-income
countries.
Two Case Studies
Cholera
In January of 2010, a massive earthquake struck Haiti, killing over 200,000 people
and injuring another 300,000. Only ten months later, in October, an “unlikely” occurrence of
cholera appeared that has led to the additional death of 8,000 people over the past four
years.56 The source of the introduction of the disease, ironically, came from one of the UN
workers from Southeast Asia sent to aid in the earthquake relief efforts.57 While the epidemic
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56 Paul Farmer, et al., Haiti After the Earthquake, (New York: PublicAffairs, 2011), 383. Here Farmer notes a
report from the CDC that cites the occurrence of cholera in Haiti was low: “While the current water, sanitation,
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in Haiti is now in its fifth year, this particular strain is in its 53 year and has affected 58
countries. These countries where the disease has both endured and recurred are
predominately lower income countries. Haiti is a country of limited economic resources,
poor sanitation infrastructure, and minimal health care and public health resources. Thus,
the challenge the country faces is a complex one. In order to address the challenge, a group
of health care workers: physicians, nurses, public health experts, industry, and government
officials gathered to begin strategizing to stop cholera’s spread.
Cholera, recalling from chapter one, is a bacterial-based disease that spreads through
contaminated water, a common experience in Haiti. The disease can be controlled through
sanitation efforts, effective rehydration, and, the use of vaccines. The debate around how to
control cholera in Haiti, as Farmer describes it, ultimately has come down to a minimalist vs.
maximalist approach.58 The minimalists argue that it would be “too difficult” to control the
spread of the disease, and opposed vaccinations in favor of water protection. Farmer notes,
“Safe, effective, and affordable oral vaccines exist, and yet remain unavailable in Haiti—as
do, too often, timely diagnosis and care. When some suggested integrating vaccination into
the response, public health officials were quick to note that vaccination was not costeffective (as if “cost” were fixed in stone and “effectiveness” well understood).”59 On the
contrary, the maximalists argue that all possible ways to stop cholera be implemented or at
least explored: improved sanitation, chlorine tables, effective and safe vaccines, rehydration
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59 Louis Ivers and Paul Farmer, “Cholera in Haiti: The Equity Agenda and the Future of Tropical Medicine,”
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therapies, and antibiotics. Farmer reports that conversations tended to default to the
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positions that academics and researchers had held for years and could not move beyond
them to address the emergent situation at hand. The continued discord between experts
resulted in a series of conference calls in the hope of developing a unified approach, the
second of which was hosted by Harvard Medical School.
Harvard Medical School served as the host of the conference call focusing on health
outcomes, and was not tied to a particular methodological or policy-based approach. The
school and its officials—including Farmer as a professor of Global Health and Social
Medicine—sought to mitigate the tensions between the two groups by assembling a team of
cholera experts. The call included over 80 such representatives from Haiti, the U.S., Geneva,
Korea, and beyond.60 The group was tasked with developing a consensus statement,
generating the a clear focus for the group and, by hearing from people on the ground in
Haiti, to appreciate the complexity of the situation at hand.
Haitian policies, lack of sanitation, lack of access to care, and a broken infrastructure,
contributed to an already challenging recovery from the earthquake. While the government
itself sought “a 10-year, $2.2 billion plan to eliminate cholera, including $1.6 billion to
improve water and sanitation,” political corruption is a rampant problem, and therefore a
major increase in aid was a tenuous solution at best.61 The university-mediated call resulted
in a more unified group, aware of the problems and differing positions, but willing to
approach treating the cholera epidemic interdisciplinarily and focused on those suffering
from the disease
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The cholera epidemic is one example of a disease that, within the last 60 years, has

primarily affected lower income countries with limited access to necessary treatments.
Farmer and his colleague, Louise Ivers, sum up the challenge quite well: “One hundred fifty
years after John Snow took the handle off the Broad Street pump, more than a century after
his suspicions of bacterial origin were confirmed, 60 years after antibiotic therapy was
discovered, and 30 years after a safe and effective oral vaccine was developed, cholera
remains—among the world’s poorest—a leading infectious killer.”62 While this disease exists
nowhere in high-income countries, except in instances of health relief workers bringing it
back, its continued prevalence points to the inequity that exists with respect to disease
burden. The fact that the disease persists, moreover, signals a lack of expectations that
curative and/or preventive treatments, when available, will be provided for resource poor
populations. This reality led Farmer and Ivers to put forward a rather simple explanation,
namely, that the failure to cure tropical diseases results from lowered expectations to cure
“diseases that disproportionately afflict poor people.”63 Despite the existence of proven
treatments, including a vaccine and means of disease prevention, there is a dearth of medical
care and a limited public health infrastructure, aside from any research limitations.
Cholera demonstrates the complexity of coordinating efforts between the public
health, medical care, and available treatments. In this instance, the lack of medical research in
and of itself was not a limitation. In fact, the research developed could serve as a supplement
to prevention and rehydration. Therefore, the research has been done on cholera in the
event of widespread outbreak, and vaccinations represented an option that could have been
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utilized within a better health care infrastructure. In many ways, cholera represents a disease
that has been prepared for adequately through medical research, but that needs a solid public
health and health care delivery research structure to be successful. At the same time, cholera
prevetion. However, this has not been the case with the recent Ebola epidemic, where
neither the research, prevention, nor treatment options have been adequate.
Ebola
There is no clearer example of the disproportionate response that the Ebola
epidemic in West Africa received, compared to the frantic responses to isolated cases of the
disease in the United States. In 2014, the Ebola virus disease (EVD) originated near the
border of three West African countries, Guinea, Liberia, and Sierra Leone, and has caused
the death of close to 9,000 people.64 Various practices have been implemented to attempt to
contain the disease at its source. In Liberia, the government attempted an area-wide
quarantine in its capital city, Monrovia. “60,000-120,000 people lived in deplorable,
unsanitary, slum like conditions. Barbed wire and live bullets confide these desperate people;
there was little or no health care available and highly infectious dead bodies lay in the streets
for hours and sometimes days. After 10 days, the scheduled 21-day quarantine was halted.”65
Large-scale quarantine, however, proves a fairly ineffective strategy for containing a disease
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spread. Treatment options, however, are also limited given the disparate number of doctors
available.
Even if both public health measures and medical delivery system were in place, no
adequate treatment of the disease exists. While ensuring that medical care and public health
structures are in place would exponentially increase survival rates, a lack of a vaccine
provides an obstacle for preventing future outbreaks. Yet, the reason that the disease has
received so much global attention is not because a vaccine does not exist, nor the deplorable
conditions of Liberia’s quarantine, nor the deaths of thousands in West Africa. Rather, the
national and international fervor was stirred by the death of one Liberian on U.S. soil. That
one Liberian man’s name was Thomas Eric Duncan.
Mr. Duncan presented to a Dallas hospital emergency depart after exhibiting
common symptoms associated with EVD: high fever, weakness, and abdominal pain. After
being attended to, he was ultimately sent home, only to return two days later more
contagious and highly symptomatic.66 When he returned, the disease had progressed
dramatically, and he ultimately died. In the process of caring for the patient, two nurses
became infected with EVD. Upon presenting with symptoms, both were treated and given
immediate care and proper precautions—including the quarantining of one patient’s dog—
were put into place. The response was immediate. A systematic health care response was in
place, public health precautions taken, and treatment was delivered quickly and effectively.
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In contrast, the health care system in which the majority of people are contracting

the disease is one in which a few dozen physicians care for the 4.2 million people of Liberia.
Moreover, the lack of a public health infrastructure, where basic hygiene and removal of
infectious and deceased bodies proves challenging, contributes to the spread of the
epidemic.67 While challenges resulting from a lack of an efficient health care delivery and
public health practices are known, these weaknesses are exacerbated by the comparatively
little research that has been done on EVD. The lack of research has resulted in the reality
that no vaccine or 100% curative treatment exists. Nevertheless, the epidemic did spur some
international conversation towards investing in research to develop a vaccine.
The WHO convened an urgent meeting from September 29-30, 2014 to evaluate and
discuss the production of a safe and effective EVD vaccine.68 70 scientists, public health
officials, and representatives from industry, and regulatory bodies gathered to discuss two
vaccines in particular: cAD3 from GlaxoSmithKline and U.S. National Institute of Allergy
and Infections Disease (NIAID), and rVSV from NewLink Genetics and the Public Health
Agency of Canada. Both vaccines have demonstrated 100% efficacy in nonhuman primates,
and the action items resulting from the meeting stressed that phase one trials should be
expedited and their results shared broadly to facilitate rapid progress in phase two. The
continued neglect of research for EVD, despite outbreaks dating back to the 1970s,
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necessitated a fast-tracking process and the immediate institutions of new policies breaking
with WHO research norms.69
While these developments come too late for Mr. Duncan and the thousands of
others who have died, international conversations have begun that raise awareness about the
need for research for under-researched diseases that affect vulnerable populations. Farmer
argues that what is needed is:
specific therapy, better and faster diagnosis, and effective vaccines. The vaccines and
drugs required to treat so-called ‘emerging infections diseases’ do not exist because
of what James Surowiecki has called ‘Ebolanomics’. When disease victims are both
poor and not very numerous,’ he says, ‘that’s a double whammy. On both scores, a
drug for Ebola looks like a bad investment.70
Again, the importance of prioritizing research based on health, not economics proves
fundamental.
The cases of EVD and cholera confront medical researchers and health care workers
with a clear option in making research and treatment decisions. Farmer, again, puts the
choice into perspective by challenging “doctors and other health providers to make an
option—a choice—for the poor, to work on their behalf. The insight is, in a sense, an
epidemiological one: most often, diseases themselves make a preferential option for the
poor.”71 Farmer’s epidemiological insight, also presents a similar epistemic option to that of
Ellacuría’s in the previous chapter, and one that has historically not been one taken up in
medical research agenda.
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This hurried approach to developing research to meet a pressing need points to the importance of having
research ethics that is focused on protecting individual research subjects, and in particular those who are
considered vulnerable subjects. Yet, it also points to the need for social bioethics to be attentive to underresearched diseases in order to avoid the situation described above.
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Broadening the Scope of Research
Reflecting on the developments of the practice of medical research through the

interactions of government, universities, industry, and burdens of disease demonstrates a
nexus of priorities that research agendas can reflect. However, it seems economic returns
receive more attention than improvements to the health of persons bearing a significant
burden of disease. A 2012 Global Health Forum Report estimates, “for each year of
potential life lost in the industrialized world, more than 200 times as much is spent on health
research as is spent for each year lost in the developing world.”72 While access to health care
and public health provide two strong pillars for a healthy society, access to and participation
in the development of affordable treatments is essential.
From Vannevar Bush to present day discussions of research priorities, innovations in
medical research focus consistently on its financial benefits. However, insofar as medical
research functions as a practice, there are both intrinsic and extrinsic goods to that particular
practice. Moreover, the epistemological reframing of the practice of medical research
requires an examination of how research shapes historical reality. In the first few sections of
this chapter, I have argued that governments, the pharmaceutical industry, and academia
have gone a long way to shape research to prioritize returns on investment first and health
second. While research, as seen in the case studies, serves as one piece of the puzzle, it
proves an important dynamic in improving health. When establishing research priorities on
both social and individual levels, medical research cannot be isolated from its constructive
dynamic that contributes to the injustices present in the global burden of disease. Therefore,
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it is necessary to reflect on the development of the relationships that make medical research
possible, as has been done above, but also to reflect on the impact that these relationships
have had.
Revisiting Responsible Conduct of Research
In Chapter Two, I discussed that responsible conduct of research focuses primarily
on respecting the rights of research subjects and fulfilling an obligation to non-maleficence.
However, when considering responsibility on a social and relational level as I have proposed,
responsible research should take more seriously its obligation to engage in research that
serves the vulnerable groups that research ethics aims to protect. When the economic gains
of research become the focus over health, the health needs of those to whom Ellacuría
referred to as the poor majority, become neglected and/or under-researched.
Focus on the economics of research lends itself to prioritization of technological innovation
that requires a significant financial investment and tends to yield profitable returns that fails
to benefit a significant portion of humanity.
The emphasis placed on finances and being on the cutting edge of research tends to
mask the health needs of the majority. Desires of individuals, predominately from high
income, western countries, obfuscate true need of the global majority. In looking at the NIH
funding priorities, it is not that funding does not exist to address concerns of the majority,
but the allocation of those funds are disproportionate to health needs as indicated by the
global burden of disease. Hille Haker argues that research choices are framed in a way that
prioritizes individual choices, which reinforces the importance of technological innovation
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that delivers health to some, while neglecting the needs of many. Lisa Sowle Cahill likewise
posits that the accumulation of individualized choices made by a select few “affect society as
a whole, changes expectation of health and normality, and reinforces economic and class
stratification.”74 Thus, in the scenario Cahill describes, certain people will be expected to be
healthy, while others are accepted to be at a higher risk of disease. This bears out in the
reactions to Ebola, until it began to effect Western and high-income countries. However, if
medical research considers its role in affecting the health for all, then interests have to move
beyond a subjective and individualized understanding of health.
Haker proposes that a rights-based framework can more adequately take up the
question of justice within scientific research ethics. She argues that linking human rights “to
a general concept of well-being… needs to be spelled out under the conditions of modern
medicine and needs to be negotiated in the process of ethical deliberation in general.”75
However, who does the negotiations for rights? Who is obligated to ensure that these rights
are met? How does the prioritization of medical research ensure that the voices of those
most in need are heard?
Cahill, in some ways answers these questions, by arguing for a participatory model of
justice frames needs, in this case health needs, as fundamental to any notion of the common
good. Given the above discussion of the organizational players in the construction of
medical research, the only ethical discussions that arose in research were worries over
conflicts of interest and violation of individual rights. A participatory model of justice would
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look first to the participants in the establishment of a medical research agenda, and also to
those who stand to benefit. To begin to discuss the ethics of medical research beyond an
economic and/or technological framework necessitates a consideration not just of interests,
but of the health needs and rights from the perspective of those who have seemingly “no
health” and “no rights.”
Cahill and Haker both begin with positive considerations, rights and the common
good; however a liberationist ethics adopts a socio-historic perspective that begins from
injustices. Though Haker, Cahill, and Ellacuría find common ground in their collective
concern over the need to address global injustice, their starting points differ. Ellacuría starts
with injustice through the biological fundament of ethics—i.e. to see what is unethical or
unjust one only needs to turn to the places where people continually die prematurely. Haker,
calls for an ethical analysis of the research beyond the individual focus demonstrated in a
technology-based ethic, to one that focuses on rights through “the interpretation (articulation
and analysis) of values and norms articulated in different and pluralistic settings, and to
confront them with moral principles considered to be essential for human life and human
flourishing.”76 While Cahill argues for a common good and participatory bioethics that
considers “a more international, dialogical, multilayered, and multifocal approach …to
handle the quandaries of globalization, including those posed by genetics-based
biotechnology.”77 Each starting point has its own value, however, if the socio-ethical
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framework of medical research is to be re-imagined in a way that considers the global burden
of disease, then hearing from and understanding the experience of those suffering from
these diseases proves fundamental.
Shifting the Agenda
Publications generated from public and privately funded research initiatives tend to
attest to a gap in research that does not benefit people living in lower income areas. In 2002,
a study showed that out of 1393 new chemical entities (NCEs) marketed between 1975 and
1999, only 16 targeted ‘‘tropical diseases’’ and tuberculosis.78 Within the world of research,
publications are the best insight as to where the field is focusing its efforts and which
projects are receiving funding. Given that publications trend away from addressing the needs
of the majority, awareness must be raised within the scientific community, not only about
their needs, but also about the potential of the scientific community to address those needs.
The WHO and United Nations have implemented international mechanisms and
standards that raise awareness of disparities in access to health care, public health
infrastructures, and medications. The most discussed of these awareness-raising platforms
are the Millennium Development Goals (MDG). The MDGs devise an action plan aimed at
alleviating poverty and focus on those people suffering from hunger, malnutrition, and
disproportionately infected by disease.79 Of the eight goals, four come to bear directly on
health: reducing childhood mortality (MDG 4); improving maternal health (MDG 5);
combat HIV/AIDS, malaria, and other diseases (MDG 6); and establishing global
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partnership for development (MDG 8). To meet each of these goals would require a highly
strategic approach to the way in which medical research can contribute to improving
maternal and child health, but also improving upon distribution of its fruits can participate in
decreasing the gap of those who bear the burden of HIV/AIDS, malaria, TB and other
diseases that disproportionately affect low-income countries. MDG 8 specifically focuses on
the necessary development of global partnerships for addressing health inequalities.
The MDGs propose a different way of addressing and prioritizing a research agenda.
Instead of a financially driven model, their model is rooted in the health needs of the poor
majority. However, in order to move towards these realities, other institutions have to
commit to the priorities that the MDGs highlight. In this way, a radical shift is necessary in
setting research priorities that explore the underlying values and injustices endemic to the
practice of medical research. It is here that bioethics and Catholic universities can play a
crucial role.
Social Bioethics
Though arguments within the last decade have emerged in the bioethics literature
about research inequalities, described at the conclusion of Chapter Two, the focus has
primarily centered on research practices within low-income countries and only limitedly
focused on priorities setting. Norman Daniels argues that this focus has resulted in “a
myopic view that misses the institutional context in which clinical relationships operate and
can overlook factors that affect health more broadly than do exotic technologies.”80 Haker
has likewise called attention to the necessary broadening of bioethics to consider the
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81
contexts in which research is implemented. Although bioethicists have been attentive to
promoting responsible conduct of research that protects vulnerable persons, it has overall
neglected the applicative dimension that disproportionately burdens the same people.
Henk ten Have argues that the traditional framing of vulnerability has been
understood as an individual deficiency, rather than the result of a social situation. “Being
vulnerable is often the result of a range of social, economic and political conditions, and
therefore beyond the power and control of individuals.” 82 Therefore, bioethics cannot be
content to consider issues only within the medical realm, but must take up broader sociopolitical factors that affect health statuses and medical realities. While bioethicists are not
responsible for developing policies addressing health inequalities, they (we) have a
responsibility of calling attention to issues within medical research that perpetuate the
vulnerability of a given population. In this case, as Farmer noted, the poor majority
consistently represent the sick majority, for whom diseases make their own preferential
option. Thus, in order to establish more equitable research practices, and distribution of the
developments from that research, broader participation is needed in the shaping of the
research agenda.
Thomas Pogge argues for a broadening of research priorities in an effort to move
beyond the disequilibrium present in current research efforts. Pogge roots his critique in one
of the four key principles of bioethics, as articulated by Beauchamp and Childress, nonmaleficence. He argues that if non-maleficence hinges on “doing no harm,” then it is
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fundamental for bioethics to take up and offer a corrective to the current system that does
harm to the majority of human beings.83 He wants to broaden the approach academics take
in their addressing injustices within the distribution of drugs, treatments, healthcare, while at
the same time incorporating industry in this task through the development of the Human
Impact Fund (HIF).
The HIF would financially incentivize innovators and industry to participate in a
system that would more reliably insure the development of “high-impact” medicines for
disease that disproportionately burden poor and vulnerable populations.84 This is the type of
structural and innovative change necessary to reshape the research agenda from its current
construct; this approach will be explored in more detail in the next chapter. Yet, any
restructuring of a research agenda must include necessarily the perspective of those often
excluded.
Advocacy and Research
Another type of approach aimed at reshaping the research agenda developed through
the efforts of HIV/AIDS research advocates who brought attention to the harm being done
to them by current research practices. The participatory action of HIV/AIDS research
advocates gradually allowed for more equitable access to medications and clinical trials.
While advocacy efforts can have potential drawbacks, the advances made by HIV/AIDS
research advocates identify the influence that they can have on reshaping the process,
funding, and distribution within medical research. Most importantly, HIV/AIDS research
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advocates were able to tell humanizing stories of those suffering from the effects of a
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relatively unknown disease.85
HIV/AIDS Research Advocates
The discovery of HIV and the subsequent onset of AIDS became a central focus of
health researchers in the 1990s due, in part, to the efforts of HIV/AIDS research advocates.
These advocates lobbied, protested, wore red ribbons, educated themselves to become a part
of the research community itself, and educated the research community about who the
people were suffering from this new and unknown disease. In the early 1980s, as
information was emerging about the disease, it increasingly became thought of as a “life style
disease,” a disease of drug users and gay men. This understanding has been proven to be
patently untrue. Nevertheless, by framing HIV/AIDS as a disease associated with personal
behaviors, society was able to distance itself from “those” people who had AIDS. Epstein
notes that to have AIDS at that time “is bound up with the cultural understandings of what
such groups are like, while the very identity of the groups is shaped by the perception of
them as ‘the sort of people who get this illness.’”86 In part, the early efforts of research
advocates was about reclaiming the identity of the affected individuals as human beings and
persons with stories and struggles that challenged the popular narrative. As the stories
emerged, it became clearer “who these people were.” They were able to tell their story and
the story of others who also suffered from the disease.87
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AIDS research advocates were uniquely positioned in the U.S. because of the

community organizing that had already taken place in the gay community. Thus, a unique
strength of AIDS research advocates was that they were already organized within the
communities and could easily “mobilize to meet a new threat…”88 Advocacy was nothing
new to this community, and they quickly developed effective strategies that raised awareness
of their health needs. AIDS research advocates utilized “creative approaches rather than
following established rules of lobbying, [created] drug buyers’ clubs…red ribbons…and
telephone ‘zaps,’ wherein the telephone switchboard of a specific company was jammed by a
coordinated barrage of incoming calls.”89 These were not only influential awareness raising
practices at the time, but they greatly shaped the way in which other disease-based research
advocacy groups would develop.
Collective efforts through “buyers’ clubs,”—made more famous by the Academy
Award winning “Dallas Buyers’ Club,”—placed pressure on the FDA to grant quicker and
larger volume access for patients to experimental drugs through clinical trials, as opposed to
importing and distributing unproven treatments.90 Due to advocacy efforts, the wait time for
an application approving a new drug dropped from 34.1 months in 1986 to 12.6 by 1999.
Yet, just as important, HIV/AIDS activists did not just raise awareness of their plight, they

!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
absence of stories fo people of color suffering from disease. Her ethnographic approach integrates the stories
of Latina women with breast cancer and the divergent experiences of the disease including: access to care,
treatment in the clinic, and approach to the disease process itself. Lifting up the experiences of those from an
underservered and underrepresented populations proves to be extremely important when advocating for
research, as seen below.
88

Epstein, “The Construction of Lay Expertise,” 414.

89

Kent A. Sepkowitz, “AIDS — the First 20 Years,” New England Journal of Medicine 344, no. 23 (2001), 1770.

90

Epstein, “The Construction of Lay Expertise,” 416.

!

188!
!
educated themselves on the science and began to actively participate in discussions about the
ongoing research.91
HIV/AIDS research advocates became credible sources of the language of medical
science and research, in addition to bringing their own cultural perspective and stories about
the realities of suffering from the disease. After their gradual success with the FDA, the
community recognized, however, that while they had increased access to experimental
medicines there were few treatments in development. These advocates shifted their efforts
beyond the FDA and towards the NIH’s “AIDS Clinical Trials Group of the National
Institute of Allergy and Infectious Diseases.”92 This shift prompted an increased emphasis
on the ability to speak the language of research in order to be informed about the ongoing
experiments, trials, and for advocates to keep researchers informed about the needs of the
community. As they increased their knowledge of medical research and the science behind it,
they were able to present “themselves as credible within the arena of credentialed expertise.
At the same time, these activists succeeded in changing the rules of the game, transforming
the very definition of what counts as credibility in scientific research such that their particular
assets would prove efficacious.”93 Not only were the activists able to speak the language of
research, they were able to share with them the effects of research on the community,
identify those within the community who needed access, note the side-effects of
medications, and personalize the stories of those living with the disease. Thus, advocacy
efforts were able to allow researchers to think beyond the mechanisms of the disease in
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order to consider their research in the context of helping another human being suffering
from a disease.
Their contributions, moreover, effectively reshaped how NIH clinical trials were
conducted. Within ten years, due to pressure from activists, there were three ways in which
AIDS research was conducted: standard clinical trial protocols through the AIDS Clinical
Trials Group, community-based programs, and the Division of AIDS Treatment Research
Initiative. The latter of the three was important for advocates because their “hallmark is
speed in conducting ‘clinical trials and related research that evaluate new therapies and novel
treatment approaches for those with HIV disease.’”94 Yet, their work did not stop there.
Advocacy efforts played a key role in increasing access to trials for women and people of
color through parallel clinical trials and increased community-participation in research.95 In
the 1990s, their efforts increased access and participation in research within the U.S. New
research advocates emerged, particularly from NGOs, who broadened the efforts to address
the global problem of access and treatment for those unable to afford treatments particularly
in Sub-Saharan Africa.
While the U.S. advocates were successful in shifting the research agenda to devote
more resources to the development of treatments, those treatments, due to the high cost of
development and patenting, were rarely affordable outside of high-income countries. Larger
organizations, such as Oxfam and Doctors without Borders, began advocating for
distribution of necessary medications to low-income countries. This debate was a much
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harder fight against the claim of the pharmaceutical industry that lower costs in low-income
countries could ultimately lower revenues in high-income countries, thereby diminishing the
profit margin and the amount available to be spent on research and development.96
These changes became all the more important when South Africa implemented a
requirement that all pharmaceuticals be made available in their generic forms. This led to
vociferous objections from pharmaceutical companies. However, despite their objections,
advocacy efforts ultimately resulted in a 2001 amendment of a framework for intellectual
property called the “Trade Related Aspects for Intellectual Property Rights Agreement”
(TRIPS). TRIPS, up until this point, had given patent-holding pharmaceutical companies a
virtual monopoly on necessary drugs.97 After this agreement, however, access to these drugs
was seen as a right, but what remained unclear was whose responsibility it was to carry out
this right, that of sovereign nations or pharmaceutical companies.
This lack of clarity came to a head in a lawsuit brought by the drug industry against
South Africa, who had modified its laws to ensure an affordable price of generic medications
for its citizens. After a long legal battle and public advocacy campaign for HIV/AIDS
patients by Oxfam, one of the major players in drug development and patenting,
GlaxoSmithKline, eventually declared it would not enforce its patent on its HIV/AIDS
drug, Zerit, and granted a license for the production of a generic version in South Africa.98
Ultimately, the pharmaceutical industry withdrew their suit, enabling negotiations between
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HIV/AIDS.99
Despite these successes, however, lower costs for treatment did not always result in
increased access. Though this is not necessarily a problem medical research itself can solve,
attention to the necessarily collaboration with public health organizations and local
organizations working in low-income countries is essential. In other words, advocating for
drug access or development without participation from the targeted community will
inevitably result in a less than ideal outcome, as could be seen in the early stages of
HIV/AIDS research advocates in the U.S. This example shows the importance of those
institutions who participate in the process of medical research, including universities, and the
distribution of benefits can play in ensuring that products reach those most in need.
However, over time these advocates were able to demonstrate the important contribution
that advocates can make in altering the research agenda.
The Good and the Bad
As can be seen from the example above, advocacy for research can positively
influence, not only where research dollars flow, but also put a human face to the disease.
This is an area in which all universities can contribute, and Catholic universities ought to be
uniquely obligated. Their efforts were able to first put a human face to the disease through
stories, struggles, and hopes expressed by advocates, dissociating the research from the
immediate financial burdens and potential economic gains in order to situate the disease and
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the research in the context of a person in need. However, given that the economy is so
closely tied to research, funding decisions often become just another policy decision.
Nevertheless, these representatives are accountable to their public and to government
agencies. By hearing from those suffering from the disease and their representatives,
advocates raise awareness for those suffering from disease and announce their role as
members of the public to whom the policy makers are accountable. Advocacy breaks the
exclusive business or political focus that the patent and profit model of the intellectual
property system encourages. In the case of HIV/AIDS, delinking access to medications and
participation in research from intellectual property rights and linking them with human rights
was a crucial step.
A second positive outcome of advocacy efforts increases the fluidity of information
exchange between researchers, patients, and industry representatives. This open flow of
information is something that HIV/AIDS advocates made possible, and that the WHO
working group on research and development believe to be essential in order to generate
better and more cost effective treatments for drugs globally. The CEWG on research and
development argues that to facilitate this open flow of information, it is necessary to create a
database in which open source content of various investigations could be held.
Creating a Global Observatory on Health for R&D could play a crucial role in
priority setting.101 Much like the advocates for HIV/AIDS research were able to increase the
flow of information and access to information for patients, an information database would
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enable all users to: analyze data on financing for global health R&D; produce analysis to
inform national R&D portfolios management; guide R&D priority-setting at different
levels; establish benchmark activities with other users; and monitor and evaluate trends
against national, regional and global strategies.102 Thus, rather than duplicating efforts and
guarding secrets, sharing information between the key players—universities, private industry,
non-profit organizations, government, etc.—would be encouraged.
In essence, HIV/AIDS research advocates were able to reimagine the way in which
patients participated in research for their diseases. Through their efforts, advocates were able
to increase the flow of information between researchers, patients, and industry. They
demonstrated the value of community-based research in developing more targeted and
widely accessible clinical trials. Perhaps most impressively, they were able to alter the
research agenda by increasing the allocation of resources—both financial and human—for a
marginalized population, both locally and globally. Although the benefits continue to be
unevenly distributed, advocates took positive steps to make the benefits of research more
accessible to marginalized populations. Yet, advocacy participation, despite the many
successes, presents challenges too.
Rebecca Dresser, overall, offers praise for advocacy work in her seminal text, When
Science offers Salvation. As can be deduced from the title, Dresser is concerned with the amount
of faith that is placed in the scientific and research community and the concerns it presents
for research ethics. There are two concerns that prove relevant to the discussion at hand.
First, Dresser cautions that advocates tend to stress the positive dimension of research.
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Namely, that the studies they are participating in are understood as “new treatments” and
“life-saving research.” The reality is, however, that in certain instances the trials may not
actually benefit them, and the “life-saving research” may save someone else’s life not their
own. 103 She notes that when HIV/AIDS activists campaigned and received more resources
for studying, they did not like what they saw. There was discontent with the randomized
controlled clinical trials, the “gold standard” of research, because it was unknown whether
one would benefit or not from the research. When research participants and patients,
moreover, were asked to discontinue other medicines, they often withdrew from the trial if
there was any chance they could receive a placebo, “a standard thereby they deemed
unsatisfactory.”104 While their advocacy efforts pushed forward more just distribution of
resources—something definitely needed—they also presented other challenges with respect
to conducting an effective clinical trial.
A second concern Dresser raises concentrates on increasingly political dimension of
advocacy work that offers only those with a seat at the table—or the ability to pay for one
through lobbyists—the opportunity to shift the research agenda. In this way, advocacy
efforts could result in increased funding for a particular disease simply because they have a
seat at the table, and thereby exacerbate social inequalities. Given that research funding
allocation functions as a political process, it would be detrimental to the just distribution
efforts highlighted in the global work of HIV/AIDS research advocates if advocacy began to
take up the more partisan lobbying efforts.
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In coupling her first concern, therapeutic misconception, with her second concern,

politically advocating for a cure, Dresser expresses a final concern that advocates can
become so involved, alongside their scientist collaborators, that the possibility of not finding
a cure becomes unimaginable. Both scientific researchers and advocates must necessarily
maintain a perspective, that is not without hope, but that is inclusive of a wide range of
available research options and alternatives. These alternatives and options, however, cannot
happen without mutual communication between the researchers, those suffering from
disease and their advocates, private industry, and public funding sources.
Communication concerning research priorities often lacks the multiple perspectives
necessary to create a socially responsible research agenda. The advocates for HIV/AIDS
research demonstrate the complexity of factors—political, economic, personal—that play a
part in establishing a research agenda. Most importantly, however, these factors put a human
face and social condition to those suffering with the disease. Yet, for the vast majority of the
world, those suffering the global burden of disease have no one to speak for them. They
have no advocates and, as Dresser rightly cautioned, only those with a voice receive funding.
It is worth noting that even those who received and participated in the shaping of
the HIV/AIDS research agenda—and perhaps a cause of their success—were predominately
white males who were the primary participants in research in the 1980s and those who were
deciding what agenda items ought to be pursued.105 Thus, the critical question for research
advocates with a horizon for the poor majority is, who are their advocates? What ought
these advocates advocate for? How can one ensure—insofar as possible— its successful
implementation?
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Conclusion: Towards Responsible Advocacy
In a 1987 essay, Jürgen Habermas focuses on the discursive dynamic that takes place

within the learning process at the university. It is through this discourse in which
“specialized internal public spheres coalesce and branch apart again in the university’s
programs.”106 This learning process, however, is not idealized within the university, but
rather creates space for discourse. Habermas argues that even though a researcher “appears
to work alone in the library, at his writing desk or the laboratory, his learning processes are
inextricably interwoven with a public ‘community of investigators.’”107 For medical research,
patients in need of new drugs, physicians working with these patients, and public health
officials aiming at disease prevention form a part of this essential community. Thus, to
engage in responsible medical research one needs to broaden the horizon of investigation.
This role is not exclusively the responsibility of a scientific researcher, but must engage the
entire community.
For Catholic universities, this discourse takes on an important facet when confronted
with injustices around complex structures in which they participate. The structure of medical
research is one such challenge that Catholic universities should reflect on in light of the
concern for justice. In the globalized context of research, however, the conversation about
how to prioritize justly particular contexts, populations, and needs with the allotted research
dollars is ongoing.
Drawing from the previous chapter, the insights of Ellacuría and liberation theology
emphasize the importance of the place or the context from which one begins the necessary
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Jurgen Habermas and John R. Blazek, “The Idea of the University: Learning Processes,” New German
Critique Spring/Summer, no. 41 (1987), 3.
106

107

Habermas and Blazek, “The Idea of the University,” 21.

!

197!
!
dialogue. If the place of the poor, or option for the poor and vulnerable groups, is to have
an epistemological impact, then it is necessary to begin reflecting on a research agenda from
their perspective. Beginning from this perspective does not necessarily mean physical
location. This consideration can take the form of an intellectual stance that prioritizes
experiences of injustice and suffering that can be omitted often in establishing research
priorities. Starting from the intellectual place of the poor shifts the conversation to concerns
about equity, distribution, and need. These concerns come into focus by reexamining the
morbidity and mortality statistics above or looking at the World Health Organization
DALYs—just as John Snow looked at London’s Weekly Returns to target his
investigations—and in so doing, recognizing those who have historically been marginalized.
The task of the Catholic university, however, is not just to know who these people
are, but also to engage in practices and dialogue that aim to reshape participation in
academy-industry relationships, targeting diseases that ought to be researched, and
participating in global advocacy networks These challenges necessarily take the university
beyond intercampus dialogues and create conversations within the larger Catholic Church,
businesses and non-profit organizations, and the communities who are in need. While
research cannot cure everything, it has historically provided a necessary piece of the
puzzle—alongside a solid public health infrastructure and access to medical care. Catholic
universities are in a unique position to be leaders in this type of research effort because of
their established global network which better enables these institutions to serve as advocates
for and with others and to ensure a more just distribution of the benefits of medical
research.
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Ellacuría describes the function of the university as inherently political, and thus one

of its tasks is to confront structures that perpetuate injustice. The structure of medical
research is one that, at least benignly, neglects the majority of the world in its efforts.
Advocacy efforts at the university level, and particularly engaging academic scientists, can
take place through targeting publications to highlight under researched diseases, grant efforts
that seek to benefit the majority of humanity, and focused hiring practices that demonstrate
the universities’ commitment to bringing in the best researchers who share both a deep
commitment to excellence in research, but also a shared concern for justice. The goal, then,
is to engage others more broadly to participate in the “community of investigators”, as
Habermas describes it. By implementing an advocacy-based institutional model of research,
the goals would be to: raise awareness around the distortion of the distribution and priorities
of medical research; restore health as the most important intrinsic good of the practice of
medical research; and to participate with partner organizations in establishing a more just
framework to distribute the benefits of the research undertaken. While this will not,
unfortunately, eradicate diseases or eliminate disparities entirely, it hopefully will position
Catholic universities as institutions engaged in a practice of medical research that prioritizes
justice and solidarity through targeted research efforts and serve as an example for others to
follow.!
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CHAPTER FIVE
SOCIALLY RESPONSIBLE MEDICAL RESEARCH
Introduction
A socially responsible medical research agenda needs to reflect on the research
structures that allow the health needs of the majority to go under researched. As seen in the
previous chapters, the development of medical research has occurred alongside the
production of technologies and drugs that have consistently promoted health benefits tied to
potential economic gains, over those with greater health benefits for more people. An
analysis of the empirical data on morbidity and mortality statistics, reviewed in Chapter Four,
reflects these disparities in research and burden of disease.
The unjust burden of disease that afflicts the poor majority, however, emerged over
time through political, economic, and university-based decisions. The tension in creating a
medical research agenda exists between research that benefits individual persons and
research poised to benefit larger groups within the population. This unjust distribution of
research, which came to prioritize particular individuals, e.g. soldiers, and diseases from highincome countries, can be seen through the historical development of medical research
described in Chapter One.
Chapter One maintains an intentional focus on research that targeted improvements
to the health of the general public. Yet, even this research was not without its injustices.
While John Snow’s cholera research focused on his immediate neighborhood and the
development of international public health practice, distortions about what type of research
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truly benefited the public became the contentious. The tension between the priorities of

public health over the future health of particular individuals, peaked with the unethical
research practices associated with eugenics. The practice of negative eugenics, a popular
method in the U.S., UK, and in Nazi Germany, served as the watershed event that prompted
a more concerted effort to focus on the ethical conduct of research and protecting the rights
of research subjects.
Despite the complex socio-historic origins of research ethics, in practice the focus
centered on protecting the individual rights of research subjects by relying on the physician’s
obligation to do no harm. This individualistic approach, however, ignored why unjust
research practices continually affected particular groups of persons, e.g. racial minorities and
those of lower socio-economic status. While consideration was given to the protection of
individuals from vulnerable populations, little ethical reflection concerned itself with the
vulnerability of these particular groups. It was, and to a large extent still is, problematic that
the application of research ethics virtually ignores the socio-historic context in which
research takes place. Particular groups continue to be excluded from the benefits of the
social practice of medical research. The historical analysis from Chapter Two, coupled with
the disparities in research described in Chapter Four, demonstrates the lacunae of a socioethical analysis of research that considers the injustices within the priorities and distribution
of medical research.
The injustices associated with the priorities of medical research, I hypothesized, were
not due to lack of good science, but rather, an epistemological problem that allowed for
science to be interpreted as morally neutral and objective practice. The turn to the work of
Xavier Zubiri and Ignacio Ellacuría in Chapter Three provided a needed epistemological
!
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shift for scientific research. Ellacuría and Zubiri both acknowledged scientific research as
fundamental not only for understanding, but also for shaping the way in which historical
reality is experienced. This experienced reality, however, is one in which the majority of
persons disproportionately experience poor health and economic poverty. While science is
often thought of as a neutral and objective practice, I follow Ellacuría and Zubiri’s argument
that the practice of scientific and medical research itself has in fact participated in shaping
the injustices within historical reality.
An epistemology of historical reality emphasizes that human actions in history
contribute to the way in which reality is constructed and that no practice should be
considered morally neutral. Given the current global health disparities, certain persons and
institutions have continually received priority, while the health needs of the economically and
socially poor have been neglected, creating both a moral an ethical dilemma. In order to right
this historical wrong, I argue that a liberationist, social, and Catholics ethic must begin from
and with the perspective of the poor majority, a majority whose health needs go largely
ignored resulting in premature death and disability of millions of individuals.
Reflecting on the social ethics of medical research begins with an analysis from, if
not physically, then at least intellectually, the places where lives are consistently lost before
their time. In this way, the health research needs of the poor majority that become the
starting point for establishing an ethical research agenda. While anyone can take up research
that focuses on the health needs of the poor majority, this approach proves constitutive for
Catholic universities that emphasize the moral importance of social justice.
This final chapter argues: Catholic universities have a moral responsibility to
prioritize medical research for health that demonstrates the effectiveness of its commitment
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to social justice, perhaps most clearly articulated after the Second Vatican Council. At the
Second Vatican Council increased attention was turned to the places in which the Catholic
Church lived and worked. The context of many Liberation Theologians was one of poverty
and oppression, and many argued for the Catholic Church to actively address the political
and social structures that permitted the oppression to continue. In El Salvador the Catholic
university, the UCA, came to play a prominent role in shedding light on present injustices.
Ellacuría, among others, emphasized that the functions of the university: teaching, research,
and service, should socially project the injustices present and challenge them. It is taking up
the preferential option for the poor that allows the injustices to be seen most clearly.
The option for the poor functions as more than a rhetorical move to emphasize those that
often bear the weight of injustice, and instead should result in institutional practices and
policies that socially project the needs of the poor in the daily work of the university.
Research that focuses on the experience and health needs of the poor that signifies
the epistemological shift that needs to take place within medical research. Making an option
of the poor serves as the standard by which justice ought to be measured. 1 The
epistemological function of the option for the poor contains a political task to confront the
socio-historic structures that perpetuate poverty, vulnerability, and marginalization of the
majority of humanity through the social practices in which one is engaged, which in this
instance is medical research.2
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University Press, 1991), 208. Also see p. 19 Chapter 3, n. 33. In this chapter, I maintain the use of Ellacuría’s
definition of the poor, “the vast bulk of humanity whose standard of living is such that they can scarcely satisfy
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While Catholic university-based medical research ultimately makes up a small

minority of the overall medical research conducted in the U.S., these institutions participate
in national and international networks of research. When working collaboratively, these
networks can focus their research efforts to confront the health problems that face the poor
majority. The first section of this chapter explores the context in which Catholic universities
take up their task of medical research. The second section argues that normative values
presented in liberationist thought should influence the social practice of medical research by
considering the option for the poor, the importance of “place”, and a notion of justice that
begins from the experience of injustice. The final section concludes in a similar way to which
the dissertation began, by offering paradigmatic examples—not specific proposals—of
research efforts that make it feasible to take up the option for the poor in establishing
research initiatives and/or cultivating partnerships aimed at benefiting those on the margins
of society.
Catholic Universities and the Context of Medical Research
It is estimated that over 200 times as many dollars are spent on a life lost in a highincome country compared to that one life lost in a low-income nation. Catholic universities
cooperate in the unjust practices of medical research insofar as they do not offer an
alternative approach to research that takes up the health needs of the poor. The option for
the poor, rooted in the Catholic Church’s social teaching, has become a key source of
identity for their universities. However, when it comes to medical research on a global scale,
it often fails to be put into practice because of its contradiction to the way in which research
is typically funded. If research continually avoids addressing issues that face the majority of
humanity, then the practice of research results in a social practice that perpetuates systemic
!
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injustices by ignoring the legitimate health needs of the majority of the world. While this
injustice is a question for all involved in medical research, it poses a unique challenge to
research at Catholic universities as institutions situated in a globalized world and amidst the
tension between the local and universal church.
Between the Local and the Global
John Paul II’s Ex Corde Ecclesiae describes the Catholic university as an institution
that exists in relationship to the church as both local and universal. The document describes
the relationship of the university most strongly in its unity with the local church; however, as
an academic institution, he also notes that it participates in the international academic
community, whereby “each institution participates in and contributes to the life and the
mission of the universal Church…”.3 While the exact nature of the relationship of the local
churches and the universal church has been the content of much theological discourse, there
is little debate from the document that the university itself in fact participates in some ways
in both dynamics. 4 Thus, the context of research for Catholic universities ought to consider
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3 John Paul II, Ex Corde Ecclesiae (1990), no. 27. “As such, it participates most directly in the life of the local
Church in which it is situated; at the same time, because it is an academic institution and therefore a part of the
international community of scholarship and inquiry, each institution participates in and contributes to the life
and the mission of the universal Church, assuming consequently a special bond with the Holy See by reason of
the service to unity which it is called to render to the whole Church.” The quote above is a partial quote of
John Paul II’s more theologically charged point that pertains to the relationship between the local and universal
church. This is relationship is important because of the general understanding of academic freedom at the
university and, in particular, the function of theology within academia. These points have been well elaborated
on elsewhere, and lie beyond the scope of this dissertation, but bear noting. Despite the disputations around
the exact nature of the Catholic university’s relationship to the universal church, it participation in the universal
church and, as John Paul II noted, the international context in which is fundamental.
4 Kilian McDonnell, “The Ratzinger/Kasper Debate: The Universal Church And Local Churches,” Theological
Studies 63, no. 2 (2002). Kasper essentially understood that the church universal exists in and develop from local
churches. Conversely, Ratzinger argued that the universal church existed ontologically prior to all local
churches, and that the only de facto remnants of the universal “The pope and the curia remain as the only
elements in the presentation [of the universal Church].”
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local needs, but also the way in which those needs relate to the globalized world in which it
is immersed.
The work of the university operates in a globalized world characterized by rapid
technological developments, increased interdependence across borders, and a widening
economic and health gap between the rich and the poor. Globalization is not a new topic,
yet it continues to defy a singular definition. David Hollenbach, for example, borrows from
Keohane and Nye to describe globalization “as the increase in networks of interdependence
among people at multicontinental distances.”5 Thomas Massaro settles on the broadest
definition possible by describing globalization simply as “everything and its opposite,” and in
so doing, “calls attention to rival construals, countervailing forces, and ethical dilemmas
unleashed when national borders seem suddenly irrelevant.”6 Sumner Twiss argues that
globalization is “the multidimensional and interactive processes of economic, political, and
cultural change across the world resulting in increased social interconnectedness as well as
opportunities for social confrontation among peoples.”7 Finally, Rebecca Todd Peters
characterizes it as “economic, social, political, and cultural processes that serve to break
down traditional barriers that have separated peoples, nations, and cultures from one
another.”8 These definitions share a common focus on globalization’s ability to transcend
boundaries, but also this ostensible absence of boundaries result in new global challenges. In
a globalized world, “local” concerns can no longer be considered as confined to a particular
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

David Hollenbach, The Common Good and Christian Ethics (Cambridge, UK; New York: Cambridge University
Press, 2002), 213.
5

6

Thomas Massaro, “Introduction,” Journal for Peace and Justice Studies 14, no. 1 (2004).
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geographic area. Instead, local actions partake in an interdependent global community that,
for good or for ill, is here to stay.
Scientific inquiry, moreover, is not absolved from the effects of globalization. Yet,
medical research traditionally remains focused on particular projects of individual researchers
that mostly reflect specifically local and national priorities. However, the prioritization of
local research, which for high-income countries projects potential future needs, can overlook
more pressing health needs that could benefit directly from immediate medical research.
Catholic medical research, given the global presence within a Church committed to justice,
should presume a fundamental orientation towards research that not just expands a reservoir
of knowledge or targets national priorities for which it can receive funding, but engages in
medical research that stands to benefit the health of all human beings.9
Catholic Research
Out of the 225 Catholic colleges and universities in the U.S., only about 10% of
them engage in medical research. 10 For the last five years, these universities have averaged
around 400 NIH grants per year, most of which are generated from six awardees:
Georgetown University, Saint Louis University, Loyola University Chicago, University of
Notre Dame, Boston College, and Creighton University.11 Within this group, Georgetown
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9 Michael J. Buckley, The Catholic University as Promise and Project : Reflections in a Jesuit Idiom (Washington, D.C.:
Georgetown University Press, 1998), see chapter two.

Catholic Data, Catholic Research, Catholic Statistics, “Frequently Cited Research,”
http://cara.georgetown.edu/CARAServices/requestedchurchstats.html (accessed March 22, 2015); Association
of Catholic Colleges and Universities, “Frequently Asked Questions,”
http://www.accunet.org/i4a/pages/index.cfm?pageid=3797#WorldPercentage (accessed March 22, 2015).
Globally there are over 1800 colleges and universities in operation.
10

All data pulled from National Institute of Health, “NIH Awards Database,”
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receives the most NIH funding, with a five-year high in 2010 of $69.4 million from 162
grants and low in 2014 of $47.5 million from 104 grants. Their grants consistently double
that of the next two Catholic university recipients, which is some variant of Loyola
University Chicago, the University of Notre Dame, and/or Saint Louis University.
The grants achieved by the universities are wide-ranging, and in many respects
mirror NIH funding priorities. The received grants focus on research in biotechnology,
clinical trials, genetics, and also HIV/AIDS, health disparities, preventive medicines, heart
disease, etc. In other words, Catholic universities do not distinguish themselves in choosing
research priorities from their non-Catholic counterparts. Thus, Catholic university medical
research reflects NIH funding, and likewise engages in medical research irrespective of the
global inequalities in health. This presents a moral challenge for Catholic universities, and
one that liberation theology argues that the Catholic university ought embrace.
Research and a Liberationist Social Ethic
If status quo medical research produces inequity and injustice, then Catholic medical
research ought to prioritize preferentially the needs of those that suffer from the inequity
and injustice, i.e. the poor. Liberation theologians have been the most vocal and consistent at
grounding socio-ethical concerns in the needs of the poor. Ignacio Ellacuría’s normative
insights for establishing a research committed to solidarity and situated intellectually in the
place of the poor, challenges structures that allow for unjust practices. Liberationists take up
the concept of justice from the experience of injustice that denies an opportunity for
participation in the co-construction of historical reality. In Chapter Three, I noted that the
participation in shaping reality proves a fundamental criterion for justice. This concept of
justice begins from contextual experiences of injustice, while at the same time creating
!
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participation and equity.
Solidarity
Solidarity values the interconnectedness of human beings by prioritizing critical
reflection that considers the actions of individuals and groups from the perspective of
mutually conditioned social relationships. Liberationists theologize the notion of solidarity
by locating its foundation in the incarnation of Jesus, through which God enters into a
mutual relationship with human history. Liberationists point to the partiality of Jesus’ actions
on behalf of those groups that were socially marginalized, in particular: women, the poor,
and those who were disabled either from birth or illness. However, solidarity is not exclusive
to liberation theology, but has a tradition rooted social theorists who likewise explore this
concept as an important social and political value is incorporated into the theological insights
of liberation theology.
Émile Durkheim describes solidarity as both a chosen and given interconnectedness
within society that shapes the social order. Durkheim distinguishes between two types of
solidarity, mechanical and organic. Mechanical solidarity exists sui generis through shared
social bonds, rules, values, and beliefs that bind individuals and provide an unmediated sense
of solidarity within the collective.12 While mechanical solidarity links the individual to society
without an intermediary, organic solidarity develops in more complex and cosmopolitan
contexts within “divisions of labor” in which each individual is called upon to play a specific
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role in society. The success of society rests, then, on the capability of individuals fulfilling
their role. As industrial societies shifted away from mechanical forms of solidarity, Durkheim
expressed concern that the individuation within modern society would make it more difficult
to maintain a sense of organic solidarity, which he saw as fundamental for social stability.14
While Durkheim was concerned about social stability, Weber and Marx focused on the
political implications of solidarity.
Politically, Max Weber and Karl Marx build on the sense of solidarity as a connection
amongst social groups that translates into political practices. For Weber, it was the formation
of meaningful relationships that would yield democratic principles of fairness and equity.15
Marx, however, was less concerned about this sense of solidarity amongst all individuals,
emphasizing the importance of solidarity within one’s social class. In a certain sense, Marx’s
solidarity operates as an exclusive form of class solidarity that functions differently than the
concept as proposed by Weber or Durkheim. While the approaches of Marx and Weber
differ from that of Durkheim, their insights lend themselves to the socio-political vision
incorporated into solidarity from the perspective of liberation theology. However, liberation
theology views solidarity from the unique perspective of the incarnation, which calls
individuals and communities to a shared commitment around solidarity.
For liberation theology, solidarity emphasizes both the importance of social and
political stability as prioritized in social theory, but does so through an individual and
collective call to conversion. Gustavo Gutiérrez focuses on conversion as fundamental in
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order to break with the old way and to re-orientate individuals and institutions toward the
way things ought to be. Conversion, he notes, calls for a recognition of the presence of sin
and suffering both in the world and in one’s own life and the desire to turn away from it.
This metanoia is not just for one’s own sake, but in recognition of one’s participation as a part
of the collective. “It becomes necessary for us to examine our own responsibility for the
existence of unjust ‘social mechanisms.’ In addition to calling for personal
transformation…[t]he conversion required will have to be radical enough to bring us into a
different world, the world of the poor.”16 Here one can observe the influence of social
theory on liberation theology insofar as it the critical analysis of social structures that allow
one (or many) to recognize the need to change course in order for society to thrive. This
conversion focuses on a new way of acting that allows for the development the whole of
society, an important departure from Marx. In this regard, conversion calls one to act for
and with those who remain most frequently left out of participating in the building up of
society.17
Therefore, conversion does not evoke the generic promotion or defense of human
rights, but one that confronts particular divisions within society. Drawing from Ellacuría, the
only way to fully encounter this reality, “means engaging, remembering, and ultimately
undoing its terrible negativity. In a word, it demands conversion, a conversion of the human
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Ashley, (New York: Paulist Press, 1998), 54-71.

!

211
!
18
heart and a conversion in historical reality.” Therefore, while solidarity may require an
individual conversion, solidarity is always situated in the political and requires social action
that promotes inclusion of those most frequently excluded. 19 For liberation theologians,
conversion begins with the recognition of injustices that burden the majority of the world
and moves towards a praxis of solidarity that turns to the places where suffering exists and
human flourishing is limited.
The Importance of Place and Story
In Chapter One, I cited that India’s Council on Medical Research (ICMR) does not
prioritize economics as a goal of medical research, but instead describes it as research
focusing on disease prevention and developing treatments for those suffering from chronic
and/or acute disease. Unlike the descriptions of high-income countries—France (Inserm),
U.K. (MRC), and U.S. (NIH)—that explicitly identify economic profit as a goal of medical
research, the ICMR omits economics as a goal of the practice itself. Instead, the ICMR
policy articulates the importance of balancing research priorities based on the public health
needs of the country with those of individuals. In the description offered by the three
western, high-income nations, no mention of public health or reducing disease burden
appears as an explicit focus of research. The context from which India articulates its research
priorities, however, is undoubtedly shaped by more widespread cases of urgent health need
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countries, like India, who make-up what Jon Sobrino refers to as the “world of the poor,”
should shape values and social practices that draw our attention to acute social problems.
The “world of the poor” draws our attention to the importance of an
epistemological shift that begins by “realizing” the fact that the basic needs of many are not
being met. Prioritizing medical research from the place of the poor necessitates addressing
the disparities in global research that contribute directly to unjust burdens of disease
“shouldered” by the poor majority. Following Ellacuría, human beings through the
structures that shape these injustices have an option of “taking charge” of the concerns for
and with the majority or ignoring them.
Ellacuría’s three-fold method of realizing, shouldering, and taking charge of the
weight of reality is done so from the perspective of the poor, which requires challenging the
injustices endemic to the experience of poverty. If this is the place from which medical
research becomes reconsidered, then the narrative of research that focuses on cures,
breakthroughs, and improved quality of life, must be reimagined. It was the telling of the
story of those suffering from HIV/AIDS and humanizing their needs that contributed to
changes in policies surrounding medical research practices. Thus, the place and the stories
from these places prove fundamental to the re-imagining and evaluation of the medical
research agenda.
Distinguished anthropologist and physician, Arthur Kleinmann, describes that
sharing experiences of suffering transforms the relationship between the hearer of the
narrative and the context from which the experience is being told. Ultimately, “the semiotic
iteration of the suffering of lay men and women into the taxonomies of healing professionals
!

213
!
20
is then shown to distort the moral world of patient and community.” While some may be
reluctant to characterize medical researchers as “healing professionals,” it does not diminish
the impact that the personalization of the stories of suffering can contribute to a reframing
of the objective of one’s engagement in the social practice of medical research. One possible
explanation is that ethnographic work, like that of Kleinmann, allows individuals or groups
to “interrogate themselves as much as they seek to learn from the people with whom a study
is undertaken.”21 Here the option of place emerges. Does one opt to remain removed from
the stories of suffering and injustice—as happened for many in the U.S. following the
current Ebola outbreak—or does one opt to see oneself as involved in the continuation of
these unjust experiences?22
In essence, liberation theology rejects abstract theories that fail to recognize the lived
experiences of those communities suffering particular injustices. As sentient-intellectual
persons, human beings have the capacity to move beyond these contexts and place oneself
in the position of the other and, thus, to be better poised to develop policies that allow for
institutional change. Liberation theology and philosophy argue that it is the option for the
context and experience of the poor majority that offers the most authentic place from which
to critique the unjust construction of reality. “The moment of option, which seeks that
place-that offers-truth and does truth, should not be blind but enlightened. It is first
enlightened by its ethical assessment of justice and freedom, or better, of ‘no justice’ and ‘no
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freedom’…”23 Rather than an abstract theory of justice, liberation theology argues that
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justice must be conceived from the place of those who have no justice.24
Justice and Structural Injustices
For Ellacuría, the concept of justice develops from places and experiences of
injustice that function on both personal and structural levels, evoking a critical response
through a dialectic between utopia and prophetism.25 In Chapter Three, I referenced one of
Ellacuría’s final essays, “Utopia and Prophetism.” Utopia, derived from the Christian
understanding of God’s Kingdom historicized through the actions of Jesus, exists in tension
with prophetism—a critical and historical response that calls for social change. “Utopia and
prophetism, if presented separately, tend to lose their historical effectiveness and become an
idealistic escapism; and so, instead of becoming forces for renewal and for liberation, they
are at best reduced to functioning as a subjective solace for individual persons or for whole
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Note here, that the starting place is the concrete experience of injustice that is challenged by the historical
teachings and actions of Jesus about God’s Kingdom. While there are resonances of Aquinas’s natural law
approach to the common good—especially in the utopic vision— at work in the efforts of liberation theology,
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people’s.” In other words, separating the two can contribute to an understanding of utopia
as describing something that ought to be patiently waited for in the future while enduring
present sufferings.
For liberation theologians, like Ellacuría, Gutierrez, and Sobrino, present injustices
have to be actively worked against in light of an already begun utopia, God’s kingdom, in
which suffering ought not exist. The act of seeking justice from the place of injustice
requires persons or people who do not directly experience injustice to transcend their own
situation in order to contemplate the reality and injustice of the condition of another and to
work for and with them to transform it. Therefore, utopia does not represent an escape
from, but rather a realization of that which is possible yet unfulfilled within the current
social, political, and economic models critiqued by prophetism.
Prophetism makes utopia present in reality through critiques of current unjust
structures that call for social change and a new way of life.27 Prophetism functions as a
critical “interpretation of the surrounding social world—and of ourselves—that uncovers a
reality in which certain possibilities are realizable while others are not.”28 Thus, it is not an
idealized notion but, instead, a notion grounded in an historical realism that draws attention
to the places and contexts in which injustice is experienced as a way of life. From the
perspective of injustices, alternatives are sought as a means by which to establish a more just
social order. Yet, this social order cannot be understood apart from historical experiences
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Justice conceived within the context of liberation hopes for the already begun
utopia, which develops through a critical stance towards unjust social structures that create
victims and disparities between race, class, and gender.
“[J]ustice, giving to each what is due to each, not only makes freedom possible but
also what is moral and just. Liberation from every form of oppression, whatever it is,
is a real process of ‘just-ification.’ This justification is the real means of promoting
freedom and the conditions that make it possible. In this sense, liberation is a
process of ‘ad-just-ment’ with oneself, in that it seeks to break one’s internal and
external chains. It is a “just” process in that it tries to overcome manifest injustice;
and it is a “justifying” process in that it seeks to create adequate conditions for the
full development of all and for an equitable use of the conditions.”29
Justice, therefore, is understood as a process that begins from and seeks to rectify inequitable
distribution of “what is due, ” while working towards conditions that allow for greater and
more equitable participation in the process of creating a just society. Ensuring the possibility
for justice, however, requires both a personal and a social process of “ad-just-ment” by
identifying and challenging those structures that deny human beings the fullness of freedom
entitled to them. Once unjust social structures become revealed, alternative policies and
practices must be established that counter the structural injustices. In discussing the unjust
distribution of medical research, Catholic universities, must serve as one of the institutions
of social change by “ad-just-ing” and “just-ifying” their institutional commitment to justresearch that prioritizes the health needs of the 90% over those of the 10%.
Catholic universities committed to justice, therefore, have a social responsibility to
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Ignacio Ellacuría, "Utopía y Profetismo Desde América Latina: Un Ensayo Concreto De Soteriología
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engage in the practice of medical research from the place of the poor and in solidarity with
those individuals and communities whose health needs remain under-researched. From the
perspective of liberation theology and the function of the Catholic university, narrative and
place converge in an act of solidarity that allows for the recognition of victims of injustice
and serves as a catalyst to pursue alternative just and inclusive policies. Given the funding for
medical research, as reflected on in the previous chapter, it is difficult to argue that current
research practices reflect the socio-ethical norms of a liberationist approach to research.
Liberation theology offers a sustained critique that challenges Catholic universities to
take up their particular responsibility to ensure that they do not participate within a structure
of medical research that allows for injustice. Alternatively, these institutions should strive
establish counter structures that promote justice and target research that benefits the health
of those most in need. In opposition to socially unjust structures, Catholic medical research
socially projects that explicitly prioritizes the needs of the poor and vulnerable in their
research agenda.
Developing a Socially Responsible Agenda
Constructing a socially responsible research agenda that maintains a preferential
option for the poor requires a creative approach requires targeting existing funding
structures, cultivating new research partners, and imagining alternative structures that enable
research for the poor majority. For some areas of research, funding structures are already in
place; however, new ways for structuring research, building capacity in underserved areas,
and distributing the fruits of research still need to be explored. This final section, like the
opening chapter, offers paradigmatic examples of medical research that reflect research
priorities that come from and develop in solidarity with the poor majority. These examples
!
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represent potential dialogue partners and offer alternative approaches for Catholic
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universities to consider in addressing injustices within the practice of medical research itself.
Existing Structures for Medical Research
Some Catholic universities will be hesitant to take up a justice-oriented research
agenda outside of currently established funding sources. While other examples in this section
examine potential ways of engaging in research outside of current funding sources, this first
example explores research that more closely aligns within socio-ethical norms described
above. Comparative Effectiveness Research (CER), recently instituted in the U.S. as the
Perspective on Patient-Centered Outcomes Research Institute (PCORI), funds research that
focuses on evaluating and improving the quality of health care outcomes pertaining to
preventive, diagnostic, and treatment options in order to better inform and support all
involved in the research process. While the current concentration of CER initiatives operates
out of high-income countries, such as the U.S., France, U.K., Germany, and Australia,
efforts have already been made to extend this type of research beyond national borders.
Given the global presence of Catholic universities and the Catholic Church, these
institutions—assuming they are willing to collaborate—have the opportunity to participate in
research that can more easily work with low and lower-middle income countries to build up
their research capacity and assist in the development of programs to improve upon health
care outcomes.
Comparative Effectiveness Research
In 2009, and Institute of Medicine (IOM) report detailed ten characteristics of a
CER. The first priority, and perhaps the most significant for the broad applicability of this
type of research, emphasizes that the “prioritization of CER topics should be a sustained
!
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and continuous process, recognizing the dynamic state of disease, interventions, and public
concern.”30 The process for establishing a CER agenda, therefore, requires continued
evaluation of current research needs, including a willingness to forego projects that do not
represent current public health needs. The continued evaluation of necessary research from
the perspective of the public is something that does not appear—or at the least is not
reflected—in the current NIH research agenda, for example.
The criteria for prioritization of CER research focuses on health, disease prevalence,
mortality, and morbidity, which will certainly reshape the priorities in need of study.31 Here
CER already takes important steps in developing a globally translatable research program
because of its focus on methods that address local health problems and engage in evaluating
the resources needed to improve health outcomes. In order to meet these health concerns,
however, the IOM report states that CER requires broad participation of key research
stakeholders and frequent updates. These updates require wide distribution if they intend to
address the most urgent health needs and identify best practices. For CER programs in
Europe, this has translated into focusing on the effectiveness of newly developed drugs,
pricing, and general availability of those drugs.
The U.K.’s National Institute for Health and Care Excellence (NICE), originally
established in 1999 as the National Institute for Clinical Excellence, operates collaboratively
with the National Health Service (NHS) to ensure the quality of care and the availability of
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needed treatments throughout the country. 32 One of the successful means of ensuring
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treatment availability is through the evaluation of new drug developments. The
recommendations of NICE serve as the measure by which a new drug is included in the
comprehensive coverage offered through the NHS. Considered in this review process is the
cost-effectiveness, which “is particularly important for drugs that have new indications, are
expensive, are expected to be widely used, or whose benefits differ by indication or patient
subgroup.”33 Thus, NICE’s role naturally led to CER’s interface with industry through
recommendations regarding the effectiveness of a drug by studying its effects on morbidity
and mortality of a given population.
Therefore, the role of CER does not focus on approval or rejection of a drug,
instead, once approved, it reviews the efficaciousness of the drug in patient care. In the
instances that a “particular health technology is found to have inconclusive or insufficient
evidence of a comparative effectiveness analysis, NICE will often make the recommendation
that the examined therapy be used only in research.”34 In this way, the recommendations
from NICE have a bearing on drug coverage through the NHS, but also provide the
pharmaceutical industry with a link to continually evaluate their product through further
research and hopefully present the efforts of companies to develop “me-too drugs,”
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knowing that they will not be brought to market. In addition to interfacing with both drug
industry and political institutions, CER engages in research that can evaluate clinical
effectiveness across under-researched populations, e.g. underserved communities, racial and
ethnic minorities, and/or gender differences.36
In the U.S., PCORI, a development from the 2010 Affordable Care Act, focuses on
research efforts that more intentionally engage patients in research that supports preventive,
diagnostic, and treatment-based options for larger patient populations.37 The focus of
PCORI’s efforts center on improving the overall quality of health care, which takes place by
targeting research that more effectively addresses the concerns facing patients within a
particular sector of the population. One of PCORI’s initiatives strives to foster engagement
with primarily underserved patient populations, in order to develop a collaborative and
trusting relationship in which the research comes from and aims to benefit that same
community. In this regard, PCORI funding demonstrates a key principle of just-research by
working in solidarity with a community that stands to benefit from the research taking place.
Developing policies for research that focus on community involvement and benefits in
research, coupled with evaluating broadly the effectiveness of existing treatment options,
demonstrates some of the possible avenues for implementing CER in a variety of settings.
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The methods of CER offer a diversity of approaches, ranging from targeting large-

scale systemic challenges in health care, to studying the effects of technology to maximize
health needs, to simply identifying basic necessary resources required to treat acute medical
needs. Unlike the previously described research typically associated with NIH or NSF, the
focus of CER research centers around health outcomes, not projected benefits, with the aim
of improving upon or validating best practices. The focus CER places on outcomes and
clinical effectiveness lends itself to broad adaptability for research in low-income countries
because it is rooted in already existing needs and evaluating the current options for
addressing those specific concerns.
Lower-middle and upper-middle income countries, like India and China, have relied
on the U.K.’s NICE program to enhance and focus their own research efforts around
addressing local health challenges.38 India, for examples, has worked with NICE to develop
clinical guidelines to assess local and national health concerns through retrospective analysis
of case studies in an effort to standardize and adapt clinical care to best meet urgent health
needs. China has similarly taken up efforts to address its health concerns through
partnership with NICE to study its healthcare infrastructure through assessing the impact of
technologies on health care outcomes. While both India and China are assessing capacity
retrospectively, their approaches have varied. India has concentrated on evaluating the
effectiveness of health care systems and concerns through focusing on outcomes more
broadly, while China is specifically interested in improving outcomes through the use of
technology. While in their infancy stages, the collaborations between NICE, India, and
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China serves as an important model for the possibilities for developing partnerships beyond
local borders.39
Positively, CER offers a model of research with prospects for current funding that
simultaneously aligns with the social values of Catholic institutions. CER can adopt research
practices that target persons typically omitted from medical research with the direct aim of
improving health care outcomes of the immediate population. With the focus clearly on
health benefits, CER does not ask the question of pharmaceutical trials, i.e. “does it work?”
Rather, the question of CER is “which works better?”40 This research, then, shifts the focus
from economics and technology to an evaluation of the effects/influences of economics and
technology on the health of a person or population.
A limitation of CER research, however, arises from its need for large and potentially
complex data sets to evaluate health care outcomes and the personnel to conduct the
evaluations. Moreover, within these complex data sets, specific questions need to be asked to
yield results that can translate into reformed practices.41 A second point of concern is the
limited methodological approaches that can yield outcomes that would be helpful for a given
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
One of the challenges to effective health care delivery is the disparity between access clinical care and the
necessary resources to provide that care. The U.S., for example, wastes an estimated thirty-cents on every dollar
spent for health care, but arguably has access to the greatest technology necessary to yield quality health care
outcomes. However, the latest technology does not equal effective outcomes. CER can enable cross analysis of
the type and/or quality of technology needed to work within countries with limited resources. Just as NICE is
partnering with other countries to develop CER techniques to assess their health care needs. Catholic
universities could similarly take up these CER endeavors on both a local and global scale. This is research,
according to the IOM report, that the U.S. is interested in developing and the mission of sustainability and
justice as equity that can be pursued through CER is worth fostering. See Institute of Medicine (U.S.).,
Committee on the Learning Healthcare System in America, Best Care at Lower Cost: The Path to Continuously
Learning Health Care in America (Washington, D.C.: Institute of Medicine, (U.S.), Committee on the Learning
Healthcare System in America, 2013).
39

40 Lisa Parker and Howard Brody, “Comparative Effectiveness Research: a Threat to Patient Autonomy?”
Health Progress, 92, no. 5, (2011), 64-71.

David Rubin, “On the Limitations of Comparative Effectiveness Research,” Statistics in Medicine. Vol. 29,
no. 19 (2010), 1991-1995.
41

!

!
population.42 Even within these limitations, there is room for research that focuses on

224

developing new methodologies as an area of research. In order to develop areas for research,
however, collaborative partners need to be established.
In pursuing collaborators and collaborations, Catholic universities should reflect on
their role as institutions at the intersection of the global and local research needs.
Developing collaborative partners proves fundamental to promote a broad research agenda
that not only does research for communities in need, but also aims to develop research
capacity within those areas. While establishing partnerships can be challenging, it reflects the
institutional commitment to socially projected research, i.e. research that reflects the needs
of the community in its research, which can be enhanced by establishing institutional policies
that set the transform of societal needs as an explicit goal. One potential partner that has
demonstrated a capacity for engaging in social projected health care has been Partner’s in
Health (PIH). In this next section, I will introduce a key consideration in developing
partnerships, which emphasizes the crucial step of identifying collaborators that challenge
existing unjust structures and policies and aim to transform them.
Cultivating New Relationships
Research alone will not result in a substantial change for the global health needs of
the majority. Therefore, targeting organizations that have deeply established roots in local
communities aimed at providing health care delivery and developing public health
infrastructures serve as important collaborators for intended research efforts. PIH serves as
one example of a locally embedded collaborative partner that focuses on increasing health
care delivery and developing more robust public health infrastructure, but relies on
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collaborative partners for research. Collaborating on research projects and building capacity
for research is something that Catholic universities can offer an organization like PIH.
However, addressing gaps in research and building capacity for research does not ensure
necessarily that the benefits of research reaches communities in need, there are also
structural and policy challenges that disincentivize medical research on major global health
challenges.
Another example of structural reform, focusing on gaps in the research delivery
pipeline, appears in the proposal of Thomas Pogge’s Health Impact Fund (HIF). The
significance of Pogge’s much criticized efforts, stemming from the complexity surrounding
the programs implementation process, posits an alternative patenting structure to address
the economic challenges that contribute to the lack of incentive for research focused on the
health needs of the poor majority. Rather than a particular form of research, the HIF offers
an opportunity for academic researchers to serve as advocates in an effort to ensure that
their own research projects have the intended impact, especially for projects that stand to
improve access to treatment for low-income communities. While Pogge’s model is not
perfect, and in reality has gained little political traction, it serves as a unique example of an
approach that tackles the structural and policy issues perpetuated by a patent system that
does not reward research on drugs needed to address global health challenges. Both the HIF
and PIH offer an example of social institutions that challenge structures that limit health care
delivery and access to essential medicines for large segments of the global poor.
Partners in Health (PIH)
PIH is a non-profit organization, founded by Jim Kim, Paul Farmer, Ophelia Dahl,
Todd McCormack, and Thomas White, that has developed a growing number of global
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partnerships with communities in low-income countries to strengthen public health
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infrastructures and access to health care services. PIH unapologetically grounds its model of
health care in a preferential option for the poor:
Our mission is to provide a preferential option for the poor in health care. By establishing
long-term relationships with sister organizations based in settings of poverty, Partners In
Health strives to achieve two overarching goals: to bring the benefits of modern medical
science to those most in need of them and to serve as an antidote to despair. We draw on
the resources of the world’s leading medical and academic institutions and on the lived
experience of the world’s poorest and sickest communities. At its root, our mission is
both medical and moral. It is based on solidarity, rather than charity alone. 43
In a sense PIH’s mission statement aligns with what ought to be the goals of medical
research writ large, but certainly with goals of medical research at a Catholic university. Their
commitment to the option for the poor, cultivating local partnerships, utilizing the latest
technological and medical advances to benefit those most often excluded, and focus on
solidarity—both intellectual and practical—demonstrates the epistemological effects of an
organization that begins with the horizon of the poor majority.
PIH has cultivated local/global relationships in Haiti, Rwanda, Lesotho, Malawi,
Mexico, Russia, Peru, Navajo Nation, and Boston that focus healthcare delivery and public
health education, with an eye towards developing a capacity for research, while also ensuring
its distribution in these areas. PIH’s research priorities do not reflect the breadth of NIH
research priorities, but rather a narrower agenda with more immediate effects. They cite their
health priorities as: Cancer & Chronic Diseases; Child Health; Cholera; Community Health
Workers; Ebola; HIV/AIDS; Mental Health; Nursing; Surgery; Tuberculosis; and Women’s
Health. These research priorities reflect the health needs of the people with whom they
work.
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Collaboration with research partners like PIH, demonstrates a commitment to

developing a socially projected research agenda that reflect the needs of a particular
community. PIH serves as an exemplar in its focus on local health needs and its cultivation
of academic and philanthropic partnerships committed to the same common goal. Through
PIH’s alliance with Harvard University and the Brigham and Women’s Hospital in Boston,
they have cultivated partnerships that research by exploring “the impact of global health
initiatives on national health systems with commissions from the World Health Organization
and UNAIDS.”44 The system for collaboration is in place. Universities educate students
about the impact and importance of global health and focus on research that addresses
health needs raised by locally embedded partners, global and local. PIH, the partner
organization, ensures the delivery of health care, establishes preventive health measures, and
implements improvements that come about through research. While PIH, and other similar
organizations, demonstrates a commitment to ensuring health care delivery and disease
prevention through public health strategies, further work has to develop research capacity
within these vulnerable places.
Developing research capacity requires a commitment to working with partner
organizations to identify areas of research need and also challenge existing research
structures. In order to be leaders in global health research, collaborative relationships must
be mutually beneficial. While PIH might not prove capable of taking on widespread clinical
trials, they can engage in research similar to CER, as discussed in the first section. In this
way, efforts could be made to study the effects and possibilities of improving the quality of
care in a given area. On the other hand, if a university wanted to conduct a large scale trial
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for an under-researched drug or with a vulnerable population, measures have to be put into
place so as to ensure that benefits resulting from that research extend to the research
population, which is already built into CER.
The example of PIH highlights the importance of international partnerships,
however, the geographic location should not dictate the partnership. Instead, the needs of
the community and collaborations with organizations that may have limited access to the
fruits of research efforts most aptly define the parameters of the partnership. The important
factor in determining a collaborative partner for research is the ability to translate the
benefits of research into effective health care. Even with effective health care delivery
systems and public health infrastructure, systemic change to the way in which research flows
will still be needed. Thus, partnering with PIH represents one way to include multiple
vulnerable populations in the process of research. However, developing partnerships alone
will not resolve the structural challenges involved in medical research. Advocacy efforts
prove essential in an effort to ensure that research developments benefit their targeted
population.
Catholic universities have the obligation to advocate for systemic changes that
allows for more just distribution of knowledge garnered through medical research to those
communities most in need. While establishing partnerships with organizations committed to
delivering health care and engaging in research that can affect the health of the poor
majority, exploring systemic changes to the unjust distribution of research also needs to be
explored. Advocacy efforts around policy change can be significantly enhanced by academic-
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researchers who recognize the social enterprise of their research efforts and see the need to
address the breakdowns in the drug development pipeline.45
Health Impact Fund (HIF)
The HIF proposes to address the challenge posed by economic forces that generate
little incentive for medical research to target neglected diseases and/or disease that
predominately affect low- and middle-income countries. 46 While, in reality, university
researchers have little to do with the market forces and intellectual property rights restricting
essential medicines, they have also done little by way of acknowledging or attempting to
reform the injustices of the system in which they participate. Systemic change proves
necessary to the consideration of medical research as a discipline that impacts society. The
example of the HIF, while not serving as an endorsement of the system, represents an
important model for rethinking the complexities associated with medical research.47
The HIF aims to alter both the politics and economics that govern research by
deemphasizing return on investments that do not positively affect the health needs of the
majority. A large portion of these efforts would require government financing to establish a
“pay-for-performance mechanism that would offer innovators the option—no obligation—
to register any new medicine or, under certain conditions, also a traditional medicine or anew
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use of an existing medicine.” The funding would be established by and paid for through
high-income governments that opt-in. However, there exists no obligation for industry or
governments to buy-in. These two entities, nevertheless, must participate in order for the
HIF to function, i.e. the greater the number of governments and industries that opt-in, the
more financial incentives would exist to research diseases that cause the greatest health
challenges for the majority.49 And, while the registration process would function similarly to
current patenting practices, the caveat would be that the return on investment takes place
based off of actual health impact measured by Quality Adjusted Life Years.50
During the first 10 years on market —half of the typical duration of patent—a drug
would be made available in the areas most in need for no more than the lowest possible cost
of production and distribution. After 10 years, generic production and distribution of the
product would then be allowed. With financial incentives, “HIF would foster the
development of new high-impact medicines—also against diseases concentrated among
poor, such as tuberculosis, malaria, and other tropical diseases, which are now neglected
because innovators cannot recover their R&D costs from sales to the poor.”51 Pogge’s
model represents an alternative, structural way of re-thinking the drug pipeline that,
unaltered, continues to exclude those most in need of treatment options.
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The description of Pogge’s HIF is not an endorsement of it, nor something that

Catholic universities should necessarily adopt. However, reconsidering the structure of
medical research is something that the university should undertake in establishing its
research priorities. Pogge rightly calls on university academics to partner with him in support
of creating the HIF and demonstrates the complex task that would benefit greatly from the
expertise of academic medical researchers. While this may not be the model universities want
to endorse, medical researchers offer unique insights into the drug development process at
the most basic level. Their perspective is enhanced further by the technical nuance to
advocate for systemic change from within the structure of medical research itself.
Medical researches, implicitly or explicitly, are already contributing to the debate
through their research. Advocates prove necessary to shift this agenda and priorities, and
“…academic silence can reasonably be interpreted as academic acceptance that the main
view represented in the public debate are credible and consistent with the available
evidence.”52 This cannot come from the ivory tower but, rather, the voices of those
marginalized by and excluded from medical research benefits need to be heard. In this way,
research advocates need to both speak broadly to the research community through
publications and presentations and to alter the structures that limit the just-distribution of
the produced innovations.
HIF and PIH both offer systemic changes to the way in which medical research is
delivered to low- and middle-income countries. HIF takes a political approach rooted in a
complex overhaul of the drug pipeline in an effort to treat those with medications for
diseases that are often under-research. The approach of PIH, perhaps most consistent with a
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liberationist approach, is rooted in a process of community engagement and locally delivery
of effective health care. If PIH represents the grassroots approach to assessing health care
and medical research needs, then Pogge’s system—even if flawed—represents a type of
socio-political overhaul that attempts to interrupt the current injustice within the distribution
of medical research.
Catholic universities have an obligation to take up the responsibility beyond simple
engagement in just-research, and to advocate additionally for reforms to structures that
contribute to its inequitable distribution. Yet, the present reality suggests that the current
structures may simply prove impermeable to suggested reform. In this case, alternative
approaches to collaboration and advocacy for social justice based on health priorities may
need to be considered. This change could necessitate a complete rethinking of the approach
to research and the adoption of alternative structures for approaching the health needs of
the poor majority.
Exploring Alternative Visions
The final two examples focus on challenging the current inequalities that exist by
developing parallel structures that strive for more targeted funding and better sharing of
information developed in the research process. The first option takes up the idea of a cooperative university, while the latter considers—following the WHO suggestion—the
development of an open source database that lists research being conducted on urgent
health needs. While these types of structures represent departures from the way in which the
process of medical research takes place, they also draw on a type of ethical imagination
needed to think through global challenges.
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Mondragón is co-operative business and educational institution developed in the
Basque region of Spain, which has grown into a sustainable Spanish business with
multinational locations. The model was developed by Father Jose Maria Arizmendi as a way
to institute, what he believed to be, a sustainable business model. The business developed
from the local community built and relying on principles of Catholic Social Teaching to
inform its mission.
Mondragón has developed into an international, multi-million dollar for-profit cooperative business. It consists of 150 co-operatives, three research and development centers,
a university, its own bank, and health care system.53 While the focus at Mondragón is not on
medical research, it does generate patents, currently holding 716, which seems crucial to the
practice of research—as presently conceived. These patents have made them one of Spain’s
leaders in alternative energy sources of wind power, fuel cells, and solar panels.54 They
emphasize these sustainable projects, not at the expense of economic returns, but also not
subservient to the economic demands. The Mondragón co-operative has created a parallel
business model and one that pharmaceutical business executives could emulate by
incorporating more social equity into the internal structures and priority setting for neglected
diseases. One of the key features of Mondragón, aside from the co-operative organizational
structure, was the creation of its own research pipeline through its university.
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Mondragón University understands that integrating the three main activities of a

university—education, research, and service—is the most effective way of increasing quality
and fulfilling its social mission. It does so, however, with a targeted and collaborative
approach throughout the co-op. Research is conducted through a collaborative model
“based on research alignment, from oriented basic research to innovation, with the
participation of three key actors: universities, technology centers, and businesses through
R&D departments.”55 They decide that in order for their research to be cost-effective, but
still to meet the socio-ethical principles held by the company, research has to align with the
cooperatives interests. The goal, then, is to incorporate researchers in order to “produce
top-quality research and bring the university closer to businesses as the key to innovative
dynamics and to the training of would-be researchers for businesses and technology
centers.”56 A key distinction between current models of university research and Mondragón’s
lies in the fact that university researchers do not set the agenda, Mondragón does.
Mondragón University considers chooses research in line with its strategies to create wealth
in the community. They hire researchers that prove capable of enacting the institutional
standards for research—as opposed to letting researchers themselves set the agenda.
To apply Mondragón’s model for medical research presents several obstacles, not the
least of which requires a significant financial investment on the part of individuals who see a
value in the mission focus and potential success of a co-operative model for business and
education. However, it demonstrates a targeted and collaborative approach to research that
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
55 Mondragon, “Research Model,” http://www.mondragon.edu/en/research/research-model, (accessed May 1,
2015).
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would more directly be able to address some of the gaps in medical research. Finances aside,
Mondragón could serve as an intriguing dialogue partner because of their commitment to
Catholic social values, equity within their institution, and their focus on education that yields
practical results. A focus on the practical results of health impact, however, will require
information sharing. Thus, while a business model and current research practices tend to
guard new and innovative information, a model for research that intends to generate the
highest health impact will need to openly share its resources in order to demonstrate
progress and not duplicate research efforts.
International Federation of Catholic Universities (IFCU)
Participation in an open source database and priority setting, as proposed by the
WHO’s Consultative Expert Working Group for health research, could prove a successful
undertaking of the International Federation of Catholic Universities (IFCU). An open source
database and working group on medical research would represent an important step in
raising awareness for diseases in need of research. An open source database and
collaborations with the IFCU would demonstrate the leading role that Catholic universities
ought to play in addressing the global need in medical research.
The IFCU, as part of its mission, aims to develop a collaborative environment for
Catholic higher education. It recognizes the importance of research in this social project and
holds within its current structure a Center for the Coordination of Research (CCR). “Aware
of the concerns, interests and expectations of Catholic universities and their respective fields
of action, the CCR offers a platform for encounter, debate, production and circulation of
knowledge, in order to permanently question the main challenges posed today to human,
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scientific, social and ecclesial development.” There is no specific mention of collaboration
on medical research. While a working group on medical research that affects the most
vulnerable would be a start and an open source database would be even better. Here, the
IFCU could provide a place for intentional dialogue to develop a research agenda that speaks
to the socially projected needs from a diverse community of representatives.
Developing a Catholic and international collaborative focused on medical research
around diseases that disproportionately affect the poor and marginalized allows for the
pooling of resources and streamlining of efforts to address global health needs. Those
already engaged in medical research targeting poor and vulnerable populations is currently a
small subset of researchers. The hope, as with other initiatives in the IFCU, would be to
bring together the leaders in research on global health needs to raise awareness and capacity
of Catholic universities to engage in collaborative research. Establishing a network of
knowledge would foster, hopefully, effective support and creativity between its members,
create space to share information, and save expense by releasing new information more
quickly, consequently limiting the duplication of work.
Collaborative research, which has been at the heart of most of these projects, can
prove to be a time-consuming and challenging effort. However, when reflecting on the
original paradigmatic examples in Chapter One, the most effective forms of research
addressing global health needs were collaborative. The above examples are emblematic of
the types of approaches, though not necessarily an exact blueprint, that can offer correctives
to structural injustices within the research process. Each of the examples challenges the
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
International Federation of Catholic Universities, “About IFCU,”
http://fiuc.org/en/docs/about_ifcu/ex_corde_ecclesiae_foundation. (accessed, May 1, 2015).
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existing economic or technological epistemology at work in research and offers the global
health of the poor as a guiding framework. Targeted research efforts, developing
partnerships, and exploring creative alternatives to enhance the health options of the poor
majority is fundamental for Catholic university research. And while these examples of
signaled potential dialogue partners, universities themselves have to restructure their own
institutional approach to medical research. By way of conclusion, the final section sketches
some fundamental steps that need to be taken for Catholic university medical research to
project an option for the poor onto their research agenda.
Conclusion: Is a Different Kind of Research Agenda Possible?
The most fundamental shift for the university has to come from instituting structural
and policy changes that ground the norms for medical research through explicitly
prioritization of the health needs of the poor majority. Ellacuría clearly articulated the
importance of social projection as the way for conducting research at the UCA. The UCA
research, however, was not about the task of research per se. Research, rather, served the task
of the university’s mission to engage in education, research, and service in order to
understand and transform the injustices within the community. Medical research must
likewise be reimagined in through a similar multifaceted approach. Therefore, relying on the
efforts of individual researchers to set up the research agenda of the institution will continue
to produce disparate results that fail to achieve desired health outcomes.
When attempting to transform a culture, challenges emerge when change is forced
from the top. Thus, while hiring for mission proves important, that mission must include the
ability to collaborate and focus on a unified goal. While Catholic universities may speak
about the option for the poor, it rarely appears as the subject of research practices or in the
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education of students on how to conduct research. Students who engage in research are
taught the importance of conducting research that respects research subjects, but more need
to be taught about the social reality of those who benefit and those who do not from the
research conducted. Conducting research as a social practice and educating for just-research,
or socially-projected research, can transform and refocus the intrinsic good of medical
research from the knowledge produced to the knowledge produced for the health and care of
individuals most in need.
While developing strategic priorities for health research may be possible, financing
for this plan proves limited. Thus, given the challenge of finding grants for these particular
areas of research, more institutional and hard money commitments prove necessary. Many
researchers finance portions of their own salaries through grant projects they have earned.
This creates practical challenges when targeting a small sub-sector of grants that one may or
may not receive. Increasing the hard money commitment for researchers frees researchers to
pursue more competitive grants as long as they maintain a focus for neglected and underresearched diseases. Moreover, reconsidering tenure requirements might also be necessary in
order to reward researchers for their commitment to engaging in medical research befitting
the institutional mission. With this type of institutional reform, Catholic universities might
be able to recruit well-published and higher profile researchers that focus on global health
and neglected diseases to working at the university, which reinforces the institutional
commitment to engage in a distinct kind of research—one that is socially projected.
The final step, and perhaps the simplest implementation for Catholic universities, is
the development of and participation in advocacy networks through publishing. In the
research community, publications represent priority. In other words, if something is
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considered important, someone is researching and publishing on the topic. What is seldom
referenced, except when crises emerge—e.g. Cholera and Ebola—are efforts to bring
awareness to neglected diseases more broadly and more consistently. While it is an
expectation that researchers engage in retrospective analysis detailing their research efforts,
attempting to establish broader areas for funding and research that benefit the poor majority
more prospective and collaborative publishing proves necessary in order to bring attention
to under-researched areas.58 This prospective approach will necessitate collaborations
interdepartmentally in order to provide ethnographic, sociological, and even theological
importance for why certain projects ought to be pursued over others. The strength of the
social science efforts, moreover, will be reinforced by the scientific approach that can point
to potential practical solutions in development in the lab or clinical trials. Yet, all of this is
for naught if the epistemology of research remains the same.
This dissertation began with a focus on paradigmatic accounts of the development of
medical research that sought to both improve the health of communities and particular
individuals. Gradually, the focus of researching for health was seen along side the possibility
of economic gain. Currently, the most economic gain stems from genetic and biotechnology
based research. Not only does it hold economic possibilities, it also represents the newest
scientific knowledge being discovered as it relates to medical research. However, the
epistemic foundation of this research begins from a perspective of new knowledge and
economic gain with little mention of health. However, if health became the hermeutic
through which medical research was understood, then medical research agenda would have
to shift.
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When making the epistemological move to reflect on research from the perspective

of health, one’s attention has to turn to places in which a lack of “health” exists. As noted in
Chapter Four, DALYs serve as tangible markers of the structural injustices endemic to the
practice of medical research itself. These injustices develop through a false epistemology for
medical research that prioritizes financial gain and future promise for the minority over
present and dire health needs for the majority. Thus, research for the common good, a
fundamental tenant of Catholic Social Teaching, proves impossible as long as current
structures prevail. In a certain sense, medical research is left with the task of avoiding the
common harm.
Catholic universities, in solidarity with those most vulnerable, must make a
preferential option for the poor apparent in the practice of medical research. While this final
chapter has proposed dialogue partners in this endeavor, individual institutions and
collaborative networks should take this occasion to reevaluate their own research priorities
and policies to see how they participate in the current injustices in medical research. This is
not an easy task, and the ways forward proposed here most certainly need nuance. However,
this is not intended to be the end of the conversation but the beginning. These pages have
focused on the importance of collaborative dialogue and health-oriented research that seeks
to transform the ways in which Catholic universities engage in the social practice of medical
research. Catholic universities committed to engaging in medical research have the obligation
to implement institutional changes that promote and prioritize the health needs of the poor
majority in pursuit of justice from places of injustice.

!

!

BIBLIOGRAPHY
Administration for Children and Families. “Assistance to States and Tribes.” U.S.
Department of Health and Human Services. accessed June 24, 2014,
https://cb100.acf.hhs.gov/cb_eBrochure_EmergencyCare
Agua-Agum J, Ariyarajah A, Aylward B, Blake IM, Brennan R, Cori A, Donnelly CA,
Dorigatti I, Dye C, Eckmanns T, Ferguson NM, Formenty P, Fraser C, Garcia E,
Garske T, Hinsley W, Holmes D, Hugonnet S, Iyengar S, Jombart T, Krishnan R,
Meijers S, Mills HL, Mohamed Y, Nedjati-Gilani G, Newton E, Nouvellet P, Pelletier L,
Perkins D, Riley S, Sagrado M, Schnitzler J, Schumacher D, Shah A, Van Kerkhove
MD, Varsaneux O, Wijekoon Kannangarage N. “West African Ebola Epidemic After
One Year--Slowing but Not Yet Under Control.” The New England Journal of Medicine
372, no. 6 (2015): 584-7.
Ahern, Kevin. Visions of Hope: Emerging Theologians and the Future of the Church. Maryknoll, NY:
Orbis Books, 2013.
Aita, Mark, Debra Bennett-Woods, Peter Clark, James M. DuBois, Amy Haddad, Mark
Kuczewski, , Carol Taylor, James Walter. “Consortium of Jesuit Bioethics Programs.”
Commonweal 136, no. 8 (2009).
Aksu, Buket, Thomas De Beer, Staffan Folestad, Jarkko Ketolainen, Hans Lindén, Joao
Almeida Lopes, Marcel de Matas, Wim Oostra, Jukka Rantanen, Marco Weimer.
“Strategic Funding Priorities in the Pharmaceutical Sciences Allied to Quality by Design
(QbD) and Process Analytical Technology (PAT).” European Journal of Pharmaceutical
Sciences 47, no. 2 (2012): 402-5.
Alexander, Caroline. “Faces of War.” Smithsonian Magazine, February 2007, accessed May 2,
2015, http://www.smithsonianmag.com/history/faces-of-war-145799854/?no-ist.
Allen, Garland. “Eugenics and American Social History, 1880-1950.” Genome 31, no. 2
(1989): 885-9.
Alvarez, Adriana. “Malaria and the Emergence of Rural Health in Argentina: An Analysis
from the Perspective of International Interaction and Co-Operation.” Canadian Bulletin
of Medical History 25, no. 1 (2008): 137-60.
Anderson, James, Natalja Strelkowa, Guy‐Bart Stan, Thomas Douglas, Julian Savulescu,
Mauricio Barahona, Antonis Papachristodoulou. “Engineering and Ethical Perspectives
in Synthetic Biology. Rigorous, Robust and Predictable Designs, Public Engagement
!

241

!

242
and a Modern Ethical Framework are Vital to the Continued Success of Synthetic
Biology.” EMBO Reports 13, no. 7 (2012): 584-90.

Anderson, Emily E. “Public Participation in Human Research Ethics Oversight: The NonAffiliated, Non-Scientist Institutional Review Board Member.” Doctor of Philosophy,
Saint Louis University, 2007.
Anderson, Warwick. “Indigenous Health in a Global Frame: From Community
Development to Human Rights.” Health and History 10, no. 2 (2008): 94.
Angell, Marcia. “Editorial Responsibility: Protecting Human Rights by Restricting
Publication of Unethical Research." In the Nazi Doctors and the Nuremberg Code: Human
Rights in Human Experimentation, eds. George Annas and Michael Grodin, 276. New
York: Oxford University Press, 1992.
________. The Truth about the Drug Companies: How they Deceive Us and what to do about it. New
York: Random House, 2004.
Annas George. “The Changing Landscape of Human Experimentation: Nuremberg,
Helsinki, and Beyond.” Health Matrix 2, no. 2 (1992): 119-40.
________. “Mengele’s Birthmark: The Nuremberg Code in United States Courts.” The
Journal of Contemporary Health Law and Policy 7 (1991): 17-45.
Annas, George and Michael Grodin. “The Nuremberg Code.” In The Oxford Textbook of
Clinical Research, eds. Ezekiel J. Emanuel, Christine Grady, Robert A. Crouch, Reidar K.
Lie, Franklin G. Miller and David Wendler, 136. New York: Oxford University Press,
2008.
________. “Introduction.” in The Nazi Doctors and the Nuremberg Code: Human Rights and the
Nuremberg Code, eds. George and Michael Grodin, 3. New York: Oxford University
Press, 1992.
Appel, Toby A. Shaping Biology the National Science Foundation and American Biological Research,
1945-1975. Baltimore, MD: Johns Hopkins University Press, 2000.
Aquino, María Pilar, Daisy Machado, Jeanette Rodriguez, eds. A Reader in Latina Feminist
Theology Religion and Justice. Austin, TX: University of Texas Press, 2002.
Arnett Donna, Steven Claas, Amy Lynch. “Has Pharmacogenetics Brought Us Closer to
'Personalized Medicine' for Initial Drug Treatment of Hypertension?” Current Opinion in
Cardiology 24, no. 4 (2009): 333-9.
Arpino, James, Edward Hancock, James Anderson. “Turning the Dials of Synthetic
Biology.” Microbiology 159, no. 7 (2013): 1236.

243
!
Ashcroft, Richard E. “The Declaration of Helsinki.” In The Oxford Textbook for Research
Ethics, eds. Ezekiel J. Emanuel, Christine Grady, Robert A. Crouch, Reidar K. Lie,
Franklin G. Miller and David Wendler, 141. Oxford University Press, 2008.
Ashley, James Matthew. “A Contemplative Under the Standard of Christ: Ignacio Ellacuría's
Interpretation of Ignatius of Loyola’s Spiritual Exercises.” Spiritus: A Journal of Christian
Spirituality 10, no. 2 (2010): 192-204.
Ashley, James Matthew, Kevin Burke, Rodolfo Cardinal, S.J., eds. A Grammar of Justice: The
Legacy of Ignacio Ellacuría. Maryknoll, NY: Orbis Books, 2014.
Association of Catholic Colleges and Universities, “Frequently Asked Questions,”
http://www.accunet.org/i4a/pages/index.cfm?pageid=3797#WorldPercentage
(accessed March 22, 2015).
Association of University Technology Managers. “Bayh Dole Act.” AUTM,
http://www.autm.net/home.htm (accessed December 15, 2014).
Astorga, Christina A. Catholic Moral Theology and Social Ethics: A New Method. Maryknoll, NY:
Orbis Books, 2014.
Atkinsona, Richard C. and William A. Blanpied “Research Universities: Core of the US
Science and Technology System.” Technology in Society 30 (2008): 30–4.
Attenborough Frederick T. “To Rid Oneself of the Uninvited Guest: Robert Koch, Sergei
Winogradsky and Competing Styles of Practice in Medical Microbiology.” Journal of
Historical Sociology 25, no. 1 (2012): 50-82.
Azoulay, Pierre, Waverly Ding, Toby Stuart. “The Impact of Academic Patenting on the
Rate, Quality and Direction of (Public) Research Output.” The Journal of Industrial
Economics 57, no. 4 (2009): 637-76.
Bacon, Francis. The Works of Francis Bacon, Volume VIII. Boston: Houghton, Mifflin and
Company, 2007.
Bailey, Ronald. Liberation Biology: The Scientific and Moral Case for the Biotech Revolution. Amherst,
N.Y.: Prometheus Books, 2005.
Baker, Robert. Before Bioethics: A History of American Medical Ethics from the Colonial Period to the
Bioethics Revolution. New York, NY: Oxford University Press, 2013.
Balkrishnan Rajesh, Jongwha Chang, Fang Yang, and Sofia D. Merahver. “Global
Comparative Healthcare Effectiveness Research: Evaluating Sustainable Programmes in
Low and Middle Resource Settings.” The Indian Journal of Medical Research 137, no. 3
(2013): 494-501.
!

244
!
Banerjee, Amitava, Aidan Hollis, and Thomas Pogge. “The Health Impact Fund: Incentives
for Improving Access to Medicines.” Lancet 375, no. 9709 (2010).
Baquet, Claudia R. “A Model for Bidirectional Community-Academic Engagement (CAE):
Overview of Partnered Research, Capacity Enhancement, Systems Transformation, and
Public Trust in Research.” Journal of Health Care for the Poor and Underserved 23, no. 4
(2012): 1806-24.
Barrett, Scott. “The Smallpox Eradication Game.” Public Choice 130, no. 1/2 (2007): 179-207.
________. “Eradication Versus Control: The Economics of Global Infectious Disease
Policies.” Bulletin of the World Health Organization 82, no. 9 (2004).
Bartsch, Sarah M., Katie Gorham, Bruce Y. Lee. “The Cost of an Ebola Case.” Pathogens and
Global Health Pathogens and Global Health 109, no. 1 (2015).
Barzilay, Ezra J., Nicolas Schaad, Roc Magloire, Kam S. Mung, Jacques Boncy, Georges A.
Dahourou, Eric D. Mintz, Maria W. Steenland, John F. Vertefeuille, and Jordan W.
Tappero. “Cholera Surveillance during the Haiti Epidemic--the First 2 Years.” The New
England Journal of Medicine 368, no. 7 (2013): 599-609.
Bashford, Alison. “Global Biopolitics and the History of World Health.” History of the Human
Sciences 19, no. 1 (March 8, 2006): 67-88.
________. Medicine at the Border: Disease, Globalization and Security, 1850 to the Present. New
York: Palgrave Macmillan, 2006.
Beauchamp, Thomas. “The Belmont Report.” In The Oxford Textbook of Clinical Research
Ethics, eds. Ezekiel J. Emanuel, Christine Grady, Robert A. Crouch, Reidar K. Lie,
Franklin G. Miller and David Wendler, 149. New York: Oxford University Press, 2008.
________. “The Origins and Evolution of the Belmont Report.” In Belmont Revisited: Ethical
Principles for Research with Human Subjects, eds. James Childress, Eric M. Meslin and
Harold T. Shapiro, 12. Washington, D.C.: Georgetown University Press, 2005.
Beauchamp, Thomas and James Childress. Principles of Biomedical Ethics. Sixth Edition. New
York and Oxford: Oxford University Press, 2009.
Beecher, Henry K. “Ethics and Clinical Research.” New England Journal of Medicine 274, no. 24
(1966): 1354-60.
Behbehani, Abbas. “The Smallpox Story: Life and Death of an Old Disease.” Microbiological
Reviews 47, no. 4 (1983): 455-509.
Beinart, William, Karen Brown, Daniel Gilfoyle. “Experts and Expertise in Colonial Africa
!

!

245
Reconsidered: Science and the Interpenetration of Knowledge.” African Affairs -LondonRoyal African Society- 108, no. 432 (2009): 413-33.

Bell, Janice F., Frederick J. Zimmerman, Gunnar R. Almgren, Jonathan D. Mayer, and
Colleen E. Huebner. “Birth Outcomes among Urban African-American Women: a
Multilevel Analysis of the Role of Racial Residential Segregation.” Social Science and
Medicine 23, no. 12 (2006): 3030-45.
Benatar, Solomon. “Justice and Medical Research: A Global Perspective.” Bioethics 15, no. 4
(2001): 333-40.
________. “Global Disparities in Health and Human Rights: A Critical Commentary.”
American Journal of Public Health 88, no. 2 (1998): 295-300.
Benatar, Solomon, Stephen Gill, and Isabella Bakker. “Global Health and the Global
Economic Crisis.” American Journal of Public Health 101, no. 4 (2011): 646-53.
Benedict XVI. A Reason Open to God: On Universities, Education, and Culture. ed. Steven Brown,
Washington, D.C.: The Catholic University of America Press, 2013.
________. Caritas in Veritate. June 29, 2009.
________. Deus Caritas Est. December, 25 2005.
Benner, Steven. “Aesthetics in Synthesis and Synthetic Biology.” Current Opinion in Chemical
Biology 16, no. 5-6 (2012): 5-6.
Benno, Müller-Hill. “The Blood from Auschwitz and the Silence of the Scholars.” History and
Philosophy of the Life Sciences 21, no. 3 (1999): 331-65.
Best, Rachel Kahn. “Disease Politics and Medical Research Funding: Three Ways Advocacy
Shapes Policy.” American Sociological Review 77, no. 5 (October 01, 2012): 780-803.
Biehl, João Guilherme. “Pharmaceuticalization: AIDS Treatment and Global Health
Politics.” Anthropological Quarterly 80, no. 4 (2007): 1083-126.
Bishop, Jeffrey P. The Anticipatory Corpse: Medicine, Power, and the Care of the Dying. Notre Dame,
IN: University of Notre Dame Press, 2011.
Bishop, Jeffrey P. and Elliott Louis Bedford. “Medically Assisted Nutrition and Hydration:
The Vegetative State and Beyond.” Christian Bioethics: Non-Ecumenical Studies in Medical
Morality 17, no. 2 (2011).
Black, Henry R. Clinical Trials in Hypertension. New York: Marcel Dekker, 2001.
!

246
!
Bluestone, Jeffrey, and Jeffrey Matthews. “The Immune Tolerance Network: Tolerance at
the Crossroads.” Philosophical Transactions: Biological Sciences 356, no. 1409 (2001): 773-6.
Blumenthal, David, Nancyanne Causino, Eric Campbell, and Karen Louis. “Relationships
between Academic Institutions and Industry in the Life Sciences - an Industry Survey.”
New England Journal of Medicine 334, no. 6 (1996): 368-73.
Boccanfuso, Anthony. “Why University-Industry Partnerships Matter.” Science Translational
Medicine Science Translational Medicine 2, no. 51 (2010): 51.
Bodenheimer, Thomas. “Uneasy Alliance: Clinical Investigators and the Pharmaceutical
Industry.” New England Journal of Medicine 342, no. 20 (2000): 1539-44.
Bonetta, Laura. “Enhancing NIH Grant Peer Review: A Broader Perspective.” Cell 135, no.
2 (2008): 201-4.
Borrell-Carrió F, Anthony Suchman, Ronald Epstein. “The Biopsychosocial Model 25 Years
Later: Principles, Practice, and Scientific Inquiry.” Annals of Family Medicine 2, no. 6
(2004).
Boslaugh, Sarah, editor. Encyclopedia of Epidemiology. New York, NY: Sage Publications, 2012.
Brackley, Dean. “Higher Standards for Higher Education: The Christian University and
Solidarity,” address delivered at Creighton University (Omaha, NE), November 4, 1999,
http://onlineministries.creighton.edu/Collaborative.
________. “Moral Theology in Latin America.” Theological Studies 63, no. 1 (2002): 123-60.
Brady, Tammy, Barabara Fivush, Rulan Parekh, Joseph Flynn. “Racial Differences among
Children with Primary Hypertension.” Pediatrics 126, no. 5 (2010): 931-7.
Breilh, Jaime. “Latin American Critical (‘Social’) Epidemiology: New Settings for an Old
Dream.” International Journal of Epidemiology 37, no. 4 (2008): 745-50.
Brigham, Erin, editor. The Church in the Modern World: Fifty Years After Gaudium Et Spes.
London: Lexington Books, 2015.
Browning, Melissa. Risky Marriage: HIV and Intimate Relationships in Tanzania. Lanham,
Maryland: Rowman and Littlefield, 2014.
Brunetti, Nattale, Luisa De Gennaro, Pier Pellegrino, and Matteo Di Biase. “Industry Or
Academia: Who Leads the Research in Medicine?” European Journal of Internal Medicine 18,
no. 1 (2007): 3-5.
Bryder, Linda. “ ‘We Shall Not Find Salvation in Inoculation’: BCG Vaccination in
!

!

247
Scandinavia, Britain and the USA, 1921–1960." Social Science and Medicine 49, no. 9
(1999): 1157-67.

Buckley, Michael J. The Catholic University as Promise and Project: Reflections in a Jesuit Idiom.
Washington, D.C.: Georgetown University Press, 1998.
Burke, Kevin F. The Ground Beneath the Cross: The Theology of Ignacio Ellacuría. Washington,
D.C.: Georgetown University Press, 2000.
Burke, Kevin and J. Matthew Ashley, eds., A Grammar of Justice: The Legacy of Ignacio Ellacuría,
New York: Orbis Books, 2014.
Burrows, Beth Elpern. “Colonialism and the Research Endeavour: Reflections on the
Human Genome Diversity Project.” Development 49, no. 4 (2006): 73-7.
Bush, Vannevar. “As We May Think.” Atlantic. 176, no. 1 (1945).
________. Endless Horizons. New York: Arno Press, 1975.
________. Science, the Endless Frontier. A Report to the President. Washington: U.S. Government,
1945.
Byass Peter. “Epidemiology without Borders: An Anational View of Global Health.” Global
Health Action 2 (2009).
Cahill, Lisa Sowle. “Bioethics, Theology, and Social Change.” Journal of Religion and Ethics 31,
no. 3 (2003): 363-98.
________. “Biotech and Justice: Catching Up with the Real World Order.” Hastings Center
Report 33, no. 5 (2003): 34-44.
________. “Caritas in Veritate: Benedict’s Global Reorientation.” Theological Studies 71, no. 2
(2010).
________. “Genetics, Commodification, and Social Justice in the Globalization Era.”
Kennedy Institute of Ethics Journal 11, no. 3 (2001): 221-38.
________. Global Justice, Christology and Christian Ethics. New York, NY: Cambridge University
Press, 2013.
________. Theological Bioethics: Participation, Justice, and Change. Washington, D.C: Georgetown
University Press, 2005.
________. “Theological Ethics as Political Ethics: A Conversation with Raymond Geuss.”
Studies in Christian Ethics 25, no. 1 (2012): 53-9.
!

!
________. “Toward Global Ethics.” Theological Studies 63, no. 2 (2002): 324-44.

248

Califf, Robert, Iain Sanderson, Mary Lynn Miranda. “The Future of Cardiovascular Clinical
Research: Informatics, Clinical Investigators, and Community Engagement.” Journal of
the American Medical Association 308, no. 17 (2012): 1747-8.
Calkins, Peter and Marc Vézina. “Transitional Paradigms to a New World Economic
Order.” International Journal of Social Economics 23, no. 10/11 (1996): 311-28.
Callahan, Daniel. “Conservatives, Liberals, and Medical Progress.” New Atlantis 10 (2005): 316.
________. What Price Better Health?: Hazards of the Research Imperative. Berkeley and Los
Angeles: Universitty of California Press, 2003.
Calvert, Jane. “Synthetic Biology: Constructing Nature?” SORE the Sociological Review 58
(2010): 95-112.
Cameron, Ewen, Caleb Bashor, and James Collins. “A Brief History of Synthetic Biology,”
Nature Reviews Microbiology. vol. 12, no. 5 (2014): 381-390
Caplan, Arthur. “The Doctors' Trial and Analogies to the Holocaust in Contemporary
Bioethical Debates.” In The Nazi Doctors and the Nuremberg Code: Human Rights in Human
Experimentation, eds. George Annas and Michael Grodin, 258. New York: Oxford
University Press, 1992.
Carlson, Robert V., Kenneth M. Boyd, and David J. Webb. “The Revision of the
Declaration of Helsinki: Past, Present, and Future.” British Journal of Clinical Pharmacology
57, no. 6 (2004): 695-713.
Carnevale, Franco. “A Conceptual and Moral Analysis of Suffering.” Nursing Ethics 16, no. 2
(2009): 173-83.
Carpenter, Daniel and Gisela Sin. “Policy Tragedy and the Emergence of Regulation: The
Food, Drug, and Cosmetic Act of 1938.” Studies in American Political Development 21, no. 2
(2007): 149-80.
Cassell Gail. “Interactions of the Public and Private Sectors in Drug Development:
Boundaries to Protect Scientific Values while Preserving Innovation.” Cleveland Clinic
Journal of Medicine 74 (2007): 45-8.
Catholic Data, Catholic Research, Catholic Statistics, “Frequently Cited Research,”
http://cara.georgetown.edu/CARAServices/requestedchurchstats.html (accessed
March 22, 2015).
!

249
!
Center for Disease Control and Prevention. “Yellow Fever.” Center for Disease Control and
Prevention. http://www.cdc.gov/yellowfever/ (accessed January 15, 2014).
________. “Smallpox Disease Overview.” Center for Disease Control and Prevention.
http://www.bt.cdc.gov/agent/smallpox/overview/disease-facts.asp (accessed
December 14, 2013).
Chalkidou, Kalipso and Gerard Anderson. Comparative Effectiveness Research: International
Experiences and Implications for the United States. Kaiser Permanente Institute for Health
Policy and the National Institute for Health Care Management Foundation, 2009.
Chalmers, Iain and Paul Glasziou. “Avoidable Waste in the Production and Reporting of
Research Evidence.” the Lancet 374, no. 9683 (2009): 86-9.
Chatterjee, Deen K. Encyclopedia of Global Justice. Dordrecht: Springer, 2011.
Cherry, Mark J. “Traditional Christian Norms and the Shaping of Public Moral Life: How
should Christians Engage in Bioethical Debate within the Public Forum?” Christian
Bioethics 13, no. 2 (2007): 129-38.
Chubin, Daryl E. and Edward Hackett. Peerless Science: Peer Review and U.S. Science Policy.
Albany, N.Y.: State University of New York Press, 1990.
Cibrie, Paul. “The French Health Service.” The British Medical Journal 1, no. 4758 (1952): 95-7.
Clamp, Christina. “The Internationalization of Mondragon.” Annals of Public and Cooperative
Economics 71 (2000): 557-78.
Clark, Meghan J. “Integrating Human Rights: Participation in John Paul II, Catholic Social
Thought and Amartya Sen.” Political Theology 8, no. 3 (2007): 299-317.
________. The Vision of Catholic Social Thought: The Virtue of Solidarity and the Praxis of Human
Rights. Minneapolis, MN: Fortress Press, 2014.
Clarke, Adele E, Janet K Shim, Laura Mamo, Laura, Jennifer Ruth Fosket, and Jennifer R
Fishman. “Biomedicalization: Technoscientific Transformations of Health, Illness, and
U.S. Biomedicine.” American Sociological Review. 68, no. 2 (2003): 161.
Coghlan, Andy. “Synthetic Biology can Build Us a Better Future.” New Scientist New Scientist
216, no. 2894 (2012): 29.
Cohen Joel. “Population and Climate Change.” Proceedings of the American Philosophical Society
154, no. 2 (2010): 158-82.
Cohen, Cynthia, Sondra Wheeler, and David Scott. “Walking a Fine Line: Physician Inquiries
!

!

250
into Patients’ Religious and Spiritual Beliefs.” Hastings Center Report 31, no. 5 (2001): 2939.

Cohen, Joshua, Ashley Malins, and Zainab Shahpurwala. “Compared to US Practice,
Evidence-Based Reviews in Europe Appear to Lead to Lower Prices for some Drugs.”
Health Affairs 32, no. 4 (April 01, 2013): 762-70.
Coleman, John and William Ryan, eds. Globalization and Catholic Social Thought: Present Crisis,
Future Hope. Maryknoll, NY: Orbis Books, 2005.
Coles LD, and JC Cloyd. “The Role of Academic Institutions in the Development of Drugs
for Rare and Neglected Diseases.” Clinical Pharmacology and Therapeutics 92, no. 2 (2012):
193-202.
Collins, Francis S. “NIH Basics.” Science 337, no. 6094 (2012).
Comfort, Nathaniel C. The Science of Human Perfection: How Genes Became the Heart of American
Medicine. New Haven: Yale University Press, 2012.
Congregation for the Doctrine of the Faith. Donum Vitae. February 22, 1987.
Cook-Deegan, Robert, and Tom Dedeurwaerdere. “The Science Commons in Life Science
Research: Structure, Function, and Value of Access to Genetic Diversity.” International
Social Science Journal 58, no. 188 (2006): 299-317.
Cooper, Terry L., ed. Handbook of Administrative Ethics. 2nd edition. New York: Marcel
Dekker, 2001.
Cooper, Dale E. “Adequate Controls for New Drugs: Good Manufacturing Practice and the
1938 Federal Food, Drug, and Cosmetic Act.” Pharmacy in History 44, no. 1 (2002): 1223.
Cooter, Roger. “The Turn of the Body: History and the Politics of the Corporeal.” Arbor
Arbor 186, no. 743 (2010): 393-405.
Corlett, J. Angelo and Marisa Diaz-Waian. “Liberating Liberation Theologies.” Philosophy and
Theology 25, no. 1 (2013): 3-32.
Cosgrove, Lisa and Sheldon Krimsky. “A Comparison of Dsm-Iv and Dsm-5 Panel
Members’ Financial Associations with Industry: A Pernicious Problem Persists.” PLoS
Medicine 9, no. 3 (2012).
Costello, Anthony, Mustafa Abbas, Adriana Allen, Sarah Ball, Sarah Bell, Richard Bellamy,
Sharon Friel, Nora Groce, Anne Johnson, Maria Kett, Maria Lee, Caren Levy, Mark
Maslin, David McCoy, Bill McGuire, Hugh Montgomery, David Napier, Christina
!

!

251
Pagel, Jinesh Patel, Jose Antonio Puppim de Oliveira, Nanneke Redclift, Hannah Rees,
Daniel Rogger, Joanne Scott, Judith Stephenson, John Twigg, Jonathan Wolff, Craig
Patterson. “Managing the Health Effects of Climate Change: Lancet and University
College London Institute for Global Health Commission.” Lancet 373, no. 9676 (2009):
1693-733.

Croft, Simon. “Public-Private Partnership: From There to Here.” Transactions of the Royal
Society of Tropical Medicine and Hygiene 99, no. supplement 1 (2005): S9-S14.
Cueto Marcus. “The Rockefeller Foundation’s Medical Policy and Scientific Research in
Latin America: The Case of Physiology.” Social Studies of Science 20, no. 2 (1990): 229-54.
Cuevas, Romero and José Manuel. “Humanism, History, and Criticism in Ignacio Ellacuría.”
The Xavier Zubiri Review 10, no. 1 (2008): 5-15.
Czarnitzki, Dirk, Katrin Hussinger, and Cédric Schneider, “Why Challenge the Ivory Tower?
New Evidence on the Basicness of Academic Patents.” Kyklos 62, no. 4 (2009): 488-99.
Dachtera, Juri, Dave Randall, and Vulker Wulf. “Research on Research: Design Research at
the Margins: Academia, Industry and End-Users.” Proceedings of the SIGCHI Conference on
Human Factors in Computing Systems (2014): 713-722.
D’Alton, Mary E. Clarissa A. Bonanno, and Richard L. Berkowitz, Haywood L. Brown,
Joshua A. Copel, F. Gary Cunningham, Thomas J. Garite, Larry C. Gilstrap, William A.
Grobman, Gary D.V. Hankins, John C. Hauth, Brian K. Iriye, George A. Macones,
James N. Martin, Stephanie R. Martin, M. Kathryn Menard, Daniel F. O’Keefe, Luis D.
Pacheco, Laura E. Riley, George R. Saade, Catherine Y. Spong. “Putting the ‘M’ Back in
Maternal-Fetal Medicine.” American Journal of Obstetrics and Gynecology (2012): 1-7.
Daniels, Norman. “Equity and Population Health: Toward a Broader Bioethics Agenda.” The
Hastings Center Report 36, no. 4 (2006).
________. Just Health Care. New York, NY: Cambridge University Press, 1985.
________. Justice and Justification. New York: Cambridge University Press, 1996.
Davidson Carl. “The Mondragon Cooperatives and 21st Century Socialism: A Review of
Five Books with Radical Critiques and New Ideas.” Perspectives on Global Development and
Technology 11, no. 1 (2012): 229-43.
Dayoub, Elias. “Lessons from Abroad and at Home: How PCORI can Improve Quality of
Care (and Prove it) by 2019.” Health Affairs Blog. (May 2, 2014) accessed: April 11, 2015.
M de S Cameron, Nigel and Arthur Caplan. “Our Synthetic Future.” Nature Biotechnology 27,
no. 12 (2009): 1103-5.
!

!
DeCrane, Susanne M. Aquinas, Feminism, and the Common Good. Washington, D.C.:
Georgetown University Press, 2004.

252

Delvecchio Good, Mary-Jo. “Cultural Studies of Biomedicine: An Agenda for Research.”
Social Science and Medicine 41, no. 4 (1995): 461-73.
Dennis, Rutledge M. “Social Darwinism, Scientific Racism and the Metaphysics of Race.”
Journal of Negro Education 64, no. 3 (1995): 243-52.
Denz, David. “Catholic Social Teaching and Healthcare.” Christian Bioethics 6, no. 3 (2000):
253-66.
Department of Health, Education, and Welfare. Ethical Principles and Guidelines for the Protection
of Human Subjects Research: The Belmont Report. Washington, D.C.: Health and Human
Services, 1979.
Dietrich, Donald J. “Catholic Eugenics in Germany, 1920-1945: Hermann Muckermann, S.J.
and Joseph Mayer.” Journal of Church and State 34, no. 3 (1992).
Diller, Lawrence H. “100 Years Later, the Flexner Report is Still Relevant.” Hastings Center
Report 40, no. 5 (2010): 5.
DiMasi, Joseph, Ronald Hansen, and Henry Grabowski. “The Price of Innovation: New
Estimates of Drug Development Costs.” Journal of Health Economics 22, no. 2 (2003):
151-85.
Dixon, Cyril William. Smallpox. London: Churchill, 1962.
dos Anjos, Marcio Fabri. “Medical Ethics in the Developing World: A Liberation Theology
Perspective.” The Journal of Medicine and Philosophy 21, no. 6 (1996): 629-37.
Docuclef, Michaeleen .“No, Seriously, How Contagious is Ebola?” National Public Radio,
http://www.npr.org/blogs/health/2014/10/02/352983774/no-seriously-howcontagious-is-ebola, (accessed, February 8, 2015).
Drazen, Jeffrey M., Rupa Kanapathipillai, Edward W. Campion, Eric J. Rubin, Scott
Hammer, Stephen Morrissey, and Lindsey R. Baden. “Ebola and Quarantine.” New
England Journal of Medicine 371, no. 21 (2014): 2029-30.
Dresser, Rebecca. “Alive and Well: The Research Imperative.” The Journal of Law, Medicine and
Ethics 40, no. 4 (2012): 915-21.
________. When Science Offers Salvation Patient Advocacy and Research Ethics. New York, NY:
Oxford University Press, 2001.
!

253
!
Durbin, Paul T. Social Responsibility in Science, Technology, and Medicine. London and Toronto:
Associated University Presses, 1992.
Durkheim, Émile. The Division of Labor in Society. ed. W.D. Hall. New York: Free Press, 1984.
Dussel, Enrique D. Ethics of Liberation in the Age of Globalization and Exclusion. trans. Alejandro
A. Vallega. Durham: Duke University Press, 2013.
Eaton, Michael. “Improving the Translation in Europe of Nanomedicines (a.k.a. Drug
Delivery) from Academia to Industry.” Journal of Controlled Release 164, no. 3 (2012): 3701.
Edleson, Paul. “Henry K. Beecher and Maurice Pappworth: Honor in the Development of
the Ethics of Human Experimentation.” In Twentieth Century Ethics of Human Subjects
Research: Historical Perspectives on Values, Practices, and Regulations, eds. Volker Roelcke and
Giovanni Maio, 219. Stuttgart: Franz Steiner Verlag, 2004.
Elkeles, Barbara. “The German Debate on Human Experimentation between 1880 and
1914.” In Twentieth Century Ethics of Human Subjects Research: Historical Perspectives on Values,
Practices, and Regulations, eds. Volker Roelcke and Giovanni Maio, 19. Stuttgart: Franz
Steiner Verlag, 2004.
Ellacuría, Ignacio. “Anthropología de Xavier Zubiri.” In Escritos Filosóficos, Vol. 2. ed. Carlos
Molina-Velásquez. 71-148. San Salvador, El Salvador: UCA Editores, 1999,
________. “The Challenge of the Poor Majority.” In Towards a Society that Serves its People: The
Intellectual Contribution of El Salvador's Murdered Jesuits, eds. John J. Hassett and Hugh
Lacey, 171-6. Washington, D.C.: Georgetown University Press, 1991.
________. “Diez Años Después, ¿es Possible Una Universidad Distinta?” In Escritos
Universitarios. Vol. 1, 49-92. San Salvador, El Salvador: UCA Editores, 1999.
________. Filosofía de la realidad histórica. San Salvador, El Salvador, CA: UCA Editores, 1990.
________. “Filosofía ¿para qué?” In Escritos Filosóficos, Vol. 3, 115-31. San Salvador, El
Salvador: UCA Editores, 2001.
________. “Funciones fundamentales de la universidad y su operativización.” In Escritos
Universitarios, 105-68. San Salvador, El Salvador: UCA Editores, 1999.
________. “Fundamentación biológica de la ética,” Escritos Filosóficos, Vol. 3, 115-31. San
Salvador, El Salvador: UCA Editores, 2001.
________. “Fundamental Human Rights and the Legal and Political Restrictions Placed on
Them.” In Towards a Society that Serves its People: The Intellectual Contribution of El Salvador´s
!

!

254
Murdered Jesuits, eds. John J. Hassett and Hugh Lacey, trans. Phillip Berryman, 91-104.
Washington, D.C.: Georgetown University Press, 1991.

________. “Is a Different Kind of University Possible?” In Towards a Society that Serves its
People: The Intellectual Contribution of El Salvador’s Murdered Jesuits, eds. John J. Hassett and
Hugh Lacey, trans. by Phillip Berryman, 177-207. Washington, D.C.: Georgetown
University Press, 1991.
________. “La inspiración Cristiana de la UCA en la docencia.” In Escritos Universitarios, 28796. San Salvador, El Salvador: UCA Editores, 1999.
________. “A Latin American Reading of the Spiritual Exercises of Saint Ignatius.” trans. J.
Matthew Ashely. Spiritus: A Journal of Christian Spirituality 10, no. 2 (2010): 205-42.
________. “El mal común y los derechos humanos.” Escritos Filosóficos. Vol. 3, San Salvador,
El Salvador: UCA Editores, 2001.
________. “Los pobres, lugar teologico en América Latina,” September 6, 1981,
http://www.uca.edu.sv/martires/CasoJesuitas/ponenciaellacuria.php (accessed January
22, 2015).
________. “Universidad y política.” In Escritos Universitarios, 169-202. San Salvador, El
Salvador: UCA Editores, 1999,
_________. “Universidad, Derechos Humanos y Mayorías.” In Escritos Universitarios, 203-20.
San Salvador, El Salvador: UCA Editores, 1999.
_________. “The University, Human Rights, and the Poor Majority.” In Towards a Society that
Serves its People: The Intellectual Contribution of El Salvador's Murdered Jesuits, eds. John J.
Hassett and Hugh Lacey, trans. Phillip Berryman, 208-19. Washington, D.C.:
Georgetown University Press, 1991.
_________. “Utopia and Prophesy in Latin America.” In Towards a Society that Serves its People:
The Intellectual Contribution of El Salvador´s Murdered Jesuits. eds. John J. Hassett and Hugh
Lacey, trans. James Brockmann, 44-90. Washington, D.C.: Georgetown University
Press, 1991.
_________. “Utopía y profetismo desde américa latina: un ensayo concreto de soteriología
histórica.” Revista Latinoamericana de Teologia 17, Mayo/Agosto (1989): 141-84.
Ellacuría, Ignacio and Jon Sobrino, eds. Mysterium Liberationis: Fundamental Concepts of
Liberation Theology. Maryknoll, N.Y.: Orbis Books, 1993.
Emanuel, Ezekiel. “Reconsidering the Declaration of Helsinki.” The Lancet 381, no. 9877
(2013): 1532-3.
!

!
Engelhardt, H. Tristram. Global Bioethics: The Collapse of Consensus. Salem, MA: M & M
Scrivener Press, 2006.

255

________. The Foundations of Bioethics. New York: Oxford University Press, 1986.
Epstein, Steven. “The Construction of Lay Expertise: AIDS Activism and the Forging of
Credibility in the Reform of Clinical Trials.” Science, Technology and Human Values 20, no.
4 (1995).
________. Inclusion: The Politics of Difference in Medical Research. Chicago: University of Chicago
Press, 2007.
ETC Group. Extreme Genetic Engineering: An Introduction to Synthetic Biology. Canada: ETC
Group, 2007.
European Academies Science Advisory Council. Synthetic Biology: An Introduction. Germnay:
European Academies Science Advisory Council, 2011.
European Commission. “Medical Research in the European Union.” European Union.
http://ec.europa.eu/research/health/medical-research/index_en.html (accessed 10/3,
2013).
Evans, Donald. “Academic Freedom and Global Health.” Journal of Medical Ethics 38, no. 2
(2012): 98-101.
Eyler, John M. Victorian Social Medicine: The Ideas and Methods of William Farr. Baltimore: Johns
Hopkins University Press, 1979.
Faden, Ruth R., Tom L Beauchamp, and Nancy King. A History and Theory of Informed Consent.
New York: Oxford University Press, 1986.
Faden, Ruth R., Nancy E. Kass, Steven N. Goodman, Peter Pronovost, Sean Tunis, and
Tom L. Beauchamp. “An Ethics Framework for a Learning Health Care System: A
Departure from Traditional Research Ethics and Clinical Ethics.” Hastings Center Report
43, no. supplement 1 (2013): S16-27.
Farley, John. To Cast Out Disease a History of the International Health Division of the Rockefeller
Foundation (1913-1951). New York, NY: Oxford University Press, 2004.
Farmer, Paul. “Editor’s Note.” Health and Human Rights 13, no. 2 (2011).
________. Haiti After the Earthquake. New York: Public Affairs, 2011.
________. Infections and Inequalities : The Modern Plagues. Berkeley, Calif.: University of
California Press, 2001.
!

256
!
________. Partner to the Poor: A Paul Farmer Reader. ed. Haun Saussy. Berkeley: University of
California Press, 2010.
________. Pathologies of Power: Health, Human Rights, and the New War on the Poor. Berkeley:
University of California Press, 2003.
________. To Repair the World: Paul Farmer Speaks to the Next Generation. ed. Jonathan Weigel.
University of California Press, 2013.
________. “Shattuck Lecture: Chronic Infectious Disease and the Future of Health Care
Delivery.” New England Journal of Medicine 369, no. 25 (2013): 2424.
Farmer, Paul, Jim Kim, Arthur Kleinman, and Matthew Basilico. Reimagining Global Health an
Introduction. Los Angeles: University of California Press, 2013.
Farmer Paul, Julio Frenk, Felicia M Knaul, Lawrence N Shulman, George Alleyne, Lance
Armstrong, Rifat Atun, Douglas Blayney, Lincoln Chen, Richard Feachem, Mary
Gospodarowicz, Julie Gralow, Sanjay Gupta, Ana Langer, Julian Lob-Levyt, Claire Neal,
Anthony Mbewu, Dina Mired, Peter Piot, K Srinath Reddy, Jeffrey D Sachs, Mahmoud
Sarhan, John R Seffrin, “Expansion of Cancer Care and Control in Countries of Low
and Middle Income: A Call to Action.” Lancet 376, no. 9747 (2010): 1186-93.
Farmer, Paul and Louise Ivers. “Cholera in Haiti: The Equity Agenda and the Future of
Tropical Medicine.” American Journal of Tropical Medicine and Hygiene 86, no. 1 (2012): 7-8.
Farmer, Paul and Nicole Gastineau Campos. “Rethinking Medical Ethics: A View from
Below.” Developing World Bioethics 4, no. 1 (2004): 17-41.
Faunce, Thomas Alured, and Hitoshi Nasu. “Three Proposals for Rewarding Novel Health
Technologies Benefiting People Living in Poverty. A Comparative Analysis of Prize
Funds, Health Impact Funds and a Cost-Effectiveness/Competitive Tender Treaty.”
Public Health Ethics 1, no. 2 (2008): 146-153.
Feldman, Arthur. “Re-Envisioning our Approach to Research in Academia.” Clinical and
Translational Science 1, no. 3 (2008): 181-2.
Fenner, Frank, Isao Arita, Donald Henderson, Zednek Jeznek, and Ivan Ladnyi. Smallpox and
its Eradication. Geneva, Switerzland: World Health Organization, 1988.
Ferber, CJ and Herman Chinn. “Toxicity of Antimalarial Drugs; Therapeutic Doses of
Chloroquine, Paludrine, and Pentaquine.” Quarterly Research Report USAF School of
Aviation Medicine 60 (1948): 1.
Ferreira, Lissett. “Access to Affordable HIV/AIDS Drugs: The Human Rights Obligations
of Multinational Pharmaceutical Corporations.” Fordham Law Review 71, no. 3 (2002):
!

!

257
1133-79.

Fetzer, John. “The Merits of an Industrial Career in Contrast to One in Academia.”
Analytical and Bioanalytical Chemistry 377, no. 3 (2003): 381-2.
Fine, Michael, Said Ibrahim, and Stephen Thomas. “The Role of Race and Genetics in
Health Disparities Research.” American Journal of Public Health 95, no. 12 (2005): 2125-8.
Finkler, Kaja. “Can Bioethics be Global and Local, Or must it be both?” Journal of
Contemporary Ethnography 37, no. 2 (2008): 155-79.
Fiorenza, Francis. “Faith and Political Engagement in a Pluralistic World: Beyond the Idols
of Public Space.” In Task of Theology: Leading Theologians on the most Compelling Questions for
Today, eds. Anselm K. Min. Maryknoll, NY: Orbis Books, 2014.
Firer Hinze, Christine. “The Drama of Social Sin and the (Im)Possibility of Solidarity:
Reinhold Niebuhr and Modern Catholic Social Teaching.” Studies in Christian Ethics 22,
no. 4 (2009): 442-60.
Flexner, Abraham and Daniel Berkeley Updike. Medical Education in the United States and
Canada : A Report to the Carnegie Foundation for the Advancement of Teaching. New York City:
Merrymount Press, 1910.
Foote Whyte, William. “Learning from the Mondragon Cooperative Experience.” Studies in
Comparative International Development. 30, no. 2 (1995): 58.
Fort, AG. “Rural Sanitation and Hookworm Disease.” American Journal of Public Health 5, no.
10 (1915): 1038-43.
Fowler, Thomas B. “The Great Paradigm Shift: Xavier Zubiri and the Scientific Revolution,
1890-1990.” Faith and Reason 20, No. 2 (1994): 163-198.
Franco, Lucas Lopardi, Mauro Vieira de Almeida, Luiz Francisco Rocha e Silva, Pedro Paulo
Ribeiro Vieira, Adrian Martin Pohlit, and Marcelo Siqueira Valle. “Synthesis and
Antimalarial Activity of Dihydroperoxides and Tetraoxanes Conjugated with
Bis(Benzyl)Acetone Derivatives.” CBDD Chemical Biology and Drug Design 79, no. 5
(2012): 790-7.
Frank, Lori, Ethan Basch, and Joe Selby. “The PCORI Perspective on Patient-Centered
Outcomes Research.” JAMA - Journal of the American Medical Association 312, no. 15
(2014): 1513-4.
Frearson, Julie and Paul Wyatt. “Drug Discovery in Academia: The Third Way?” Expert
Opinion on Drug Discovery 5, no. 10 (2010): 909-19.
!

258
!
Fredrickson Donald. “James Augustine Shannon (9 August 1904-20 may 1994).” Proceedings of
the American Philosophical Society 140, no. 1 (1996): 105-13.
Frewer, Andreas. “Debates on Human Experimentation in Weimar and Early Nazi Germany
as Reflected in the Journal ‘Ethik’ (1922-1938) and its Context.” In Twentieth Century
Ethics of Human Subjects Research: Historical Perspectives on Values, Practices, and Regulations,
eds. Volker Roelcke and Giovanni Maio, 137. Stuttgart: Franz Steiner Verlag, 2004.
Fullam, Lisa and William O’Neill. “Bioethics and Public Policy.” Theological Studies 71, no. 1
(2010): 168-90.
Gagnon, Michelle L. and Ronald LaBonte. “Human Rights in Global Health Diplomacy: A
Critical Assessment.” Journal of Human Rights 10, no. 2 (2011): 189-213.
Gaillardetz, Richard R. and Catherine E. Clifford. Keys to the Council: Unlocking the Teaching of
Vatican II. Collegeville, Minn.: Liturgical Press, 2012.
Galarneau, Charlene. “‘Ever Vigilant’ in ‘Ethically Impossible’: Structural Injustice and
Responsibility in PHS Research in Guatemala,” Hastings Center Report 43, no. 3 (2013):
36-45.
Galbraith, James K. “A Perfect Crime: Inequality in the Age of Globalization.” Daedalus 131,
no. 1 (2002).
Galton, Francis. Inquires into Human Faculty and its Development. New York: AMS Press, 1973.
Gamble, Vanessa. “Under the Shadow of Tuskegee: African Americans and Health Care.”
American Journal of Public Health 87, no. 11 (1997): 1773-8.
Gandolfo, David Ignatius. “Human Essence, History and Liberation: Karl Marx and Ignacio
Ellacuría on being Human.” Doctor of Philosophy, Loyola University Chicago, 2003.
Gaw, Allan. “Exposing Unethical Human Research: The Transatlantic Correspondence of
Beecher and Pappworth.”Annals Intern Medicine 156, no. 2 (2012): 150-155.
Germann, Paul, Alexander Schuhmacher, Juan Harrison, Ronald Law, Kevin Haug, and
Gordon Wong. “How to Create Innovation by Building the Translation Bridge from
Basic Research into Medicinal Drugs: An Industrial Perspective.” Human Genomics 7, no.
1 (2013).
Gibbons, Chris. “Stress, Coping and Burn-Out in Nursing Students.” International Journal of
Nursing Studies 47, no. 10 (10, 2010): 1299-309.
Gill, Robin, ed. Reflecting Theologically on AIDS: A Global Challenge. London, UK: SCM Press,
2007.
!

259
!
Gilsselmann, Marit Dahlén and Orjan Hemstrom. “The Contribution of Maternal Working
Conditions to Socio-Economic Inequalities in Birth Outcome.” Social Science and Medicine
66 (2008): 1297-309.
Glennerster, Rachel and Michael Kremer. “A Better Way to Spur Medical Research and
Development.” Research and Development 23, no. 2 (2000): 34-9.
Global Health Delivery Project at Harvard University. “Our Work.” Global Health Delivery
Project, http://www.globalhealthdelivery.org/our-work/(accessed, May 2, 2015).
Gluckman, Peter D and Mark Hanson. “Living with the Past: Evolution, Development, and
Patterns of Disease.” Science 305, no. 5691 (2004): 1733-6.
Goering, Sara, Suzanne Holland, and Kelly Fryer-Edwards. “Transforming Genetic Research
Practices with Marginalized Communities: A Case for Responsive Justice.” The Hastings
Center Report 38, no. 2 (2008): 43-53.
Goldstein, David and Michael Wilson. “Perceived Conflicts of Interest in Clinical Research:
Industry and Academia.” Drug Information Journal 30, no. 2 (1996): 425-32.
Gonzalez, Antonio. “Assessing the Philosophical Achievement of Ignacio Ellacuría.” In Love
that Produces Hope: the Thought of Ignacio Ellacuría, eds. Kevin F. Burke and Robert
Lassalle-Klein, 73-87. Collegeville, MN: Liturgical Press, 2006.
Goozner, Merrill. “PCORI in the Hot Seat.” Modern Healthcare 43, no. 17 (2013).
Gordis, Leon. Epidemiology. Philadelphia: W.B. Saunders, 2000.
Gradmann, Christoph. “Robert Koch and the Pressures of Scientific Research: Tuberculosis
and Tuberculin.” Medical History 45, no. 1 (2001): 1-32.
Graham Loren. “Science and Values: The Eugenics Movement in Germany and Russia in
the 1920s.” The American Historical Review 82, no. 5 (1977): 1133-64.
Green, Ronald M, Aine Donovan, and Steven Jauss, eds. Global Bioethics: Issues in Biomedical
Ethics. Oxford: Oxford University Press, 2008.
Greenberg, Daniel S. Science, Money, and Politics: Political Triumph and Ethical Erosion. Chicago:
University of Chicago Press, 2001.
Greenberg, Michael D. “AIDS, Experimental Drug Approval, and the FDA New Drug
Screening Process.” New York University Journal of Legislation and Public Policy. 3, no. 2
(2000): 1999-2000.
Griffin, Michael, and Jennie Weiss Block, eds. In the Company of the Poor: Conversations between
!

!

260
Dr. Paul Farmer and Fr. Gustavo Gutierrez. Maryknoll: Orbis, 2013.

Grimaldi, Rosa, Martin Kenney, Donald Siegel, and Mike Wright. “30 Years After BayhDole: Reassessing Academic Entrepreneurship.” Research Policy 40, no. 8 (2011): 104557.
Grodin, Michael. “Historical Origins of the Nuremberg Code.” In The Nazi Doctors and the
Nuremberg Code: Human Rights in Human Experimentation, eds. George Annas and Michael
Grodin, 121. New York: Oxford University Press, 1992.
Groft Steven and, Yaffa Rubinstein. “New and Evolving Rare Diseases Research Programs
at the National Institutes of Health.” Public Health Genomics 16, no. 6 (2013): 259-67.
Groody, Daniel. “Globalizing Solidarity: Christian Anthropology and the Challenge of
Human Liberation.” Theological Studies 69, no. 2 (2008).
________. “A God of Life, a Civilization of Love: Justice, Mission, and Catholic Social
Teaching.” International Review of Mission 102, no. 1 (2013): 17-29.
Grueber, Martin and Tim Studt. “2014 Global R&D Funding Forecast.” Battelle.
http://www.battelle.org/docs/tpp/2014_global_rd_funding_forecast.pdf (accessed
January 6, 2015).
Gruskin Sofia and Norman Daniels. “Process is the Point: Justice and Human Rights:
Priority Setting and Fair Deliberative Process.” American Journal of Public Health 98, no. 9
(2008): 1573-7.
Gurwitz, D., E. Zika, M. M. Hopkins, S. Gaisser, and D. Ibarreta. “Pharmacogenetics in
Europe: Barriers and Opportunities.” Public Health Genomics 12, no. 3 (2009): 134-41.
Gutiérrez, Gustavo. The God of Life. Maryknoll, N.Y.: Orbis Books, 1991.
________. On Job: God-Talk and the Suffering of the Innocent. Maryknoll, N.Y.: Orbis Books,
1987.
________. “The Option for the Poor Arises from Faith in Christ.” Theological Studies 70, no.
2 (2009): 317-26.
________. A Theology of Liberation: History, Politics, and Salvation. Maryknoll, N.Y.: Orbis
Books, 1973.
Habermas, Jurgen. The Future of Human Nature. Oxford: Polity Press, 2003.
Habermas, Jurgen and John R. Blazek. “The Idea of the University: Learning Processes.”
New German Critique Spring/Summer, no. 41 (1987): 3-22.
!

!
Haiken, Elizabeth. Venus Envy: A History of Cosmetic Surgery. Baltimore: Johns Hopkins
University Press, 1997.

261

Haker, Hille. “Autonomy and Care in Medicine.” Lugano, Switzerland, Linkoping University
Press, April 25-27, 2011.
________. “Ethical Reflexions on Nanomedicine.” In Nanobiotechnology, Nanomedicine, and
Human Enhancement, eds. Johann S. Ach and Beate Lüttenberg, 53. Berlin: Lit Verlag,
2008.
________. “The Institutional Corruption of Health Care Bodies.” Concilium 2014, no. 5
(2014): 57.
________. “On the Limits of a Liberal Bioethics: A ‘Critical Ethics of Responsibility’
Approach.” In The Contingent Nature of Life: Bioethics and Limits of Human Existence, edited
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